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ABSTRACT
Haemophilia A and B are X-linked recessive bleeding disorders caused by a 
deficiency of the procoagulant function of clotting factors VIII and IX in the intrinsic 
coagulation pathway, respectively. The two main objectives of this project were: (I) to 
carry out a comprehensive search for mutations in the factor VIII gene of patients with 
haemophilia A and (II) to investigate the possibility of keratinocyte-specific expression of 
factor IX as a potential method for somatic cell gene therapy for haemophilia B.
Using a combination of RT-PCR of ectopic factor VIII transcripts and DNA-PCR of 
individual exons, the entire essential sequence of the factor VIII gene was screened for 
mutations using chemical cleavage of mismatches (CCM) and single strand conformation 
analysis (SSCP). A total of 11 different mutations were characterised. These include 7 
single base substitutions, 3 deletions and 1 gross mRNA abnormality due to the intron 22- 
mediated inversion. The 7 single base substitutions included 5 missense (D56E, V162M, 
G701D, A1834T and R1869I), 1 nonsense (R-5X) and 1 splice donor site mutation in 
intron 6 (787+3A—>G). The 3 deletions included a single base deletion in exon 17 
(5697delC), a five base pair deletion in exon 4 (519delTACCT) and a gross deletion of 
exon 16. Six mutations are predicted to result in a truncated or shortened factor VIII 
polypeptide. The five missense mutations were evaluated for pathogenicity by analysing 
the mutated amino acid positions for evolutionary conservation and their involvement with 
functionally important sequence motifs. Analysis of the sequence in the immediate vicinity 
of the various mutations revealed sequence features that may have been involved in the 
mechanism of mutagenesis.
To investigate the role of keratinocytes as a target cell type for somatic gene therapy 
of haemophilia B, a number of factor IX (FIX) gene expression vectors were constructed 
in order to achieve keratinocyte-specific expression from the bovine counterpart of the 
human cytokeratin 10 (K10) gene promoter. To optimise the efficiency of recombinant
factor IX expression by the basic K10-FIX-II construct, two sequence modifications were 
performed. A favourable sequence context was created surrounding the translation 
initiation codon (K10-FIX-G4) and synthetic oligonucleotides were used to lengthen the 5' 
leader sequence thus closely resembling the endogenous K10 gene (K10RB-FIX and 
K10RB-FTX-G4).
Since primary keratinocytes do not express K10 in monolayer cultures, a 
spontaneously transformed, non-tumorigenic, human keratinocyte cell line (HaCaT) was 
used to assess the absolute and relative factor IX expression by the various gene 
constructs. It is known that 5-10% of HaCaT cells in confluent cultures express K10 at 
low levels. Stably transfected HaCaT cell lines (pools and individual clones) were 
generated with each gene expression construct. Expression of factor IX mRNA was 
detected in every transfected keratinocyte cell line using RT-PCR analysis. Northern blot 
analysis of total cellular RNA extracted from all pools of transfected clones (each 
representing 125-750 clones) detected a 2.5 kb recombinant factor IX transcript. Factor 
IX protein that was y-carboxylated and secreted into conditioned medium, was detected 
using a double antibody (A5/A7) ELISA. A maximum expression of 35 ng / 10^ cells / 24 
hours was achieved by the K10-FIX-G4 construct. The three constructs with potentially 
favourable sequence manipulations, expressed significantly higher amounts of factor IX 
than the basic K10-FIX-II construct. As only a few HaCaT cells express K10, the 
observed level of factor IX expression can be considered comparable to that achieved by 
other investigators who used strong viral promoters in similar experiments. These results 
indicate the suitability of using cytokeratin gene promoters to target the expression of 
biologically active factor IX in keratinocytes, for somatic gene therapy of haemophilia B.
SUMMARY
Haemophilia A (classical haemophilia) and haemophilia B (Christmas disease) are 
clinically indistinguishable, X-linked recessive bleeding disorders, caused by deleterious 
mutations in the genes for clotting factors VIII and IX, respectively. These two proteins 
are essential components of the intrinsic coagulation cascade. The genes for factors VIII 
and IX were cloned over a decade ago and in the past five years, a number of disease- 
causing mutations have been reported and some progress been made towards correcting 
these diseases by gene therapy. The overall objectives of this project were: (I) to carry 
out a comprehensive search for mutations in the factor VIII gene of patients with 
haemophilia A and (II) to investigate the possibility of keratinocyte-specific expression of 
factor IX as a potential method for somatic cell gene therapy for haemophilia B.
In haemophilia A, analysis of a sufficiently large number of naturally occurring 
mutations in the factor VIII gene would help to further elucidate the functionally 
important domains of the large and complex factor VIII protein. In an attempt to identify 
mutations in the factor VIII gene, two strategies were employed in this study. The choice 
of the strategy was mainly governed by the availability of RNA from the patient. When 
RNA was available, the method involving a combination of RT-PCR of ectopic 
transcripts and DNA-PCR to amplify the entire essential sequence of the factor VIII gene 
was used (Naylor et al., 1991,1993a). Thirteen randomly selected unrelated haemophilia 
A patients were analysed by this method (group 1). Large sequence alterations detected 
following the initial PCR amplification, were completely characterised by direct 
sequencing. Chemical mismatch cleavage (CCM) analysis was used to screen and 
accurately localise small sequence alterations, which were then fully characterised by 
direct sequencing. Twelve unrelated patients from whom only DNA samples were 
available, were also selected (at random) for mutation analysis (group 2). Exons 4, 7, 8, 
11, 12 and 16 were screened using single strand conformation polymorphism (SSCP) 
analysis. Exons 7, 11, 12 and 16 in particular were selected because of the 
disproportionate harbouring of mutations in these small exons (Tuddenham et al., 1991).
Using the above two strategies, a total of 4 gross mRNA abnormalities, 13 
positive CCM and 2 positive SSCP results were detected while screening for mutations 
within the factor VIII gene. All mutations were tentatively mapped to individual exons of 
the factor VIII gene. A total of 11 different and potentially pathogenic mutations were 
fully characterised. These include 7 single base substitutions, 3 deletions and 1 gross 
mRNA abnormality due to the intron 22-mediated inversion (Naylor et al., 1992, 1993b; 
Lakich et al., 1993). The 7 single base substitutions included 5 missense (D56E, V162M, 
G701D, A1834T and R1869I), 1 nonsense (R-5X) and 1 splice donor site mutation in 
intron 6 (787+3A->G). The 3 deletions included a single base deletion in exon 17 
(5697delC), a five base pair deletion in exon 4 (519delTACCT) and a gross deletion of 
exon 16. Eight of these are novel changes affecting the factor VUI gene.
Correlation of the genotype with the phenotype was carried out for each of the 
potentially pathogenic mutations. A total of 6 mutations are predicted to result in either a 
truncation or internal loss of amino acids from the factor VIII polypeptide. All these 
mutations, except the intron 6 splice donor mutation which resulted in the skipping of 
exons 5 and 6, resulted in a severe phenotype. Naylor et al. (1993a) reported a DNA 
deletion of the same two exons in a severe haemophilia patient. The moderate phenotype 
observed in the two patients with the splice mutation is probably due to a small fraction 
of normally spliced factor VIII mRNA detected. Four of the five missense mutations were 
the only change detected on screening the entire essential sequence of the factor VIII 
gene (A1834T was one of two CCM results in the same patient). These are therefore 
likely to be the cause of the severe (G701D, R1869I), moderate (D56E) and mild 
(V162M) haemophilia A in these patients. The pathogenicity of the missense mutations 
was assessed by analysing the affected residues for evolutionary sequence conservation 
and for involvement with known or predicted functional domains, as catalogued in the 
"PROSITE dictionary of protein sites and patterns" (Release 10.1; using the computer 
program "MOTIFS"). The "A" domains of human and murine factor VIII, factor V and 
ceruloplasmin were aligned using a computer program, "PileUp" (all missense mutations 
mapped to the "A" domains of factor VIII). Three missense mutations affected highly 
conserved residues (D56E and G701D occurred in 11/12 and V162M in 9/12 "A"
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domains analysed). Analysis with "MOTIFS" showed that G701D involved a multicopper 
oxidase I signature sequence and V162M, a casein kinase II phosphorylation site.
Two of the twelve patients in whom a potentially pathogenic mutation was 
detected, developed inhibitors to therapeutically administered factor VIII (the inhibitor 
status in three patients was not known). One was a patient with the frame-shifting single 
base deletion in exon 17, predicted to cause a severe truncation of the factor VIII 
polypeptide. Interestingly, the other was a patient with a missense mutation (G701D; 9.4 
Bethesda units).
The intron 6 splice donor mutation (787+3A—>G) was detected in two of the 
thirteen patients in group 1 (a four generation family history suggested they were 
unrelated, but the mothers of both patients were shown to be carriers and a haplotype 
analysis was unable to exclude identity by descent). The two single base substitutions, 
V162M and R-5X, have each been reported twice before. Only one of the seven single 
base substitutions detected, occurred in a hypermutable CpG dinucleotide (R-5X). Of the 
eight severe haemophilia A cases in whom a complete ascertainment of mutations was 
carried out (group 1), only one showed the characteristic intron 22 mRNA abnormality. 
The latter two findings suggest that this small group of patients was not a representative 
sample of the population. The distribution of mutations among the various exons was not 
totally random. Exons 4, 16, 17 and 21 were seen to be affected by two mutations each 
and three mutations were found to affect exon 14.
The sequence in the immediate vicinity of the various mutations was analysed for 
potential mechanisms of their origin (and recurrence in some cases). The five base pair 
deletion in exon 4 (519delTACCT) was shown to be concordant with the model of 
slipped mispairing at DNA replication, proposed by Krawczak and Cooper (1991). The 
nonsense mutation, R-5X, occurred at a hypermutable CpG dinucleotide and this was the 
third independent report of this mutation. This study is also the third independent report 
of the V162M missense mutation and sequence analysis surrounding this non-CpG site 
mutation revealed a tetranucleotide motif "TGGA" immediately flanking the G—»A at 
position 541. This is a putative arrest site (during DNA replication) for DNA polymerase 
a  and is reported to be a mutation hotspot for both single base substitutions and small
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deletions (Krawczak and Cooper, 1991; Cooper and Krawczak, 1993). In addition, the 
trinucleotide topoisomerase I cleavage site consensus sequence "CTT", was also noted in 
the immediate vicinity. The D56E mutation affects the same codon that harbours a known 
polymorphic missense mutation (D56V). A tetranucleotide direct repeat "TCAC" was 
seen immediately flanking the base change responsible for D56E (and overlapping the 
base change causing D56V) that may have mediated a four-base slippage, producing the 
misincorporation error (s). The trinucleotide topoisomerase I cleavage site sequence 
"CTT", was also noted in the immediate vicinity of the D56E mutation site. The R-5X 
and A1834 mutation sites were both flanked on either side by a "CTT" motif. Another 
such sequence was also observed on the opposite strand as the R1869I mutation, which 
occurred within a direct dinucleotide "GA" repeat sequence.
The two strategies used for mutation detection were evaluated for their efficacy. 
Thirteen cleavage products were obtained after a complete screen of the factor VIII gene 
in nine patients (i.e., those in group 1 who did not show a grossly abnormal segment), 
with >1 seen in three of them. It is thought that a near total ascertainment was achieved 
using this strategy. The efficiency of SSCP analysis of selected exons (all amplified as 
PCR products of <400 bp) was estimated to be <70%.
Haemophilia is a candidate disease for somatic gene therapy. Many groups have 
used strong viral promoters to achieve ectopic expression of factor IX in various cell 
types. Most groups attempting an ex vivo approach, however, achieved low and transient 
expression after transplantation of the genetically modified cells in vivo. It is now clear 
that the choice of cell type and promoter is crucial in determining the long-term success 
of expression in vivo. In general, it was shown that the use of endogenous cellular 
promoters are capable of directing sustained heterologous expression in vivo, albeit at 
least presently, only at low levels (Scharfmann et al., 1991; Dai et al., 1992).
Keratinocytes are attractive target cells for somatic gene therapy. Gerrard et al. 
(1993) have recently demonstrated the ability of keratinocytes to successfully carry out 
the necessary post-translational modifications of factor IX and actively secrete it into the 
systemic circulation. But the use of a viral promoter in vivo achieved only a transient 
effect. In the present project, an attempt was made to achieve sustained and high level
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expression of factor IX, by using a strong cytokeratin gene promoter to direct expression 
in a keratinocyte-specific fashion. The bovine counterpart of the differentiation-specific 
human cytokeratin 10 (K10) gene promoter was used for this purpose. The ability of this 
promoter to direct keratinocyte-specific gene expression has previously been 
demonstrated (Bailleul et al., 1990).
The aim of this project was to create a variety of K10 promoter-driven human 
factor IX cDNA-based gene constructs and test their relative efficiencies in an in vitro 
keratinocyte model. In collaboration with Dr. Y. Alexander, the efficiency of a construct 
was also tested in vivo in transgenic mice. A basic construct (K10-FIX-II) was first 
created by linking the human factor IX cDNA to the K10 promoter (in an expression 
vector that also contained an intron and polyadenylation signal sequence from the SV40 
viral genome). Three sequence modifications were then introduced into the basic 
construct, in order to theoretically improve factor IX expression. These changes included: 
(i) site-directed mutagenesis to create a favourable sequence context surrounding the 
"AUG” initiation codon (K10-FIX-G4) to improve the efficiency of translation initiation 
(Kozak, 1987, 1991a). This necessitated the induction of a missense (probably 
conservative) mutation in the second codon of factor IX (Q-45V); (ii) the use of synthetic 
oligonucleotides to repair the 5' untranslated region (5'UTR), which involved the 
replacement of the existing polylinker with the original K10 cap site and 5'UTR (K10RB- 
FIX and K10RB-FIX-G4), effectively increasing its length and reducing the GC content 
(Kozak, 1991b,c,d, 1994); (iii) "splicing by overlap extension" (Horton et al., 1989) to 
replace the SV40 viral sequence at the 3' end of the gene construct with the 3' end of the 
K10 gene. All sequence modifications were confirmed by direct sequencing.
Primary keratinocytes do not express keratin 10 (K10) in conventional monolayer 
cultures. The HaCaT cell line, which is a spontaneously transformed (non-tumorigenic) 
keratinocyte cell line expresses a wide range of keratins in vitro, including K10 (Ryle et 
al., 1989). This cell line was therefore used as the in vitro model to test the relative 
efficiencies of the various K10-FIX gene constructs. Liposome-mediated transfections 
were performed using the basic construct (K10-FIX-I and II) and those gene constructs 
with the favourable translation initiation consensus (K10-FIX-G4), the repaired 5'UTR
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(K10RB-FIX) and with both these changes (K10RB-FTX-G4). The efficiency of 
transfection was estimated using a lacZ reporter construct. Transfected cells were 
selected for the co-transfected neomycin resistance gene (pSV2Neo) and both, pools and 
individually selected stably transfected clones were analysed for expression of factor IX. 
All transfected pools and clones showed expression of factor IX mRNA on RT-PCR. All 
transfected pools showed the presence of a -2.5 kb recombinant factor IX mRNA by 
Northern blot analysis. Secreted factor IX was estimated in conditioned tissue culture 
medium using a double antibody ("sandwich”) ELISA. The "A7" antibody used in the 
assay detects only that fraction of factor IX that is 7-carboxylated at its N-terminal 
glutamic acid residues (Smith et al., 1986; Smith, 1988) and was used as an indirect 
estimate of post-translationally modified and potentially biologically active factor IX 
(vitamin K was added in the tissue culture medium as it is an essential cofactor in the 
carboxylation). All pools and clones of transfected HaCaT cells expressed factor IX 
above background levels.
One of the basic constructs (K10-FIX-I) was shown to have a missense mutation 
(S136T) and since it had already been used for the generation of transgenic mice, in vitro 
gene expression studies were also carried out using this construct. Both the basic 
constructs i.e., the one with the normal factor IX sequence and the one with the S136T 
mutation expressed similar levels of factor IX, suggesting that the S136T mutation may 
be a conservative change. K10-FIX-G4 was the highest expressing gene construct and 
secreted factor IX at a level of 35 (26-45) ng/106 cells/24 hours and expressed 
significantly more than both the basic constructs (t test showed p<0.01 for K10-FIX-II 
and p<0.02 for K10-FTX-I). This indicated that Q-45V is probably a conservative change. 
The other manipulated constructs, K10RB-FIX and K10RB-FIX-G4 also expressed 
significantly higher levels than the basic construct. Surprisingly, K10RB-F1X-G4, which 
had the repaired 5'UTR in addition to the change in K10-FTX-G4, did not express higher 
levels of factor IX than the latter construct. Retrospectively, an analysis of the repaired 
5'UTR sequence (with a computer program, "STEMLOOP") predicted the presence of a 
detrimental hairpin structure close to the cap site (Kozak, 1991b, 1994). Interestingly, 
Northern analysis revealed that all three manipulated constructs showed more intense
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recombinant factor IX bands than both the basic constructs. Since the sequence 
modifications were aimed at increasing the translational efficiency of the basic construct 
(seen from the factor IX protein levels), it is proposed that the discrepancy in the levels of 
factor IX mRNA represent some post-transcriptional protection, offered either by the 
process or by the product of translation.
HaCaT cells express very low levels of K10 (only at confluence) and en face 
immunofluoresence indicates that this is due to only a few cells showing expression (the 
signals from which become more intense as cell density increases, Ryle et al., 1989). Thus 
even after the selection of transfected cells, it would be expected that only a few cells 
would express factor IX. Even though the in vitro factor IX expression is 10-15 fold less 
than that obtained using primary keratinocytes transduced with a retroviral construct 
containing factor IX cDNA driven by a strong viral promoter, followed by G418 
selection (Gerrard et al., 1993), deficiencies in the in vitro model used in this project 
indicate that the expression levels may be comparable. K10-FIX-I was also used to 
generate transgenic mice (created by Dr. Y. Alexander). Screening of the mice for 
transgene integration and measurement of plasma factor IX levels were performed as part 
of this project, to assess the efficacy of the K10-FIX construct in vivo. The mice 
produced enough y-carboxylated factor IX to maintain an average level of 28 (22-34) 
ng/ml in their plasma, as measured by the same ELISA using the "A7" antibody. This 
level is similar to that achieved by repeated administrations of retrovirally transduced 
myoblasts (containing a recombinant factor IX construct and a cellular muscle creatine 
kinase enhancer element), in nude mice (Dai et al., 1992).
Keratinocytes have been shown to be effective target cells for somatic gene 
therapy of haemophilia B (Gerrard et al., 1993). The results obtained in this project 
(including the data gathered in collaboration with Dr. Y. Alexander) substantiate this 
finding, and in addition, indicate the suitability of using tissue-specific cellular promoters 
to achieve sustained and high level expression of factor IX for this purpose.
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CHAPTER: 1 
INTRODUCTION
1.0 INTRODUCTION
1.1 HAEMOPHILIA A and B
1.1.1 INTRODUCTION
Genetic defects or deficiencies in blood coagulation proteins are associated with a 
bleeding disorder known as haemophilia. Deficiency or defects in clotting factor VIII 
result in haemophilia A (classical haemophilia) which accounts for about 85% of all 
haemophilias. Deficiency or defects in clotting factor IX result in haemophilia B 
(Christmas disease) which comprises 10-12% of this hereditary disorder. Defects in other 
coagulation proteins are rare, but deficiency states have been recognised for most of the 
blood clotting proteins (Furie and Furie, 1988). Haemophilias A and B are both X-linked 
recessive disorders (McKusick catalogue no. 306700 and 306900, respectively) with an 
incidence of about 1:5,000 (Hoyer, 1994) and 1:30,000 (Connor et al., 1985) males, 
respectively. The two disorders are clinically indistinguishable and can only be separately 
diagnosed by specific assays for their respective cofactors. The clinical hallmarks include 
haemorrhage that is either spontaneous or follows minor trauma, and mainly involves 
large joints and deep muscles.
Factor VIII and IX are both essential components of the intrinsic coagulation 
cascade. Factor IX is a vitamin K-dependent serine-protease that, in its activated form 
(factor IXa), serves to proteolytically activate factor X. Activated factor VIII (factor 
Villa) acts as a cofactor to increase the Vmax of this reaction by at least 4 orders of 
magnitude (in the presence of negatively charged phospholipids and calcium ions; van 
Dieijen et al., 1981). Factor VIII is stabilised in the circulation (in plasma) by non- 
covalent complex formation with a large multimeric plasma protein, von Willebrand 
factor (vWF; Hoyer, 1981). The genes responsible for clotting factors VTII (Gitschier et 
al., 1984) and IX (Anson et al., 1984; Yoshitake et al., 1985) have been cloned and 
completely characterised.
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1.1.2 CLINICAL FEATURES & COMPLICATIONS
Haemophilia A and B are both X-linked recessive disorders of bleeding, and 
therefore almost invariably affect males (although some females have been reported to 
have clinical disease due to non-random X-inactivation; Nisen et al., 1986; Nisen and 
Waber, 1989; Giannelli et al., 1993). Haemophilia A and B are clinically heterogeneous 
disorders in which the severity of disease correlates well with the biochemical phenotype. 
Normal levels of factor VIII and factor IX coagulant activity (factor VIII:C and IX:C) 
range between 50-150 IU/dl. Levels of <2, 2-5 and 5-30 IU/dl result in severe, moderate 
and mild clinical disease, respectively.
Severe haemophilia is characterised by spontaneous and recurrent haemarthroses 
into knees, elbows, ankles, shoulder and hip joints. Bleeds usually start at the age of 6 
months when the baby becomes mobile. The bleeding may be as frequent as 2-4 times per 
month. Untreated haemarthroses result in persistent severe pain and due to their recurrent 
nature, eventually lead to loss of cartilage and secondary osteoarthrosis; the haemophilic 
arthropathy. Deep muscle haematomas and frank haematuria are also observed. 
Spontaneous intracranial bleeds can occur and in adults can be severe and often fatal. 
This was the most common cause of death before the AIDS epidemic which started in the 
early eighties (Hoyer, 1994).
Moderate haemophilia usually leads to bleeding in response to minor trauma and 
is usually only seen 1-5 times a year. Mild haemophiliacs on the other hand only bleed 
after relatively severe trauma and because of this, diagnosis may be delayed until adult 
life. An interesting subgroup of haemophilia B patients, the Leyden variant (Veltkamp et 
al., 1970), have a severe phenotype during childhood, but gradually improve with 
eventual conversion to mild disease after puberty.
Before effective replacement therapy was introduced at the end of the 1960s, 
haemophilia caused severe disability and death at a young age. A spectacular 
improvement in life expectancy has resulted from the introduction of specific replacement 
therapy (Larrson, 1985; Smit et al., 1989; Jones and Ratnoff, 1991).
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1.1.3 CURRENT MODALITIES OF THERAPY
In the UK, clinical management of haemophilia is carried out in specialised 
comprehensive haemophilia centres. Treatment is often initiated following a bleeding 
episode. The main objective being to increase and maintain the plasma levels of the 
deficient cofactor. Presently, this is best achieved by infusions of treated factor VIII 
(reviewed by Brettler and Levine, 1989) or factor IX concentrates. Due to the short half- 
lives of factors VIII and IX in circulation, (10 and 24 hours, respectively) repeated 
administrations are required. Mild haemophiliacs require intravenous therapy only if they 
have a haemarthrosis or if they are to undergo a surgical procedure. Those with more 
severe haemophilia may be candidates for home therapy as they are aware of the onset of 
haemorrhage before there is any clinical evidence. In Sweden, severe haemophiliacs have 
been treated prophylactically for the past twenty-five years with infusions given thrice a 
week. This has effectively converted their disease to that of moderate severity (Nilsson et 
al., 1992).
However, since concentrates are usually prepared from plasma pools derived from 
2000-30,000 individuals, they form a potential source for the transmission of blood borne 
diseases. Infectious complications from transfusion-transmitted viruses began to be noted 
in haemophiliacs in the late 1970s and are still a major concern. Many newer types of 
cofactor concentrates are now produced, both to eliminate infectious complications and 
to increase purity. Even though the infectivity of the currently available concentrates 
(heat / chemically treated; Brettler and Levine, 1989) is considerably reduced, the sizeable 
number of patients already infected in the past, continue to have associated 
complications. Contamination of the plasma pool by human immunodeficiency virus 
(HIV) has led to many haemophiliacs being infected, and a survey performed a few years 
ago showed 1201 UK haemophiliacs to be HIV positive, with 85 cases of AIDS and 47 
deaths (Darby et al., 1989). AIDS is now the most common cause of death in severe 
haemophilia A patients. Virtually every individual who received untreated cofactor 
preparations developed hepatitis B or non-A, non-B. Consequently, many haemophilia 
patients have, and will develop chronic progressive liver disease (Hay et al., 1985). 
Various trials have suggested that the viruses responsible for hepatitis are more difficult
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to inactivate (Brettler and Levine, 1989), however, the "super dry heat" method for 
inactivation used in the UK, has been reported to be more successful (Study Group of the 
UK Haemophilia Centre Directors, 1988).
To eliminate the potential complications of plasma-derived products, two 
biotechnology companies have invested efforts in the development of recombinant factor 
VIII synthesised in mammalian cell cultures. Clinical trials have shown these products to 
be as effective as concentrates and with no immediate side effects (White et al., 1989; 
Lusher et al., 1993). These products are not yet being widely used and it is thought that 
costs may be prohibitive (Hoyer, 1994).
One of the most difficult problems in the clinical management of haemophilia 
(especially haemophilia A) is the development of inhibitory antibodies to the exogenously 
administered cofactor, making them ineffective. This complication is seen to affect about 
20% of haemophilia A patients (Ljung et al., 1992; Lorenzo et al., 1992). Patients whose 
haemophilia is due to gross deletions or nonsense mutations are more likely to develop 
inhibitors although certain missense mutations have also resulted in an inhibitor 
phenotype (Tuddenham et al., 1991).
Clearly, due to the reactive nature of treatment initiation, the need for repeated 
injections and the associated complications, the current form of therapy is sub optimal.
1.2 HAEMOSTASIS AND TH E R O LF OF CLO TTIN G  FACTORS V III AND IX
Haemostasis is maintained by a complex sequence of interactions between 
endothelial cells, platelets and a series of plasma proteins (Davie and Ratnoff, 1964; 
MacFarlane, 1964). Trauma to the vessel wall results in damage of the endothelial lining 
and exposure of the subendothelial matrix. vWF plays an active role in binding and 
subsequent accumulation of platelets at the site of injury (Tuddenham, 1989; Handin and 
Wagner, 1989). This platelet plug forms the first line of action in the prevention of blood 
loss. The intrinsic and extrinsic coagulation cascades are initiated by the exposure of the 
subendothelial negatively-charged matrix, and the release of tissue thromboplastin from 
the damaged cells in the vicinity, respectively. Sequential proteolytic reactions result from
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the activation of these coagulation pathways, which converge at the activation of factor X 
(figure 1).
Both, factor VTII and IX are part of the intrinsic coagulation cascade. The 
coagulation cascade can be divided into three main stages namely, the contact phase, 
procoagulant and anticoagulant phases. There are two main classes of proteins that take 
part in the coagulation cascade. These are the serine proteases and the protein cofactors. 
One of each, forms an enzyme complex on a suitable surface (in the presence of calcium 
ions), which forms the functional units of the coagulation cascade (Mann et al., 1988). 
The serine protease in each enzyme complex, in the presence of the active cofactor 
(which has no proteolytic function), proteolytically activates another zymogen to 
protease, which in turn forms another complex downstream in the cascade. As seen in 
figure 1, in the activation of factor X (inactive zymogen) to Xa (active protease), 
activated factor IX (IXa) is the serine protease whose proteolytic function is catalysed by 
active cofactor VIII (Villa). In the presence of negatively charged phospholipids and 
calcium ions the proteolytic cleavage of factor X by factor IXa is increased by at least 
four orders of magnitude by factor Villa (van Dieijen et al., 1981; Mann et al., 1990).
The intrinsic coagulation cascade is initiated by the activation of factor XII, which 
at the end of the contact phase results in activated factor XI (XIa). Factor XIa activates 
factor IX, which is the first enzyme complex after the contact phase. The extrinsic 
pathway on the other hand first activates factor VII (Vila). Both, Vila and IXa serve to 
activate factor X (Xa). The intrinsic and extrinsic cascades follow a common pathway 
after this step.
Factor Xa converts prothrombin to thrombin, which in turn converts fibrinogen to 
insoluble fibrin, which gets polymerised to form a fibrin network in the presence of XHIa 
(which was also activated by thrombin). Thrombin also activates platelets, factor V and 
VHI, thus playing an important role in the amplification of the cascade reaction.
Reactions within the cascade are further regulated via a variety of feedback loops. 
The anticoagulant pathway is activated to prevent the excessive formation of thrombin. 
This is done by plasma proteins, antithrombin III and heparin cofactor II, as well as 
thrombomodulin on the endothelial cell surface. Eventual dissolution of the fibrin clot is
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Figure 1: The coagulation cascade
Glycoprotein components of the intrinsic pathway include factors XII, XI, IX, VIII, 
V, prothrombin and fibrinogen. Glycoprotein components of the extrinsic pathway, 
initiated by the action of the tissue factor located on cell surfaces include, factors VII, 
X, II and fibrinogen. The intrinsic and extrinsic cascade reactions are shown, which 
culminate in the conversion of fibrinogen to fibrin and the formation of a fibrin clot. 
Where indicated reactions are Ca+2 dependent. Numbered factors are abbreviated 
FXI, FXII, etc. Other abbreviations include HMWK=high molecular weight 
kininogen, TF=tissue factor, PL=phospholipid.
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promoted by plasmin which is broken down from plasminogen by tissue plasminogen 
activator.
Thus the enzyme complexes which form the functional units of the clotting 
cascade, not only cause an amplification of the reaction but also serve to localise it to the 
site of vascular injury due to the membrane binding domain of the vitamin K-dependent 
serine-proteases (Mann et al., 1988). The formation of the complexes also provide 
numerous opportunities for the modulation of the reaction rate via the various positive 
and negative feedback loops.
The three main phases are also distinct in their pathophysiological consequences 
on the coagulation system, in the event of genetic or acquired defects in their protein 
components. Whilst a functional deficiency in any of the factors of the procoagulant 
phase (e.g. factor VIII and IX) causes a bleeding disorder warranting protein replacement 
therapy, a similar deficiency in factors of the contact phase results in little, if any, effects. 
This is probably due to the capacity of the activated platelets to convert factor XI to XIa, 
thus activating the intrinsic cascade (bypassing the factor XII activation and initiation). A 
deficiency of the factors in the anticoagulant phase (antithrombin III, proteins C and S) 
predisposes to venous thrombosis. A deficiency of platelet number or function results in a 
characteristic bleeding profile involving mainly mucocutaneous surfaces.
1.3 CLOTTING FACTORS VIII AND IX
1.3.1 THE FACTOR VIII GENE 
Cloning of the factor VIII gene
The factor VIII gene was independently cloned by two groups, one at Genentech 
(Gitschier et al., 1984) and the other at the Genetics Institute (Toole et al., 1984). Both 
groups used the same basic method to characterise factor Vm  genomic clones, followed 
by the cloning and sequencing of the entire factor VIII cDNA (Wood et al., 1984; Toole 
et al., 1984). Both groups also transfected the full length cDNA into mammalian cells and
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demonstrated the successful expression of active factor VIII protein (Toole et al., 1984; 
Wood et al., 1984).
The method employed by both groups involved the use of partial amino acid 
sequence of human (Vehar et al., 1984) or porcine (Toole et al., 1984) highly purified 
factor VDI protein (human, Rotblat et al., 1983; porcine, Fass et al., 1982) to synthesise a 
cocktail of oligonucleotide probes for the screening of genomic DNA libraries. Genomic 
DNA libraries were screened instead of cDNA libraries because it was not known which 
cells expressed factor VTII and due to the low concentration of plasma factor VIII (100- 
200 ng/ml), a low mRNA abundance was anticipated. Both groups then used probes 
isolated from the genomic DNA library to screen a series of cell lines by Northern 
blotting, in order to identify cell types expressing factor VIII. Both groups identified the 
liver as the source of human factor VIII, but the Genentech group used an expressing T- 
cell hybridoma cell line cDNA library to isolate the factor VDI cDNA.
To confirm that they had indeed isolated the gene and cDNA for factor VIII, both 
groups constructed full length cDNA clones and linked them to viral promoters. These 
constructs were introduced into mammalian cell lines (Genentech: hamster kidney cells; 
Genetics Institute: monkey kidney cells), following which a human factor VIII:C-like 
activity was secreted into conditioned media. This was quantified using a sensitive assay 
based on the activation of factor X and hydrolysis of a chromogenic substrate. The factor 
VIII:C activity was found to be 1% and 7% of normal plasma concentrations by the 
groups at the Genetics Institute and at Genentech, respectively. On affinity purification 
this was shown to partially correct the clotting time of plasma from a haemophiliac.
The clotting activity was shown to be increased by thrombin (a physiological 
activator of factor VIII) and decreased by specific anti-factor VIII antibodies. The 
Genentech group also demonstrated specific and reversible binding to vWF on an affinity 
column, which was inhibited by protein C (an inactivator of factor VHQ.
The structure of the factor VIII gene and cDNA
The factor VIII gene is relatively large and has 26 exons and 25 introns that span 
186 kb of genomic DNA (Gitschier et al., 1984). The gene maps to Xq28 i.e., at the 
telomere of the long arm of the X chromosome (Purrello et al., 1985; Tantravahi et al.,
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1986). It is estimated to constitute up to 0.1% of the entire length of the X chromosome 
(Gitschier et al., 1984).
The 26 exons of the factor VTII gene, range from 69 to 3,106 bp (median size of 
164 bp). All exons are fairly normal in size, except for exons 5, 20, 14 and 26. Exons 5 
and 20, at 69 and 72 bp respectively, are about half the average size of vertebrate exons 
(137 bp; Hawkins, 1988). Exon 14 is 3,106 bp long and codes for the central connecting 
region or "B" domain of the factor VIII polypeptide (section 1.3.2). Exon 26, which is 
the last exon, is 1,958 bp long, of which 1,805 bp constitutes the 3' untranslated sequence 
of the factor VHI gene.
The 25 introns of the factor VIII gene range from 0.2 kb to 32.4 kb in length. All 
the splice donor and acceptor sites conform to the GT..AG rule (Breathnach and 
Chambon, 1981). Intron 22, which is 32.4 kb in length, is the largest intron in the factor 
VIII gene. It contains an unmethylated GC rich sequence (CpG island) of the type known 
to be associated with 5' regions of vertebrate genes (Bird, 1986). This island appears to 
serve as a bi-directional promoter for two genes emanating from it, referred to as factor 
VUI-associated genes A and B (F8A and F8B). F8A is an intronless gene that is 
completely nested within intron 22 of the factor VIII gene (Levinson et al., 1990). It is 
transcribed in a direction opposite to that of the factor VIII gene, and produces a 
transcript that is 1,739 nucleotides long. This was the first example of an intron- 
embedded gene to be identified in a vertebrate genome. Two additional copies of this 
gene have been identified approximately 500 kb upstream of the factor VIII gene i.e., 
further telomeric on the X chromosome (Patterson et al., 1989; Levinson et al., 1990; 
Freije et al., 1992; Lakich et al., 1993). This intron 22-embedded gene, along with the 
two telomeric copies, has recently been implicated in the causation of about half the cases 
of severe haemophilia A (Lakich et al., 1993; Naylor et al., 1993a,b; section 1.7.2). F8B 
in contrast, is transcribed in the same direction as the factor VIII gene. Its first exon is 
contained within intron 22, but it uses exons 23 - 26 of the factor VIII gene as its own 
exons 2 - 5 (Levinson et al., 1992). It produces a transcript which is formed by the 
splicing of its exon 1 with exon 23 of the factor VIII gene and utilises the polyadenylation
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signal of the factor VIII gene. In contrast to the factor VIII gene, both, F8A and F8^ a r e  
ubiquitiously transcribed.
The factor VIII cDNA is approximately 9 kb long and has an open reading frame 
that codes for a polypeptide of 2,351 amino acids, the first 19 of which comprise the 
hydrophobic signal sequence. Both, RNase protection and Northern blotting revealed that 
the liver was the main site of factor VIII expression. RNase protection assays revealed 
that the mRNA start site was 170 (less frequently 172) nucleotides upstream of the 
translation start site. The poly (A) tail is attached 1,805 nucleotides following the 
translation termination codon. A consensus polyadenylation signal, "AATAAA" is located 
19 nucleotides upstream from the poly (A) tail.
A consensus promoter element, "GATAAA", is seen at position -30 from the 
mRNA start site (200 nucleotides before the translation initiation site) and is thought to 
be the equivalent of the TATA-box seen in many tissue-specific genes (Breathnach and 
Chambon, 1981). No "CAAT" sequence was observed around position -70 from the 
mRNA start site.
1.3.2 THE FACTOR VIII PROTEIN
Factor VIII is a high molecular weight glycoprotein (360 kDa; Rotblat et al., 
1985) which is proteolytically activated by thrombin and factor Xa. In plasma, factor VIII 
exists as a heavy chain extending from 90 to 200 kDa in a metal ion association with a 
light chain of 80 kDa (Vehar et al., 1984; Rotblat et al., 1985; Andersson et al., 1986). 
This complex is stabilised by a non-covalent association with another plasma 
glycoprotein, von Willebrand factor (vWF; Hoyer, 1981).
For many years the characterisation of factor Vm  was complicated by its low 
concentration in plasma (200 ng/ml or 1/2,000,000 the molar concentration of serum 
albumin), its heterogeneity in size and its extreme sensitivity to proteolysis. Small 
amounts of highly purified factor VIII were prepared from porcine and human plasmas in 
the early 1980s (Fass et al., 1982; Fulcher and Zimmerman et al., 1982; Rotblat et al., 
1983). As described before, this information was used to clone the factor VIII gene and 
to sequence the entire factor VIII cDNA. This work allowed the determination of the
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primary structure of factor VIII. Expression of factor VTII in mammalian cells using 
recombinant DNA techniques (Kaufman et al., 1988,1989), coupled with the use of site- 
directed mutagenesis (Toole et al., 1986; Pittman and Kaufman, 1988; Pittman et al., 
1992a,b) and classical protein biochemistry experiments (Fulcher et al., 1984; Rotblat et 
al., 1985; Eaton et al., 1986; O'Brien et al., 1992) have led to an increased understanding 
of the structure-function correlation of this large and complex protein. Furthermore, the 
delineation of naturally occurring mutations in patients with haemophilia A (Tuddenham 
et al., 1991) have also contributed to our understanding of some aspects of the 
functioning of factor VIII (Arai et al., 1989a; O'Brien et al., 1990; McGinniss et al., 
1993). Electron microscopy has also added some information regarding the structural 
organisation of factor VTII (Mosesson et al., 1990; Fowler et al., 1990). These results 
suggest that the heavy-chain subunits (Al and A2) and the light-chain subunit (A3-C1- 
C2) are closely associated in a small globular core (10-12 nm in diameter) and the B- 
domain forms a 25 nm tail-like structure. Analysis of factor Villa revealed only the small 
globular core, consistent with the thrombin-mediated cleavage of the tail-like B-domain 
appendage (a diagrammatic representation is presented by Hoyer, 1994).
Computer-aided analysis of the factor VIII amino acid sequence revealed two 
types of internal homologies (Vehar et al., 1984; figure 2). The first consists of a 
triplicated segment called the "A" domains (A1-A3) and the second consists of a 
duplicated segment called the "C" domains (Cl, C2). The three "A" domains consist of 
about 330 residues each, and are found at the following positions, Al: 1-336, A2: 372- 
740 and A3: 1689-2019, of the factor VIII polypeptide. The A2 and A3 domains are 
separated by a large region of 983 amino acids which is called the "B" domain. The "C" 
domains consist of 150 residues each, and are found at the following positions, Cl: 2020- 
2172 and C2: 2173-2332, of the factor VIII polypeptide.
The three "A" domains share about 30% sequence identity with each other and 
the two "C" domains about 40% (Vehar et al., 1984). Factor V, which is another plasma 
glycoprotein cofactor in the coagulation cascade, also shows a similar structure with 
three repeated "A" domains (with a large connecting region separating A2 and A3) and 
two repeated "C" domains (Kane and Davie, 1986; Kane et al., 1987; Jenny et al., 1987).
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Figure 2: Structure of Factor VIII
The figure shows a diagrammatic representation of the factor VTII polypeptide. The 
triplicated A domains (hatched boxes), the duplicated C domains (dotted boxes) and 
the central B domain represented by an open box are indicated. The positions of 
cleavage by thrombin (Ila), activated factor X (Xa) and activated protein C (APC) 
are shown. The sites of thrombin cleavage essential for activation of factor VIII (372, 
1689) are marked by an asterisk. The sites of binding with von Willebrand factor 
(vWF) and phospholipid (PL) are indicated. The amino acid numbering is according 
to Wood et al., 1984.
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The "A" and "C" domains of factor VIII and V share approximately 40% and 35% 
sequence identity, respectively (Kane and Davie, 1988). Ceruloplasmin, a major copper 
binding protein in plasma, also has three repeated "A" domains, but unlike factor VIII and 
V, lacks the duplicated "C" domains and the large connecting region separating the A2 
and A3 domains (Takahashi et al., 1984; Kochinsky et al., 1986). The three "A" domains 
of ceruloplasmin share about 30% sequence identity with those of factor VIII (Vehar et 
al., 1984) and V (Kane and Davie, 1988). In addition, the "C" domains of factor VIII and 
V share about 20% sequence identity with the first 150 residues of the slime mold lectin 
discoidin I (Kane and Davie, 1988; Poole et al., 1981) and about 40% with the more 
recently described mouse milk fat globule membrane protein (Stubbs et al., 1990). The 
large interconnecting regions ("B" domain) between the A2 and A3 domains of factor 
VDI and V show no sequence similarity (Kane and Davie, 1988).
There are 23 cysteine residues in the mature factor VIII polypeptide. Most of 
these are clustered in the "A" and "C" domains and occupy very similar positions (Vehar 
et al., 1984). This suggests that the structures of both repeated domains of factor VIII 
reflect conserved disulphide bonding arrangements.
The exceptionally large "B" domain of factor VIII is delimited by residues 740 
and 1648. Although these are sites for proteolytic cleavage by thrombin, site-directed 
mutagenesis has revealed that they are not important for factor VIII activity (Pittman and 
Kaufman, 1988). This region is extremely rich in potential asparagine-linked glycosylation 
sites, containing 20 of the 25 sites found in factor VIII. Comparison of the deduced 
amino acid sequence of porcine and human factor VIII shows a striking divergence 
between the "B" domains, whereas the region of the A2 and A3 domains immediately 
flanking them, revealed 80-85% homology (Toole et al., 1986). Since porcine factor VIII 
can be used to treat haemophilia A, it was speculated that the "B" domain may be 
dispensable for factor VIII procoagulant activity. This was shown to be the case by site- 
directed mutagenesis (Toole et al., 1986; Eaton et al., 1986). The entire "B" domain 
deleted from the full length cDNA in an expression construct used to transfect 
mammalian cells, expressed factor VIII with procoagulant function, thrombin cleavage 
products and an activation profile comparable to the wild type molecule. This is the
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rationale for using factor VIII cDNA constructs devoid of the large "B" domain, in 
current haemophilia A gene therapy experiments (Hoeben et al., 1990,1992; Lynch et al.,
1993).
Treatment of factor VIII with thrombin causes a rapid activation followed by a 
subsequent first order decay of its procoagulant activity. The activation coincides with 
proteolysis of both the heavy and light chains. The heavy chain is first cleaved at position 
740 which releases the "B" domain. Then two further thrombin cleavages occur at 
positions 372 and 1689 resulting in the heavy chain splitting into 50 and 43 kDa 
fragments and the light chain being cleaved into a 73 kDa fragment. By site-directed 
mutagenesis at these residues it was shown that the cleavages at 372 and 1689 are in fact 
crucial for activation (Pittman and Kaufman, 1988; figure 2). The codons for the arginine 
residues at 372 and 1689 have both been affected by recurrent mutations in unrelated 
haemophilia A patients due to the hypermutable CpG dinucleotides at these sites 
(Pattinson et al., 1990a; Tuddenham et al., 1991). Hill-Eubanks and Lollar (1990) 
showed that cleavage at position 372 was the rate-limiting step in the activation of factor 
VIII. Inactivation of factor VIII is associated with proteolytic cleavage by activated 
protein C at positions 336 and 562 (Fulcher et al., 1984; Fay et al., 1991; Walker and 
Fay, 1992). There is also evidence to indicate that the inactivation of factor VIII takes 
place as a result of spontaneous dissociation of the low-solubility A2 subunit (Lollar and 
Parker, 1990).
The factor VIII molecule is known to interact with vWF, factors Xa and IXa, 
phospholipid, calcium ions and perhaps with copper ions. The residues for the binding of 
vWF were shown to map in the acidic region between positions 1649 and 1689. 
Deletional mutagenesis revealed the consequent loss of the normal stabilising effect of 
vWF in vitro (Pittman and Kaufman, 1989). The sulphated tyrosine residues at 1664 and 
1680 were mutated to phenylalanine (a conservative change that would block sulphation 
at these residues), which showed the same effect. Further, monoclonal antibodies that 
recognise the aspartic acid and tyrosine residues at 1679 and 1680 inhibited the 
interaction with vWF (Foster et al., 1988). Thus residues at 1664 and 1680 are likely to 
be responsible for vWF binding of the factor VIII molecule.
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The C2 domain has been shown to be the site of phospholipid binding to factor 
VIIL Antibodies to the factor VIII light chain that recognise epitopes between residues 
2178-2332 (Arai et al., 1989b) and peptides spanning residues 2302-2332 (Foster et al., 
1990), were shown to inhibit the binding of phosphatidylserine to factor VIIL
The homology of factor VIII with ceruloplasmin suggests the possible 
involvement of factor VTII with copper or other metal ions. The residues implicated for 
copper binding in ceruloplasmin are conserved in the Al and A3 domains of factor VIII, 
which may be involved in some metal ion binding function (Vehar et al., 1984).
1.3.3 THE FACTOR IX GENE 
Cloning of the factor IX gene
By 1982, 20% of the human (DiScipio et al., 1978) and 100% of the bovine 
(Katayama et al., 1979) factor IX amino acid sequence had been determined. Two 
groups, used this information and screened human cDNA libraries using a mixture of 
synthetic oligonucleotides (Kurachi and Davie, 1982; Choo et al., 1982). Similar methods 
were used by other groups to isolate human factor IX cDNA clones (Jaye et al., 1983; 
Anson et al., 1984; Jagadeeswaran et al., 1984). Kurachi and Davie (1982) also used 
another probe for this purpose, where they obtained a single stranded DNA probe 
prepared from enriched mRNA for baboon factor IX. This was obtained by injecting a 
baboon with goat anti-human factor IX antibodies, followed by extraction of the enriched 
poly (A) RNA from its liver.
Following the isolation of the factor IX cDNA, these clones were used to isolate 
genomic DNA clones containing the factor IX gene. Anson et al. (1984) thus reported 
the characterisation and structure of the factor IX gene. Yoshitake et al. (1985) reported 
the sequence of the entire 33.5 kb factor IX gene.
Structure of the factor IX gene and cDNA
The entire factor IX gene has been sequenced (Yoshitake et al., 1985). The gene 
spans 33.5 kb of genomic DNA at Xq27.1. It has eight exons (I-VTII) and seven introns 
(A-G) (Anson et al., 1984; Yoshitake et al., 1985). The exons range in size from 25 bp 
(exon III, which codes for only 8 amino acids), to 1,935 bp (exon VIII, which encodes
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182 amino acids and forms the 1,390 nucleotide 3' untranslated sequence). The introns 
range in size from 188 bp (intron B) to 9,473 bp (intron F). All splice sites conform to the 
GT..AG rule (Breathnach and Chambon, 1981). The seven introns in the factor IX gene 
are located essentially in the same position as those of the gene for human protein C, and 
the first three are in positions identical to those in the human prothrombin gene 
(Yoshitake et al., 1985).
There are several potential "TATA" sequences upstream from the mRNA start 
site (Anson et al., 1984; Yoshitake et al., 1985; Salier et al., 1990). The "TGTA" 
observed at position -27 may serve as the "TATA box" sequence. The "G" in this 
sequence is unusual but not unknown (Breathnach and Chambon, 1981). No "CCAAT" 
box was observed upstream of this box. The polyadenylation signal sequence 
"AATAAA" was observed 16 nucleotides before the addition of the poly (A) tail (1,367 
nucleotides downstream of the "TAA" stop codon; Yoshitake et al., 1985).
The factor IX cDNA is 2,802 bp long. It has a 29 nucleotide 5' non-coding 
sequence and a 3' non-coding sequence of 1,390 nucleotides. The translation initiation 
codon is at position 30 and the termination codon is just after position 1412. The codons 
-46 to -1 encode the precursor region, where -46 to -21 codes for the hydrophobic signal 
peptide and -20 to -1 the hydrophilic propeptide. The mature peptide is encoded by 
codons 1-415 (Anson et al., 1984).
1.3.4 THE FACTOR IX PROTEIN
Factor IX is a vitamin K-dependent, serine protease, that circulates in the plasma 
as a 415 amino acid zymogen. In the intrinsic coagulation cascade, its activated form 
proteolytically activates factor X in the presence of factor Villa, calcium ions and 
negatively charged phospholipids. It has a domain structure very similar to that of other 
vitamin K-dependent proteins in the coagulation pathway, namely, prothrombin, factors 
VII and X, protein C and protein S (reviewed in Furie and Furie, 1988).
The eight exons (I-VIII) of the factor IX gene code for six major domains of 
factor IX. Exon I (-46 to -17) codes for the hydrophobic signal peptide which targets the 
protein for secretion from the hepatocyte into the blood stream. Exons II (-17 to 37) and
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Ill (38 to 47) encode the propeptide and the gla domain. The latter domain has the 12 N- 
terminal glutamyl residues (the first 11 encoded by exon II and the last one by exon HI) 
that are modified to y-carboxyglutamyl residues by vitamin K-dependent carboxylase 
(Vermeer, 1990). This post-translational modification occurs in the endoplasmic 
reticulum of the hepatocyte and is essential for this domain to bind calcium ions and 
negatively charged phospholipid surfaces. Exon IV (47 to 85) encodes the first (type B) 
epidermal growth factor-like domain which is homologous to epidermal growth factor 
(EGF) and has conserved carboxylate residues, including a (3-hydroxyaspartate at amino 
acid position 64 (Stenflo, 1991). This domain is involved in calcium ion binding 
(Handford et al., 1990) and may also bind factor VTII. Exon V (85 to 128) codes for the 
second (type A) epidermal growth factor-like domain whose function is not known. Exon 
VI (128 to 195) codes for the activation domain within which factorIX a is cleaved twice 
(at positions 145 and 180), thus activating factor IX. Exons VII (196 to 234) and VIII 
(234 to 415) encode the serine protease or catalytic domain which is responsible for the 
proteolytic activation of factor X to Xa. This region is homologous to other well studied 
serine proteases or chymotrypsin-like enzymes, and it is thought likely that the conserved 
residues, histidine-221 (encoded by exon VII), aspartate-269 and serine-365 (both 
encoded by exon VDI), all participate in the classical catalytic mechanism.
Factor IX is initially synthesised as a precursor molecule, some 40 residues longer 
at its N-terminus than the 415 amino acid peptide found circulating in the plasma. The 
sequential removal of the hydrophobic signal peptide and propeptide occur in the 
hepatocyte prior to secretion (Bristol et al., 1993). In addition to the y-carboxylation of 
the N-terminal glutamyl residues (Vermeer, 1990) and the partial |3-hydroxylation of 
aspartate at 64 (Stenflo, 1991), N-linked carbohydrate side chains are added at residues 
157 and 167 and an O-linked carbohydrate at serine-53 and 61 (Hase et al., 1990; 
Nishimura et al., 1992).
1.4 BIOCHEMICAL STUDIES
Screening tests of the coagulation cascade include the activated partial 
thromboplastin time (APTT) for the intrinsic system, prothrombin time for the extrinsic
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system and fibrinogen levels and thrombin time for the dysfibrinogenaemias. Tests used in 
the initial investigation of bleeding disorders include, APTT, prothrombin time, thrombin 
clotting time, bleeding time and platelet count. If an abnormality in any of these tests is 
observed, then the appropriate coagulation factors are assayed. In mild deficiencies, 
screening tests may not reveal the defect and a strong clinical suspicion may warrant a 
coagulation factor assay.
The activities of factor VIII and IX can be measured by functional or 
Immunological assays. The former activity is termed factor VH[:C and IX:C, respectively, 
and can be measured by clotting and chromogenic assays. The immunological activity, 
termed factor VTILAg and IX:Ag, respectively, are measured using polyclonal or 
monoclonal antibodies. Individuals with haemophilia A have a good correlation between 
the functional and antigenic assays, and factor VIII levels are either not detectable or are 
comparably reduced in most cases. In a few (-5%), however, a functionally defective 
protein is produced and the antigenic levels are considerably higher than the functional 
assay would suggest. The latter are termed cross-reacting-material positive (CRM+) 
haemophilia. A significantly higher proportion of haemophilia B (>30%) patients fall in 
this category (Bertina and Veltkamp, 1978; Kasper et al., 1977). Since these mutations 
affect mainly the function of an otherwise stable clotting factor molecule, delineation of 
these help in correlation with functionally important residues / domains of the protein 
(Tuddenham et al., 1991; McGinniss et al., 1993).
Although the factor VIII:C and IX:C levels vary widely among normal males (50- 
150 IU/dl), there is good correlation between levels of coagulant activity and clinical 
severity. Levels of <2, 2-5 and >5 IU/dl represent severe, moderate and mild clinical 
phenotypes, respectively.
Patients with von Willebrand's disease also have factor VIII deficiency. The vast 
majority of these patients can be distinguished from haemophilia A by the bleeding profile 
that mainly involves bruising and gastro-intestinal bleeding, von Willebrand factor antigen 
level and ristocetin cofactor activity. Rarely, however, a variant form of von Willebrand's 
disease, where the defect lies in the binding of factor VIII by vWF (Nishino et al., 1989; 
Mazurier et al., 1990; Gaucher et al., 1991), could be confused with haemophilia A. This
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condition mimics haemophilia A on standard laboratory tests and it is necessary to 
measure factor VIII-vWF binding to establish the diagnosis.
A particular problem arises when it comes to diagnosing female carriers of 
haemophilia A or B. Although a female carrier is heterozygous for the deleterious 
mutation at the factor VIII or IX locus and should theoretically have half the normal level 
of the concerned clotting factor, due to random X-inactivation this is not always the case. 
In the case of haemophilia A, the measurement of a ratio of factor VIII to vWF improves 
the accuracy of carrier prediction (Klein et al., 1977), but even this may result in 
misclassification of up to 30% of haemophilia A carriers (Antonarakis et al., 1985). The 
problem is even greater in haemophilia B, where 30-50% mutations result in a CRM+ 
phenotype. In this case, measurement of both, factor IX:C and factor IX antigen levels as 
a ratio helps to predict the carrier status. The reliance on only biochemical parameters for 
carrier assignment is not entirely satisfactory, and presently, the diagnosis of female 
carriers of haemophilia A and B is primarily performed by DNA-based methods.
1 GENETtQ PREDICTION
Due to the fact that the factor VTII and IX genes are affected by a heterogeneous 
group of mutations, of which the vast majority include single base alterations, no uniform 
direct mutation detection strategy is feasible for the genetic prediction of either of these 
conditions. Haemophilia A and B were among the first common genetic disorders for 
which linked markers became available to help with carrier assignment and prenatal 
diagnosis (Gitschier et al., 1985a,b; Antonarakis et al., 1985; Winship et al., 1984; 
Giannelli et al., 1984). Several intragenic and extragenic markers have since been 
described for this purpose. These were initially described as restriction fragment length 
polymorphisms (RFLPs) detected by Southern blotting and hybridisation with appropriate 
radiolabelled DNA probes. Although most of these RFLPs are still being used, they have 
now been replaced by polymerase chain reaction (PCR) based detection methods (Kogan 
et al., 1987; Kogan and Gitschier, 1990). Genetic prediction using the battery of 
polymorphic markers can predict the carrier status of up to 70% of female relatives (of
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familial cases) at risk. In addition to these di-allelic polymorphisms, a different class of 
PCR-based, highly polymorphic dinucleotide repeat elements have been identified, which 
greatly increase the feasibility and accuracy of genetic prediction (Lalloz et al., 1991).
Gene tracking using linked markers has certain distinct disadvantages. A family 
segregation analysis entails the collection of samples from a number of individuals, some 
of whom may be either dead, otherwise unavailable or even unwilling to comply. In order 
to be able to differentiate between the two X chromosomes in a carrier female, the 
individual has to be heterozygous (informative) for these markers. Even though a large 
number of RFLPs have been identified in and around the factor VIII and IX genes, it is 
not always possible to get informative markers (although this is now changing due to the 
availability of highly polymorphic repeat elements). Another problem is the reduction in 
the useful information from multiple markers because of a high percentage of linkage 
disequilibrium amongst the markers (Connor et al., 1986; Kogan and Gitschier, 1990). 
For the large factor VIII gene, recombination between the causative mutation and the 
linked marker may necessitate the use of flanking markers. A third of haemophilia cases 
represent new mutations (true sporadic cases) and therefore it is not possible to use this 
system, which essentially relies on the assumption that one of the X chromosomes of the 
mother of the affected male bears the causative mutation. This is further complicated by 
the possibility of gonadal mosaicism. Interpretation of the segregation analysis relies on 
the accuracy of the pedigree information obtained. This is clearly not always the case, as 
was exemplified by the finding of a relatively high level of non-paternity among 
haemophilia B families in the West of Scotland (Bidichandani, 1991).
1.6 MUTATION ANALYSIS
1.6.1 IMPORTANCE OF MUTATION DETECTION
In the field of human genetics, detection of naturally occurring germline/somatic 
mutations are used to determine whether a candidate gene is causally related to a 
phenotype or to identify new alleles at a known locus. The latter involves the detection of
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novel and recurrent mutations in previously characterised genes. While the former is 
essential to confirm the causative role of a particular gene in the pathogenesis of human 
disease, the latter expands on the biological properties of the gene/protein and is useful 
for genetic diagnosis. Analysis of mutations at a previously characterised locus allow the 
determination of: (i) mutational spectrum, for example: -65% of patients with 
Duchenne/Becker muscular dystrophy (DMD/BMD) have large deletions (den Dunnen et 
al., 1989), >80% of haemophilia B patients have point mutations (Giannelli et al., 1993)
(ii) mutational distribution and the identification of hotspots, for example: deletion 
hotspots in the dystrophin gene (Forrest et al., 1987, 1988; Wapenaar et al., 1988) and 
the clustering of mutations affecting the first nucleotide-binding fold of the CFTR gene 
(exon 11) in cystic fibrosis patients (Cutting et al., 1990), (iii) identification of functional 
domains in proteins, for example: the GAP-related domain in the neurofibromatosis type 
1 gene (Li et al., 1992), (iv) population genetics, for example: the geographic variation in 
the frequency of the AF508 mutation in Europe (European Working Group on CF 
Genetics, 1990), (v) identification of novel mechanisms of mutagenesis, for example: 
trinucleotide repeat expansions in fragile X syndrome (Fu et al., 1991; Verkerk et al., 
1991; Oberle et al., 1991; Yu et al., 1991) and myotonic dystrophy (Harley et al., 1992; 
Buxton et al., 1992) and (vi) the role of somatic mutations, for example: in the ras group 
of oncogenes in human malignancies (Bos, 1989).
At the start of the present project, the molecular pathology was not known in 
about 50% of severe haemophilia A patients (Higuchi et al., 1991a,b). This meant that the 
knowledge of the spectrum and distribution of factor VIII mutations was probably 
incomplete. Although various site-directed mutagenesis studies and other in vitro studies 
have contributed to an understanding of the structure-function relationship of the factor 
VIII protein, this knowledge is rather limited (reviewed by Pittman and Kaufman, 1989). 
It is hoped that with careful cataloguing and analysis of many naturally occurring factor 
VIII mutations, a better understanding of the functions of the various domains of the 
factor VIII protein might be possible (Tuddenham et al., 1991).
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1.6.2 METHODOLOGY OF MUTATION DETECTION
In general, the methods for the detection of mutations can be subdivided into 
those that are designed to predominantly detect small or large sequence alterations. The 
detection of mutations has been revolutionised with the introduction of PCR technology 
(Saiki et al., 1988) and presently, the detection of small sequence alterations is almost 
exclusively performed by PCR-based methods (Grompe, 1993). The methods for the 
detection of large mutations include the use of Southern blotting (Southern, 1975), pulse 
field gel electrophoresis (PFGE; Smith et al., 1988) and Northern blotting (Alwine et al., 
1977).
The strategy used for the detection of mutations greatly depends on the known 
(or expected) spectrum of mutations affecting a particular gene. This usually means 
tailoring the strategy to suit a particular disease. For example in DMD/BMD, where the 
majority of cases have gross deletions (or duplications), either Southern blotting or PFGE 
is used as an initial screen. As the dystrophin gene is on the X-chromosome, hemizygous 
males are detected with relative ease. With the identification of deletion hotspots and the 
optimisation (and commercial availability) of a multiplex PCR strategy (Chamberlain et 
al., 1988), it is now possible to rapidly detect the deletion in -60% of cases. In a disease 
like Charcot-Marie-Tooth disease type 1A where >90% cases are due to a large DNA 
duplication involving a 1.5 Mb monomer unit (Lupski et al., 1991), PFGE is used as the 
first diagnostic test before using other PCR-based methods to detect smaller sequence 
alterations (Roa et al., 1993).
Both, genomic DNA and mRNA can be used as templates for the PCR-based 
mutation detection strategies. The advantage of using mRNA (reverse transcribed to 
cDNA) as the template are, that large non-coding regions are omitted thus permitting the 
analysis of a potentially smaller target region (with fewer PCRs) and the rapid detection 
of gross deletions or splicing errors. Until recently, this was not possible for genes 
expressed in specific tissues (example dystrophin). Chelly et al. (1988,1989) and Sarkar 
and Sommer (1989) demonstrated that all genes were expressed in all cell types, albeit at 
low levels. This made it possible to exploit the extreme sensitivity and specificity of PCR 
to analyse cDNAs of large tissue-specific genes for the detection of disease causing
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mutations (Roberts et al., 1990; Berg et al., 1990; Naylor et al., 1991). For small genes 
with fewer exons, it is possible to achieve the amplification of the entire essential 
sequence using a few DNA-based PCRs (example for the p-globin gene).
Mutations (especially small sequence alterations) are ultimately characterised by 
nucleotide sequencing. It is now possible to directly sequence PCR products without the 
necessity for prior cloning (Gyllensten, 1989). In order to avoid having to sequence the 
entire amplified template, several mutation screening strategies have been developed and 
used with varying degrees of success (Grompe, 1993). The various strategies have 
varying capacities for mutation detection and localisation. Some genes with relatively 
short coding sequences have been directly sequenced in order to detect mutations 
(porphobilinogen deaminase cDNA in acute intermittent porphyria, Mgone et al., 1992). 
The most commonly used mutation screening methods include, (i) analysis of single 
strand conformation polymorphisms (SSCP; Orita et al., 1989), (ii) heteroduplex analysis 
(HA; White et al., 1992), (iii) denaturing gradient gel electrophoresis (DGGE; Fischer 
and Lerman, 1983; Myers et al., 1985a), (iv) chemical cleavage of mismatches (CCM; 
Cotton et al., 1988) and (v) direct sequencing (Gyllensten, 1989).
SSCP is based on the principle that the electrophoretic mobility of a single 
stranded DNA molecule is a function of both its length and its nucleotide sequence. 
Double stranded PCR products when denatured and electrophoresed on a non-denaturing 
polyacrylamide gel (under conditions that enhance the formation of conformations in 
single strands), show altered mobilities caused by differences as small as single base pair 
substitutions. The detectability is greatly increased in smaller sized PCR products, being 
-79-95% in <200 bp segments, and rapidly falls to <50% when the size is >400 bp 
(reviewed by Hayashi, 1991 and Grompe, 1993). HA is based on the principle that the 
heteroduplex formed between wild-type and mutant DNA segments has a different 
secondary structure from either wild-type or mutant homoduplexes, and would be 
detected as altered electrophoretic mobilities on non-denaturing gels. White et al. (1992) 
reported a higher detectability rate than SSCP, but since the same PCR product can be 
used for both methods, it is possible to potentially complement each technique. 
Furthermore, novel gel matrices have been developed (Hydrolink™ and MDE™; Hoefer)
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in order to increase the sensitivity of SSCP and HA. DGGE is based on the principle that 
when double stranded DNA is electrophoresed through a gradient of denaturant, it 
migrates up to a certain point where the strands melt and no further migration occurs 
(Fischer and Lerman, 1983). Since the melting behaviour of a double stranded DNA 
molecule is the function of its nucleotide sequence (melting domains), a single base 
substitution in a heteroduplex can be detected as an altered mobility on such a denaturing 
gradient gel. Incorporation of GC-clamps (at the 5' ends) increases the sensitivity of this 
method to over 90%. This method however requires the use of specialist equipment, 
longer primers with GC-clamps and does not accurately localise the mutation in a given 
DNA segment.
CCM is a mutation detection method that has the potential for detecting and 
accurately localising all mutations in a given PCR product. Unlike SSCP, HA and DGGE, 
it is not dependent on the size of the DNA fragment being analysed (up to 1.7 kb, 
Grompe, 1993) or the electrophoretic conditions. This method however is lengthy, 
complicated and makes use of toxic chemicals. CCM is based on the chemical reactivity 
of mismatched "C" or "T" bases in DNA-DNA hybrids, that make them susceptible to 
cleavage with piperidine (Cotton et al., 1988). This method is not only extremely 
sensitive but also aids in the accurate localisation of the mutation by estimation of the size 
of the cleavage product. Prior to the description of this method, other less sensitive 
methods had been described that were based on a similar principle. Cleavage of the single 
stranded mismatch was attempted using SI nuclease (in DNA-DNA hybrids; Shenk et al., 
1975), RNase A (in RNA-DNA hybrids; Myers et al., 1985b) and reactivity with 
carbodiimide (in DNA-DNA hybrids; Novack et al., 1986).
Finally, all positive mutation screening results have to be completely characterised 
by nucleotide sequencing. Direct sequencing of PCR products has also been used as the 
primary mutation screening method to detect mutations in parts of large genes (Higuchi 
et al., 1990) or by sequencing entire coding sequences (Mgone et al., 1992). This is 
however very labour intensive and perhaps even unnecessary due to the availability of 
various rapid mutation screening methods. In the direct sequencing of PCR products, the 
quality of sequence was shown to be superior when a preliminary asymmetric PCR was
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performed in order to generate single stranded PCR products (Gyllensten and Ehrlich, 
1988; Gyllensten, 1989; Mgone et al., 1992).
Mutations that have been detected by the above methods may need to be screened 
for the purpose of familial segregation or population studies. This can be easily achieved 
by one of the following methods: (i) restriction enzyme digestion (if a site has been 
created or abolished), (ii) allele-specific oligonucleotide discriminant hybridisation (ASO; 
Connor et al., 1983), (iii) allele-specific PCR amplifications (ASA/ARMS; Wu et al., 
1989; Sarkar et al., 1990) or (iv) the same screening method that was used to detect it 
originally (example SSCP or HA).
1.7 DETECTION OF MUTATIONS IN THE FACTOR VIII GENE
1.7.1 DIFFICULTIES ASSOCIATED WITH DETECTION OF MUTATIONS IN 
THE FACTOR VIII GENE
The main factors complicating the detection of mutations in the factor VIII gene 
are: (i) a mutational spectrum that largely comprises point mutations, (ii) the high de novo 
mutation rate with the consequence that most unrelated patients have unique mutations,
(iii) the large size of the gene and (iv) the hepatocyte-specific expression of factor VUI.
Haemophilia A, with an incidence of 1 in 5000 males, is a relatively common 
monogenic disease affecting man. Unlike other common genetic diseases like cystic 
fibrosis (CF), Charcot-Marie-Tooth disease type 1A (CMT1A), fragile X syndrome and 
Duchenne/Becker muscular dystrophy (DMD/BMD) that are mainly caused by one 
common mutation or type of mutation, a heterogenous group of mutations have been 
reported in the factor VIII gene of haemophilia A patients (Tuddenham et al., 1991). 
Recently a novel mechanism of mutagenesis was discovered that implicated the sequence 
of F8A, a gene embedded in intron 22 of the factor VIII gene, in the causation of half the 
severe cases of haemophilia A (Lakich et al., 1993; Naylor et al., 1993b). However, the 
vast majority of patients, perhaps over 70%, have a variety of single base substitutions. 
Due to the high de novo mutation rate affecting the factor VTII gene, the vast majority of
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these are unique mutations (a few recurrences have nevertheless been reported, 
Tuddenham et al., 1991). The fact that unique single base substitutions (or small 
sequence alterations) have to be identified in the vast majority of haemophilia A patients, 
is the main reason complicating the analysis of factor VTII mutations.
Furthermore, the factor VIII gene is very large, comprising 26 exons, scattered 
over 186 kb of genomic DNA (Gitschier et al., 1984). The factor VIII gene produces a 9 
kb, hepatocyte-specific transcript, that codes for a single polypeptide of 2332 amino acids 
preceded by a 19 amino acid hydrophobic leader sequence (Wood et al., 1984; Toole et 
al., 1984; Vehar et al., 1984). For this reason, until recently, most groups have only 
screened limited sections of the factor VIII gene (Gitschier et al., 1985c; Higuchi et al., 
1990; Pattinson et al., 1990a; Traystman et al., 1990). Recently however, at least four 
groups have screened the entire essential sequence of the factor VTII gene i.e., including 
the complete coding sequence, splice sites, putative promoter and polyadenylation /  
cleavage sequences (Higuchi et al., 1991a,b; Naylor et al., 1991, 1993a; Diamond et al., 
1992; Lin etal., 1993).
The factor VIII mRNA is expressed predominantly in hepatocytes and represents 
about 5% of the size of the factor VIII gene (Gitschier et al., 1984; Wood et al., 1984; 
Toole et al., 1984). There are several advantages in searching for mutations within the 
factor VIII mRNA. These include: (i) screening of a relatively shorter target region is 
required (due to the exclusion of large intronic sequences), (ii) screening of only the 
coding sequence increases the probability for most mutations to be pathogenic and (iii) 
errors of splicing and large gene alterations are readily detectable. Until the discovery of 
ectopic / illegitimate transcription, it was thought that liver biopsies would be required to 
allow such an analysis. Chelly et al. (1988) discovered spliced dystrophin transcripts 
(normally expressed in muscle and brain) in cultured fibroblasts, lymphoblasts and Hep 
G2 hepatoma cells. They and others later reported (Chelly et al., 1989; Sarkar and 
Sommer, 1989) the detection of spliced forms of a variety of tissue-specific mRNAs in 
various cell types i.e., concluding that any gene was transcribed (albeit at low levels) in 
any cell type. Chelly et al. (1988) estimated that these illegitimate or ectopic transcripts 
were expressed at a level of less than 1 in every 500 to 1000 non-specific cells. The
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discovery of this amazing phenomenon obviated the need to obtain cells that 
predominantly express a tissue-specific gene. In fact recently, RT-PCR of various large 
tissue-specific mRNAs have been used as templates for various mutation screening 
strategies (Berg et al., 1990; Chelly et al., 1991; Chalkey and Harris, 1991; Roberts et al., 
1991,1992; Naylor et al., 1991,1993a; Fonknechten et al., 1992). In order to facilitate a 
comprehensive search for mutations, the method described by Naylor et al. (1991,1993a) 
i.e., using a combination of RT-PCR of ectopic transcripts and DNA-PCR to amplify the 
entire essential sequence of the factor VIII gene, was employed in this project.
1.7.2 MUTATIONAL SPECTRUM IN HAEMOPHILIA A
Haemophilia A is the most common severe inherited disease of blood coagulation, 
affecting approximately 1 in 5,000 males. It is caused by a heterogeneous group of 
mutations, predominantly point mutations, affecting the factor VUI gene.
By analysing the factor VIII coding sequence, adjacent intron sequences, putative 
promoter and polyadenylation signal sequences in DNA, Higuchi et al. (1991a,b) aimed 
to define the causative mutation in every haemophilia A patient analysed. Mutations were 
found in almost all the mild and moderate cases, but were identified in only about half of 
the severe cases. This led to speculation that causative mutations in these cases might lie 
outside the regions analysed, for example, in other expression regulatory elements, within 
introns or even at another (tightly linked) locus. Subsequently, Naylor et al. (1992, 
1993a) made a discovery using RT-PCR of ectopic factor VIII mRNA transcripts, that it 
was not possible to perform an amplification across the junction of exons 22 and 23 in 
40% of their severe cases, whereas, amplification on either side yielded products of the 
expected size. Naylor et al. (1992, 1993a) concluded that changes in intron 22 were 
responsible for half the cases of severe haemophilia A.
Intron 22 is the largest intron in the factor VUI gene and has two genes emanating 
from a CpG island within it (Levinson et al., 1990, 1992). F8A, which is fully embedded 
in intron 22 and transcribed in a direction opposite to that of factor VUI, has two 
additional copies approximately 500 kb upstream of the factor VUI gene (Patterson et al., 
1989; Levinson et al., 1990; Freije et al., 1992; Lakich et al., 1993). It was subsequently
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shown by two groups (Lakich et al., 1993; Naylor et al., 1993b) that the mutation 
affecting half the severe cases of haemophilia A was due to a homologous recombination 
between the intron 22 embedded copy of F8A and one of the two additional copies 
upstream (telomeric on the X chromosome) of the factor VIII gene. This crossover 
results in a large inversion, dividing the factor VIII gene into two parts, with an intact 
promoter and exons 1-22 greatly separated from, and in opposite orientation to exons 23- 
26. At least six groups have now shown that this mutation is responsible for up to 45% of 
all severe cases or approximately 20% of all haemophilia A patients (Lakich et al., 1993; 
Naylor et al., 1993a; Goodeve et al., 1994; Collins et al., 1994; Ljung, 1994; Tizzano et 
al., 1994). It was observed that, of the two homologues of F8A, recombination with the 
distal copy was more common than with the proximal one (Collins et al., 1994; Ljung,
1994). A rare third variant pattern was seen on Southern blot analysis, that indicated the 
presence of additional copies of F8A (Collins et al., 1994 observed it in 1 of their 40 
patients with this inversion; Ljung, 1994 observed it in 1 of their 19 inversion cases; 
Rossiter et al., 1994). Furthermore, Rossiter et al. (1994) tested and confirmed their 
hypothesis that this inversion was possible only in male meiosis, probably because the 
lone X chromosome does not have a homologue to pair with.
The rest of the severe haemophilia A cases are caused by a variety of mutations 
including, minor and major gene deletions or insertions and point mutations that include 
nonsense, missense and those causing errors of splicing (Tuddenham et al., 1991). The 
frequency of large deletions of the factor VTII gene determined by Southern blotting in a 
recent study of pooled data was 2.5% (34 out of 1386 haemophilia A patients; Millar et 
al., 1990). The frequency of small deletions / insertions (ranging between 1 - 2 3  bp) was 
determined to be about 7% of all haemophilia A patients, in a comprehensive search for 
mutations by Higuchi et al. (1991a,b). Over 60 partial deletions have been incorporated in 
the database of all mutations affecting the factor VTII gene (Tuddenham et al., 1991). All 
but 3 of these result in a severe phenotype. Three in-frame deletions, two of exon 22 and 
one involving exons 23 and 24 resulted in moderately severe haemophilia A. No evidence 
of hotspots have been identified for the large deletions. Two of the small deletions 
described in the database (involving 2 and 4 bp) occurred in the same amino acid position
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340-341 and involved the postulated deletion hotspot consensus sequence of Krawczak 
and Cooper (1991). Antonarakis and Kazazian (1988) reported in two patients with 
severe haemophilia A, insertions of partial LINE-1 (LI) repeat elements. Both insertions 
were in exon 14, involved the 3' portions of the LI sequence (including the poly (A) 
tract) and occurred within 12-13 nucleotide duplication sites.
Mild and moderate haemophilia A on the other hand, almost always results from a 
wide variety of missense mutations that presumably affect regions important for factor 
VIII function and/or stability. In general all nonsense mutations result in severe disease 
and all point mutations causing mild and moderate phenotypes are of the missense type 
(Tuddenham et al., 1991).
An excess of point mutations are reported to affect exons 8, 14, 18, 23, 24 and 
26. This is likely to be due to the large size of exons 14 and 26 and due to the fact that 
mutations at CpG sites in exons 18, 23, 24 and 26 were specifically looked for using 
restriction digestion (Gitschier et al., 1985c). Evidence from groups searching the entire 
factor VIII coding sequence and from the database of haemophilia A mutations, suggest 
that there may be a disproportionate harbouring of mutations in the small exons 7, 11, 12 
and 16 (Tuddenham et al., 1991).
38% of point mutations reported in the haemophilia A mutation database are at 
hypermutable CpG dinucleotides resulting in CG-»TG/CA substitutions. This is 
consistent with deamination of the methylated cytosine (5-methyl cytosine) to thymine, 
which is not corrected by the DNA repair mechanisms and results in either of the above 
changes depending on its occurrence on the sense or antisense strand (Cooper and 
Youssouffian, 1988; Cooper and Krawczak, 1990). The true frequency is probably lower, 
perhaps 32% as gathered from Higuchi et al. (1991a,b), because some of the point 
mutations reported in the database have been detected by the deliberate screening for 
CpG dinucleotide mutations (Gitschier et al., 1985c, 1988; Pattinson et al., 1990a). There 
are a total of 71 CpG dinucleotides in the factor VIII cDNA and recurrent mutation in at 
least 16 such sites has been reported in unrelated haemophilia A patients (Tuddenham et 
al., 1991). A similar directed search for nonsense mutations at 12 CpG sites was
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conducted by Reiner and Thompson (1992). Recurrence at non-CpG sites is rarely seen 
and when seen, identity by descent may account for the majority of these.
About half of all haemophilia A patients have no detectable factor VIII protein 
levels (termed Cross Reacting Material Negative, CRM") and -5% have an excess of 
factor VIII antigen over functional activity due to the presence of a dysfunctional factor 
VIII molecule (termed Cross Reacting Material Positive, CRM+). About 45% have 
reduced factor VIII levels comparable to the reductions in factor VTII coagulant activity 
(CRM reduced). Mutations resulting in the CRM+ or CRM reduced phenotype are 
considered to be those that affect sites critical for factor VIII function. Indeed CRM+ 
haemophilia A has been caused by recurrent mutations in the two arginine residues at 372 
and 1689 (Gitschier et al., 1988; Arai et al., 1989a, 1990; Shima et al., 1989; Higuchi et 
al., 1990; Pattinson et al., 1990a,b; Schwaab et al., 1991), which are thrombin cleavage 
sites for the proteolytic activation of factor VIII. This phenotype was also seen with a 
missense mutation affecting the putative binding site for von Willebrand factor (Y1680F; 
Higuchi et al., 1990). In this respect, it is important to identify those mutations resulting 
in a CRM+ phenotype in order to delineate those residues critically important for factor 
VIII function. In one such study, 11 of the 26 mutations resulting in a CRM+ or reduced 
phenotype were found to affect the A2 domain of factor VIII (McGinniss et al., 1993).
Inhibitor development is an important complication associated with factor VIII 
replacement therapy (seen in -20% of those who receive exogenous factor VIII). 
Deletion of the factor VIII gene is associated with a five-fold higher risk of this 
complication. Inhibitor development has been reported for 12 patients with point 
mutations described in the database of mutations causing haemophilia A (Tuddenham et 
al., 1991). Ten of these are in severe haemophiliacs with nonsense mutations. Goodeve et 
al. (1994) reported that none of their 10 patients with the intron 22-mediated inversion 
mutation developed inhibitors, whereas 7 of 12 without the inversion did. Two 
subsequent studies showed this to be atypical and thus ruled out any such correlation 
(Ljung, 1994; Tizzano et al., 1994).
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1.8 GENE THERAPY
1.8.1 DEFINITIONS
Gene therapy is defined as "the transfer of genetic material into the cells of an 
organism to treat disease" (Miller, 1990). Although theoretically it is possible to transfer 
genetic material into both somatic (somatic gene therapy) and germ cells (germline gene 
therapy), for socio-ethical (and medical) reasons only somatic cells are presently being 
targeted. This has led to some investigators defining gene therapy as "the delivery of a 
functional gene for expression in somatic tissues with the intent to cure disease" (Mitani 
and Caskey, 1993). A document published by the Center for Biologies Evaluation and 
Research at the Food and Drug Administration (FDA) in the USA (1991), used a similar 
definition but extended the application of somatic gene therapy for prophylactic and 
diagnostic uses as well. So far there has not been much success with homologous 
recombination (Smithies et al., 1985) to correct a defective gene by physically replacing it 
i.e., "replacement therapy". At present, therefore, gene therapy can be regarded as "gene 
supplementation" since it involves the addition of corrective genes to the host cell 
genome (Akhurst, 1989). Consequently, most work has focused on the treatment of 
recessive single gene disorders.
Somatic gene therapy can be delivered by either an ex vivo or in vivo approach. In 
the ex vivo approach, cells are first harvested from an in vivo site and then expanded and 
manipulated in vitro. This is then followed by re-implantation of the genetically modified 
cells. The type of cells used for the ex vivo approach can be described as either 
autologous, allogenic or xenogenic living cells. Manipulation of cells ex vivo, may involve 
propagation, expansion, selection, and pharmacological or other biological modifications. 
Genetically modified cells can be returned by infusion, injection or surgical implantation. 
Advantages of the ex vivo approach are: (i) gene-transfer efficiency is generally high and 
a wide variety of transfer methods can be used, (ii) the transduced cells can be enriched if 
the vector has a selectable marker and the (iii) successful transduction and expression can 
be assessed before re-implantation. The in vivo approach involves the direct transfer of 
genes to cells residing in the body. Problems associated with this method include: (i)
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requirement for a means of targeting the desired cell type or achieving tissue-specific 
expression, (ii) sufficient numbers of cells should be transduced, (iii) association with a 
low efficiency of stable gene transfer necessitates repeated treatment and (iv) problems 
with host immune response.
Proposals for gene therapy made by research groups are reviewed by various 
governmental bodies. In the USA various guidelines for human gene transfer have been 
adopted by the Recombinant DNA Advisory Committee (RAC; 1990) and the FDA 
(1991). The principle concerns include the safety of the procedure (for both the patient 
and the general public) and the anticipated benefit in comparison to the potential risk of 
the procedure. Since the first approved gene marking trial in 1989 (Rosenberg et al., 
1990) and the first gene therapy trial in 1990 (Culver et al., 1991), many more clinical 
trials have been approved (Anderson, 1992; Miller, 1992). It is also now clear that even 
though the initially intended targets for this form of therapy were largely single gene 
disorders, acquired diseases such as malignancies and ADDS have recently become the 
focus of much attention (Anderson, 1992; Miller, 1992; Mulligan, 1993). On the whole, 
somatic gene therapy is now generally viewed as a viable and ethical therapeutic option 
for the treatment of serious disease (Anderson, 1992).
1.8.2 GENE DELIVERY SYSTEMS
Highly efficient gene transfer is essential for gene therapy. Several technologies 
have been considered to be applicable for human gene transfer. Although, the most 
successful and commonly used method includes the use of viral vectors, many non-viral 
methods are also promising.
Viral vectors
The use of viruses as gene transfer vehicles arose from the observation that 
viruses are extremely efficient at introducing genes into their host cells, and that they 
might therefore be useful as vectors for introducing genes in order to correct genetic 
diseases in man. It was proposed that if the deleterious features of these viruses were 
eliminated, they might be able to safely deliver a desirable gene to correct cellular defects 
caused by genetic disorders (Anderson, 1984; Freidmann, 1989).
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Retroviral vectors are the best characterised viral vectors for human gene transfer 
and were the first to be employed in human gene therapy clinical trials (Culver et al., 
1991; Anderson, 1992). Retroviral vectors transduce dividing cells in culture with an 
efficiency approaching 100% and stably integrate into the host cell genome without 
causing gross rearrangements. Although these vectors are ideal for ex vivo applications, 
several features of the transfer method may limit their applicability, particularly with 
regard to in vivo therapies. First, retroviral entry into cells is absolutely dependent on the 
existence of appropriate viral receptor on the target cell. Although packaging cell lines 
that generate vectors with a wide host range have been developed (Miller, 1990), 
problems have still been encountered in the transduction of certain cell types. Secondly, 
replication of the target cell is a prerequisite for proviral integration to occur. It is for this 
reason that it is necessary to perform partial hepatectomies in order to achieve a 
reasonable efficiency of hepatocyte transduction (Kay et al., 1993). Thirdly, the retroviral 
particle is relatively labile in comparison to other viruses and is rapidly inactivated in vivo 
in primates (Mulligan, 1993). In addition, questions regarding the safety of the procedure 
were raised after three monkeys recently developed malignant T-cell lymphomas after the 
transplantation of bone marrow that had been retrovirally transduced (due to 
contamination with helper virus; Miller, 1992).
Adenoviral vectors are capable of transducing a wide variety of cells and may be 
particularly attractive when considering gene transfer into non-dividing cells in vivo. (e.g. 
airway epithelium: Rosenfeld et al., 1991; 1992; cardiac and skeletal muscle: Stratford- 
Perricaudet et al., 1992; Ragot et al., 1993; central nervous system: Davidson et al., 
1993; Akli et al., 1993; Bajocchi et al., 1993; hepatocytes: Smith et al., 1993). They are 
structurally stable and can be prepared at high titre (109-1011 plaque forming units per 
ml, as opposed to 106 for retroviral vectors) making them suitable for in vivo delivery. In 
addition, US military recruits vaccinated with wild type adenoviruses showed no side 
effects, demonstrating their safety for human use (Mitani and Caskey, 1993). Adenoviral 
vectors however, do not result in stable integration into the host cell genome. This 
feature may be advantageous from the point of view that insertional mutagenesis would 
not occur, but makes it necessary to perform repeated deliveries. Gene transfer with
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adenoviral vectors in vivo has been complicated by the immune response that develops 
against the administered adenoviral particles, which also neutralises the effect of any 
further administrations (Smith et al., 1993).
Vectors derived from the non-pathogenic human adeno-associated virus (AAV) 
are also promising tools for human gene transfer. They specifically integrate into a region 
in chromosome 19. They however have a limited substitution capacity of -5 kb and 
although not pathogenic themselves, they require co-infection with helper adenoviruses 
or other herpes viruses which may contaminate AAV stocks. Herpes simplex virus type 1 
(HSV-1) vectors have been found to be useful for gene delivery to post-mitotic neurons. 
In common with adenoviruses, they too are not integrated into the host cell genome. 
Recently, the Sendai virus (Haemagglutinating virus of Japan [HVJ]; Kaneda et al., 1989) 
has been used for efficient in vivo delivery of genes (Dzau et al., 1993). In this method 
foreign DNA is complexed with liposomes, a nuclear protein and the viral protein coat of 
HVJ.
Non-viral delivery systems
The efficiency with which intact viruses introduce genes into cells led to the 
search to identify synthetic systems that could emulate viral delivery while avoiding viral 
infectivity. Cationic liposomes (cytofectins) have been developed that are much more 
efficient than the conventional liposome preparations which had much lower 
encapsulation and transfection efficiencies (Feigner and Ringold, 1989; Nabel and 
Feigner, 1993). Cationic-lipid-mediated gene transfer has been shown to be effective as 
an in vivo delivery system, by direct administration to the lung using aerosols or 
intubation (Yoshimura et al., 1992; Stribling et al., 1992).
In addition, direct application to the skin surface (Bums et al., 1991), 
intramuscular injections (Wolff et al., 1990), high energy microprojectile bombardment 
(Williams et al., 1991) and catheter-based delivery (Nabel et al., 1990; 1992) of genetic 
material have all been shown to be effective as in vivo delivery systems. The polylysine- 
ligand conjugate system (Wu et al., 1987; Cotten et al., 1992) has also shown promise as 
an alternate to viral methods for in vivo gene delivery. Transfenin-polylysine to target 
transferrin receptors (Wagner et al., 1992) and asialoglycoprotein-DNA conjugates to
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target asialoglycoprotein receptors (Wu et al., 1991) have been shown to achieve 
hepatocyte-specific delivery.
1.8.3 CANDIDATE DISEASES AND TARGET TISSUES
Research in gene therapy has focused on a variety of diseases, most of which 
include recessive single-gene disorders that can be corrected by the addition of a 
functional gene. In cases like the clotting factor deficiencies resulting in the haemophilias, 
almost any somatic cell can be targeted, as long as the biologically-active gene product 
can enter the systemic circulation. On the other hand, correction of various diseases 
require the corrective gene product to be expressed in a tissue-specific manner, for 
example, p-globin in haematopoietic cells (in p-thalassaemia) and dystrophin in skeletal 
muscle cells (in Duchenne muscular dystrophy). Acquired diseases such as cancer, AIDS, 
certain cardiovascular and neurological disorders have also been considered as suitable 
candidates for somatic gene therapy.
In general, for the ex vivo strategy to be effective, it is necessary to select cells 
that can be easily obtained (biopsied) and manipulated in vitro. The in vivo approach is 
particularly attractive for those organs or tissues that cannot be easily accessed, as in the 
case of neurological or cardiovascular disorders. The various tissues that have been 
considered as suitable targets for somatic gene therapy include, haematopoietic stem 
cells, lymphocytes, hepatocytes, airway epithelial cells, fibroblasts, myoblasts, endothelial 
cells and keratinocytes.
Preclinical studies in the case of those diseases where the gene product needs to 
be delivered to the systemic circulation have generally been more successful than when a 
specific cell type has to be targeted. In this case the choice of target cells is governed by 
certain practical considerations: (i) the ease of isolation, (ii) feasibility of culture and 
genetic manipulation in vitro, (iii) half-life of the cells in vivo, (iv) capacity of the cells to 
express and actively secrete the particular protein, including the capacity to carryout 
post-translational modifications necessary for biological activity and (iv) capacity to make 
contact with the general circulation. More recently researchers have started using primary 
cells as opposed to established cell lines. Although a wide variety of cells have been used,
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most progress has been made in the transplantation of transduced fibroblasts, myoblasts 
and keratinocytes (Mulligan, 1993). They are all readily explanted, grown in culture, 
genetically modified and transplanted. Fibroblasts can be returned to the body by 
subdermal injections. Considerable experience has been gained in grafting keratinocytes 
to heal epidermis in human bums patients (Gallico et al., 1984; Compton et al., 1989). 
Myoblasts injected directly into skeletal muscles fuse with existing muscle cells and 
continue to express the transferred gene (Dhawan et al., 1991; Dai et al., 1992). Each of 
these cell types have been induced to produce a variety of gene products following 
transduction with retroviral vectors. Fibroblasts have been made to express adenosine 
deaminase (ADA), glucocerebrosidase, purine nucleoside phosphorylase, low density 
lipoprotein receptors (LDL-R), factor VIII and factor IX. Myoblasts and keratinocytes 
have both been induced to produce factor IX (Dai et al., 1992; Gerrard et al., 1993) and 
growth hormone (Dhawan et al., 1991; Morgan et al., 1987; Teumer et al., 1990).
Success with somatic gene therapy when specific cell types have to be targeted 
has been less frequent. The most successful example was the transduction of autologous 
T-lymphocytes with retroviral vectors expressing the human adenosine deaminase (ADA) 
gene (Culver et al., 1991; Anderson, 1992). Many groups have reported transfer and 
long-term expression of genes into mouse haematopoietic stem cells (reviewed in Miller,
1990), but similar success has not been achieved in larger animals, like monkey or dog 
(Miller, 1990; 1992). The main problems in the transduction of haematopoietic stem cells 
are their sparse population, primarily quiescent nature and the unavailability of an 
effective assay to identify and quantify them. Moreover, transduction of haematopoietic 
stem cells with retroviral vectors expressing the (3-globin gene did not yield high levels of 
expression (Dzierzak et al., 1988; Bender et al., 1989, Bodine et al., 1989), and has been 
one of the main reasons for the delay in progress towards gene therapy for (3 thalassaemia 
(which was the focus for most of the initial research in gene therapy; Anderson, 1992). 
Diseases such as hyperammonaemia due to ornithine transcarbamylase (OTC) deficiency, 
phenylketonuria and disorders of cholesterol metabolism are due to mutations that affect 
hepatic function and are considered to be candidate diseases for somatic gene therapy. 
Hepatocytes are natural targets for the correction of these disorders. Hepatocytes cannot
41
be extensively manipulated in vitro because they undergo only a few cell divisions and 
transduction efficiencies with retroviral vectors is rather low (Chowdhury et al., 1991). 
Both ex vivo and in vivo methods have been investigated. Obviously the in vivo methods 
would be more appropriate for clinical application. Both, adenoviral (Jaffe et al., 1992; 
Smith et al., 1993) and retroviral (Ferry et al., 1991, Kay et al., 1993) vectors have been 
shown to be efficient methods for direct gene delivery to the liver. Retroviral vectors 
require that the hepatocytes be actively proliferating, which has been achieved by partial 
hepatectomies (Kay et al., 1993). Adenoviral vectors do not integrate in the genome and 
their effect is therefore short-lived and re-infection does not result in a similar beneficial 
effect as with the first infection (Smith et al., 1993). Asialo-glycoprotein receptors have 
been exploited for in vivo delivery to the liver (Wu et al., 1991). Herpes simplex virus 
(type 1) vectors (HSV-1) have been used to effect in vivo gene delivery to the central 
nervous system (Breakfield and DeLuca, 1991; Friedmann and Jinnah, 1993). Respiratory 
epithelium has been targeted in vivo using direct instillation of adenoviral vectors 
(Rosenfeld et al., 1991,1992) and by lipofection (Yoshimura et al., 1992).
More recently, acquired diseases have been considered as suitable targets for 
somatic gene therapy. Several modalities are being considered for the treatment of 
malignant disease and AIDS (Mulligan, 1993). Preclinical experiments for therapy of 
cardiovascular diseases (e.g. familial hypercholesterolaemia, restenosis after angioplasty) 
has been investigated by the ex vivo (genetically modified endothelial or smooth muscle 
cells; Wilson et al., 1989; Nabel et al., 1989; Dichek et al., 1989) and in vivo methods 
using various viral and nonviral methods (Nabel et al., 1992; Leclerc et al., 1992), 
including direct intracardiac injections (Lin et al., 1990).
1.9 GENE THERAPY FOR HAEMOPHILIA B
1.9.1 WHY GENE THERAPY FOR HAEMOPHILIA?
The main argument that may be forwarded in favour of developing gene therapy 
for haemophilia is the inadequacy of, and complications associated with, the current
42
therapeutic regimen. A major consideration for this disease is also the feasibility of a gene 
therapeutic strategy.
Currently, treatment is initiated only once bleeding starts and this "reactive 
strategy" results in considerable morbidity due to recurrent spontaneous bleeds. Due to 
the short half-life of the cofactors in circulation, repeated administrations are necessary. 
The treatment which depends on replacement of the deficient or defective clotting factor 
is not without complications. Although the spread of HIV and the hepatitis B virus have 
been greatly reduced by appropriate screening programmes and heat treatment, cofactor 
concentrates still transmit hepatitis non A-non B (C) infection (Brettler and Levine,
1989). This is likely to result in the development of chronic progressive liver disease in a 
number of these patients (Hay et al., 1985). The cost of the management of bleeding 
episodes is estimated to be between $50,000 to $100,000 per year, per severe 
haemophiliac (in the USA). This does not include the cost of treatment of associated 
complications and the loss of productivity caused by the loss of working hours from both 
physical and psychological effects.
The haemophilias are relatively easy diseases to treat by gene therapy, from a 
technological point of view. The factor VIII and IX genes have both been cloned and 
reasonably well studied. Clotting factor levels as low as 5 to 10% of normal can prevent 
spontaneous bleeds and protect against minor trauma, resulting in a considerable 
improvement in the quality of life. Moreover, the clotting factor levels do not have to be 
precisely regulated, unlike other proteins e.g. insulin. As long as a delivering tissue can 
express the active form of the deficient clotting factor and secrete it into the plasma, no 
special tissue-specific expression is required, unlike for certain other proteins e.g. 
dystrophin expression in skeletal muscle.
In summary, the current treatment is sub-optimal, expensive and associated with 
unacceptable complications and the delivery of both factor VIII and IX by gene 
therapeutic strategies can be considered as a feasible option.
Haemophilia A is at least five times more prevalent than haemophilia B and the 
normal human plasma level of factor VUI is 25-fold less than that of factor IX (200 ng/ml 
and 5 pg/ml, respectively). For these reasons it would seem that haemophilia A is a better
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disease target for a gene therapy strategy. However, due to the large size of the factor 
VIII coding sequence compared to that of factor IX (7 kb and 1.4 kb, respectively) and 
the detection of negative sequence elements in the factor VIII cDNA, that are responsible 
for reduced RNA accumulation (Lynch et al., 1993), factor VIII has proved to be a more 
difficult protein to express. Several groups have attempted and achieved efficient 
expression of factor IX by targeting various cell types (see next section). On the other 
hand, only a few groups have tried expressing factor VUI. They have mainly used 
retroviral vectors and some have used factor VIII cDNA clones with a deletion of the 
large segment coding for the central B domain (-2.5 kb; with no known procoagulant 
function). All attempts have resulted in low levels of factor VIII expression (Israel and 
Kaufman, 1990; Hoeben et al., 1992; Lynch et al., 1993).
1.9.2 GENE THERAPY FOR HAEMOPHILIA B
Many research groups have been attempting to develop gene therapy protocols 
for haemophilia B with the aim to prevent bleeding by providing a constant, prophylactic 
blood level of factor IX. So far, research efforts have mainly focused on ex vivo gene 
transfer approaches. A number of primary cell types have been targeted for somatic gene 
therapy of haemophilia B. These include fibroblasts (St. Louis and Verma, 1988; Palmer 
et al., 1989, Axelrod et al., 1990; Scharfmann et al., 1991), myoblasts (Yao and Kurachi, 
1992, Dai et al., 1992), endothelial cells (Yao et al., 1991), hepatocytes (Kay et al., 1993) 
and keratinocytes (Gerrard et al., 1993). All of the above groups used recombinant 
retroviral vectors to transduce the various cell types and demonstrated high levels of 
expression in vitro. Most of them, however, experienced very low and transient levels of 
factor IX expression in vivo. Scharfmann et al. (1991) demonstrated that this was due to 
the use of viral promoters and that the use of a house keeping gene (dihydrofolate 
reductase) promoter resulted in prolonged, but low levels of expression. The same group 
(Dai et al., 1992) later demonstrated sustained expression of factor IX (over 6 months) 
from retrovirally transduced primary myoblasts that were transplanted into athymic mice, 
due to the addition of the (207 bp) mouse muscle creatine kinase (MCK) enhancer 
element upstream from the original (579 bp) cytomegalovirus (CMV) promoter/enhancer
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(Axelrod et al., 1990) driving the expression of the factor IX cDNA. Kay et al. (1993) 
transduced canine hepatocytes in vivo, with retroviral vectors containing the factor IX 
cDNA being expressed by the viral LTR (long terminal repeats) itself. On intraportal 
delivery (following a partial hepatectomy), hepatocytes were transduced and sustained, 
but low level expression was observed in the canine haemophilia B model targeted (see 
discussion for choice of promoter and cell type, section 1.10.2).
Smith et al. (1993) used adenoviral vectors expressing factor IX, using an in vivo 
approach and achieved high level but transient expression. They showed that even though 
there was very efficient hepatocyte transduction, development of an immune response 
resulted in transient expression.
Furthermore, a canine model for haemophilia B exists (Brinkhous et al., 1973). It 
was shown that affected animals had a missense mutation (G379E; corresponding to 
position 381 of human factor IX) at a highly conserved residue in the factor IX catalytic 
domain (Evans et al., 1989). This mutation (unexpectedly) resulted in a complete lack of 
circulating factor IX in the affected animals. This canine model is being used by at least 
two groups in the USA for preclinical trials of somatic gene therapy for haemophilia B 
(Savio Woo, Baylor College of Medicine; Inder Verma, Salk Institute).
1.10 KERATINOCYTE-BASED GENE THERAPY
1.10.1 KERATINOCYTES AS A TARGET FOR SOMATIC CELL GENE 
THERAPY
The keratinocyte is an attractive target cell to provide somatic gene therapy for 
haemophilia. Keratinocytes are easily obtained from small skin biopsies and readily 
expanded in culture (Rheinwald and Green, 1975). It is possible to expand a 1 cm2 biopsy 
to 1 m2 of epithelium within about 3 weeks (Morgan et al., 1987). Cultured epithelial 
cells can be detached from the surface of the tissue culture dish as an intact sheet and 
grafted onto a suitable dermal bed in vivo. This method has been extensively used to 
regenerate the epidermis in patients with bums (Gallico et al., 1984). Due to the ease of
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their culture, keratinocytes are suitable target cells for genetic manipulation in vitro. 
These properties make keratinocytes ideal for targeting by an ex vivo method and also 
due to their easy access, DNA could be applied directly to the surface of the skin as a 
method for in vivo delivery. Easy access also facilitates the monitoring of the graft, 
including a subsequent diagnostic biopsy to assess transgene integrity and expression in 
vivo. The graft can be easily removed if there is an undesirable response. If an inducible 
promoter were used, for example with a steroid-responsive element, it may be possible to 
selectively induce expression by topical steroid applications (Vogel, 1993).
There are however certain characteristics of keratinocytes that have to be 
addressed, namely (a) the continuous loss of the genetically modified cells by normal 
desquamation, (b) the avascular nature of epidermal keratinocytes and (c) the ability of 
keratinocytes to perform the necessary post-translational modifications required to result 
in the active form of the ectopically synthesised protein (factor IX).
Keratinocytes have the ability for self-renewal throughout life due to the 
proliferative potential of their stem cell population. Targeting of the stem cells would 
therefore serve to continuously replenish the genetically-modified cells being lost by 
desquamation. The isolation / enrichment of stem cells has been an overriding goal for 
somatic gene therapeutic strategies in general. For long it has proved difficult to identify 
the presence of keratinocyte stem cells in vivo and in vitro, although recently Jones and 
Watt (1993) have reported some progress in enriching and identifying them in culture 
systems. They found that keratinocytes with characteristics of stem cells could be isolated 
from cultured human epidermis on the basis of high surface expression of (3j integrins and 
rapid adhesion to extracellular matrix proteins. This method is especially useful to achieve 
separation of the authentic stem cells (-10% of basal keratinocytes) from "transit 
amplifying cells" (equivalent to the committed progenitor cells of haematopoietic tissue; 
-50% of basal keratinocytes; [Potten and Morris, 1988]) up to greater than 90% purity. 
This has the potential to greatly facilitate the long-term persistence of genetically- 
modified keratinocytes in vivo.
Keratinocytes in the epidermis are not vascularised, and proteins synthesised in 
these cells will have to traverse the dermo-epidermal basement membrane to successfully
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enter the systemic circulation. Several factors would lead us to believe that ectopically 
synthesised factor IX in keratinocytes would traverse the basement membrane. Fenjves et 
al. (1989) showed that apolipoprotein E (ApoE) (normally) synthesised by a human 
epidermal graft on an athymic mouse was detected in the systemic circulation. This was 
detected for as long as the graft was present (12 weeks) and disappeared when the graft 
was removed. ApoE has 299 amino acids and a molecular weight of JO kDa. Milstone 
and Edelson (1988) have reviewed various studies indicating the active secretory nature 
of keratinocytes and have shown them to be responsible for the secretion of lymphokines, 
hormones and growth factors for systemic delivery. Geirard et al. (1993) recently showed 
that keratinocytes were able to (at least partially) post-translationally modify and secrete 
biologically active factor IX.
1.10.2 VIRAL Vs CELLULAR GENE PROMOTERS
An important consideration for any somatic cell gene therapeutic strategy is the 
choice of promoter in driving expression of the foreign gene. Besides being biologically 
safe, it is also important to achieve long-term, efficient and in some cases tissue-specific 
expression. Most groups attempting somatic gene therapy have made use of viral LTRs 
(long terminal repeats) and heterologous viral promoters to achieve efficient expression. 
Notably, most groups attempting to achieve high level expression of factor IX have used 
either recombinant retroviral vectors (St. Louis and Verma, 1988; Palmer et al., 1989; 
Axelrod et al., 1990; Armentano et al., 1990; Yao et al., 1991; Yao and Kurachi, 1992; 
Gerrard et al., 1993; Kay et al., 1993) (in many cases the vectors described by Miller and 
Rosman, 1989, were used) or adenoviral vectors (Smith et al., 1993) either under the 
control of the viral LTR or a heterologous viral promoter. A variety of (primary) cell 
types including fibroblasts, myoblasts, hepatocytes and keratinocytes were targeted, in 
order to eventually facilitate an ex vivo approach in the majority of cases.
In all cases, the various viral promoters (MMLV-LTR/SV40 early/CMV 
immediate early promoters) achieved high levels of factor IX expression in vitro. Their 
use in vivo, was however followed by inactivation of the promoters leading to only short 
term expression (St. Louis and Verma, 1988; Palmer et al., 1989). A systematic study
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carried out by Palmer et al. (1991) revealed that hADA (human adenosine deaminase) 
expression in primary fibroblasts in an in vivo situation was down-regulated >1,500 fold 
in <1 month. No cell- or antibody-mediated immune response was detected and the 
survival of the transplanted cells was largely unaffected. When harvested and regrown in 
vitro, the cells failed to regain their transgene expression. Some evidence was presented 
in support of a methylation-mediated inactivation.
Intriguingly, although this phenomenon was encountered in fibroblasts (St. Louis 
and Verma, 1988; Palmer et al., 1989), primary myoblasts (Dai et al., 1992) and 
lymphoid cells (Osborne et al., 1990), similar (or even identical) viral vector/promoter 
constructs used in myeloid haematopoietic cells (Kaleko et al., 1990; Osborne et al.,
1990), smooth muscle cells (Lynch et al., 1992) and hepatocytes (Kay et al., 1993) did 
not result in inactivation. Scharfmann et al. (1991) used a housekeeping gene 
(dihydrofolate reductase) promoter and achieved low but sustained levels of expression 
from mouse fibroblast implants. The same group then achieved long-term (>6 months) 
expression of factor IX from transplanted myoblasts after incorporating a 207 bp muscle 
creatine kinase (MCK) enhancer element into their retroviral-based, CMV promoter- 
driven factor IX cDNA in athymic mice (Dai et al., 1992). Similar success, using cellular 
regulatory sequences, was reported for the correction of the lysosomal storage defect in (3 
-glucuronidase-deficient mice using genetically-modified fibroblasts in vivo (Mouller et 
al., 1993). Clearly the choice of cell-type is an important variable in determining the 
eventual success of a viral promoter in vivo.
The data for keratinocytes, although not substantial, would lead us to believe that 
viral promoters alone would not achieve long-term expression in vivo. Morgan et al. 
(1987) used a retroviral vector to transduce keratinocytes with a human growth hormone 
gene (hGH) and, after achieving efficient expression in vitro, grafted the cultured 
keratinocytes onto athymic mice. The cells reconstituted a normal epidermis, and hGH 
assayed in a biopsy of the graft showed very low levels, and no secreted hGH was 
detectable in the systemic circulation (using an assay with a sensitivity of 0.2 ng/ml). The 
same group later demonstrated in vivo secretion of hGH when an endogenous cellular 
promoter (mouse metallothionein) was used to drive expression of the transduced gene
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(Teumer et al., 1990). Gerrard et al. (1993) using a retroviral vector with the factor IX 
cDNA under the control of the viral LTR, achieved very high levels of active factor IX 
expression in in vitro transduced primary keratinocytes. On transplanting these cells to a 
sub-dermal site in athymic mice, they could detect low levels of factor IX in the plasma, 
but expression ceased within 7 days. A report by Flowers et al. (1990) claimed to have 
achieved long-term expression of retrovirally transduced primary canine keratinocytes 
after grafting them in vivo. They used a recombinant retroviral vector containing the 
bacterial neo gene and ranging from 27-130 days after transplantation, these transduced 
cells were harvested and tested for formation of G418 resistant colonies in vitro. On 
average they isolated 0.6% (30/5119 in 10 separate biopsies) G418 resistant colonies 
(34% [10-76%] were resistant prior to transplantation). The findings from this sensitive 
assay system indicate a considerable reduction of expression in vivo, and indeed, this 
number of cells continuing to express the foreign gene probably also existed in the 
experiments performed by Morgan et al. (1987) and Gerrard et al. (1993). Although these 
studies demonstrate the ability of keratinocytes to secrete the active forms of proteins and 
the successful transfer across the dermo-epidermal basement membrane, viral vectors 
alone would probably not be sufficient to achieve sustained expression in transduced 
primary keratinocytes in vivo.
1.10.3 THE USE OF CYTOKERATIN GENE PROMOTERS
The cytokeratins (or keratins) are a family of at least 20 different intermediate 
filament (IF) cytoskeletal proteins expressed in keratinocytes. On the basis of 
biochemical, immunological and nucleic acid sequence data, the keratins have been 
classified into two main groups: the acidic (type I) and the more basic (type II) (Moll et 
al., 1982). This subdivision has a functional significance, since at least one representative 
of either type is required for the formation of the heterotypic subunit complexes of 
cytokeratin IF. Different "expression-pairs" of keratins are expressed depending on the 
state of differentiation of the keratinocytes. In vivo, in keratinocytes of the mammalian 
epidermis, cells of the basal layer express just one pair of cytokeratins, K5 and K14, 
whereas the differentiated suprabasal layers express K1 (variably K2) and K10 (and K ll).
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The latter pair of keratins have therefore been regarded as markers for "terminal 
differentiation" or "keratinisation". Epidermal keratinocytes in culture, however, express 
in addition to the basal keratins, a set of smaller keratins, K6 and K16 (and K17). These 
are referred to as the "hyperproliferative keratins".
Keratin gene expression seems to be regulated in a tissue-, differentiation- and 
development-specific fashion (Fuchs, 1988). Little is known so far regarding keratinocyte 
transcription factors, but the number of keratin genes cloned and characterised have 
served as a useful tool for comparative sequence analyses. Certain conclusions can be 
drawn on the basis of these sequence analyses, (a) the genes for type I and II keratins 
show striking similarities in their genomic organisation (especially regarding intron 
positions in the region coding for the central "a-helical rod" domains) (reviewed in 
Steinert and Roop, 1988) (b) various keratin genes co-expressed in the epidermis do not 
show extensive sequence homology in their coding/non-coding regions (except for certain 
shared motifs in their 5' UTRs) (Blessing et al., 1987; Steinert and Roop, 1988; Fuchs, 
1990; Leask et al., 1991) and (c) the corresponding genes for human, murine and bovine 
keratins expressed in a similar differentiation-specific manner show extensive sequence 
homology (Blessing et al., 1987; Reiger et al., 1988; Fuchs, 1990).
In accordance with these observations the human K10 (HK10) gene and the 
bovine and murine counterparts, BKVIb and murine Mr 59,000 keratin genes (MK10) 
respectively, show extensive sequence homology that extends to both the coding and 
noncoding sequences (Reiger et al., 1988). Exons 2-6 which code for the a-helical rod 
domains are identical in size and exons 1, 7 and 8 are also very similar in size. They show 
95% amino acid homology in their entire coding sequence which is not only confined to 
the usually conserved "a-helical rod" domain but also in the "head", "tail" and "spacer" 
regions. Exon 8, which codes for only the last amino acid (Tyr) and forms the 3'UTR in 
all three genes, also shows only minimal size variation among them. Remarkably it was 
also observed that the intron sizes are very similar between the species and surprisingly 
share extensive regions of sequence homology. It was noted that there were islands of 
>80% sequence identity scattered in regions with 40-60% identity. For example, the 
entire intron 2 in HK10 and BKVIb showed 74.5% sequence identity. None of this
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intronic sequence identity was attributable to repeat elements. This extensive sequence 
homology of introns, in the absence of any obvious selective pressure may indicate that 
some of these sequences are likely to have a role in regulation of gene expression. This is 
known to be true for the first introns of many genes, for example: al(I) collagen gene 
(Bomstein et al., 1987), troponin I gene (Konieczny and Emerson, 1987), human growth 
hormone gene (Moore et al., 1985), human smooth muscle a-actin gene (Nakano et al.,
1991) and the muscle creatine kinase gene (Sternberg et al., 1988). Transcriptional 
enhancer-like elements have been reported to exist in introns other than the first and even 
in the 3' region of a gene, for example in the second intron and 3' to the structural gene 
for human (3-globin (Behringer et al., 1987).
The 5' and 3' regions of the K10 genes in different species also shows extensive 
sequence homology. The HK10 and BKVIb genes in the region of the 3'UTR and 275 bp 
downstream of the polyadenylation signal, showed 90% sequence identity. In the region 
1.15 kb upstream from the translation initiation site, HK10 and BKVIb show 73% 
sequence identity (83% similarity).
In common with all characterised cytokeratin genes the HK10, BKVIb and MK10 
genes have a typical TATA-box situated 26 nucleotides upstream from the cap site. Also 
present 78 nucleotides upstream from the TATA-box, is the ''AAPuCCAAA" consensus 
motif, seen upstream of the TATA-box in all epidermally-expressed keratin genes 
(Blessing et al., 1987) and in the involucrin gene (another epidermally-expressed gene; 
Eckert and Green, 1986). Significantly, this motif is not seen in non-epidermal keratin 
genes (Blessing et al., 1987). An AP2 binding site demonstrated in the 5' upstream region 
of the genes for K14, K5, K1 and K6b (Leask et al., 1991) does not exist in the HK10, 
BKVIb or MK10 genes. It is perhaps not unusual to have this lack of extensive homology 
in the 5'UTRs of genes co-expressed in the same tissue but at different stages of 
differentiation, as evidenced in the co-ordinately expressed genes coding for the several 
constituents of striated muscle and in the a-actin genes of chicken skeletal and cardiac 
muscle (co-expressed in skeletal muscle during embryonic development; Eldridge et al., 
1985).
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Since keratins can account for 30-85% (depending upon their stage of 
differentiation) of the total protein of an epithelial cell, their genes might be expected to 
have relatively strong promoter/enhancer elements (Fuchs, 1988). It has been regarded 
that the tissue- and differentiation-specific expression of keratin genes is mainly regulated 
at the transcriptional level (Blessing et al., 1989; Lersch et al., 1989; Stellmach et al.,
1991). Practically, the 5' upstream sequences of various keratin genes, presumably 
containing the cw-acting elements required for efficient and tissue-specific expression, 
have been used to achieve keratinocyte-specific expression in vitro and in vivo (in 
transgenic mice). Blessing et al. (1989) used CAT (chloramphenicol acetyltransferase) 
transfection assays in primary epithelial cultures to demonstrate the tissue-specific 
promoter function of 5' upstream sequences of the BKIV (human keratin 6) gene. They 
also demonstrated the enhancer function of a 425 nucleotide sequence by upregulation of 
reporter expression by placing it downstream and in an opposite orientation to the 
reporter gene. Various groups have achieved keratinocyte-specific expression of either 
mutant/normal keratin genes (HK14 [Vassar et al., 1989] ; HK10 [Fuchs et al., 1992]; 
HK1 [Rosenthal et al., 1991]) or heterologous genes (BKVTb-mutant H-ras gene 
[Bailleul et al., 1990]; HK14-TGFa [Vassar et al., 1991]; BKIII/IV-BMP4 [Blessing et 
al., 1993]; HKl-TGFpl [Sellheyer et al., 1993]; BKVIb-TGFpl [Cui et al., 1994]) in 
transgenic mice. In every case, variable lengths (>1 kb) of 5' upstream regions of the 
named cytokeratin genes were used and keratinocyte- and differentiation-specific 
expression was demonstrated.
The gene promoter/enhancer and upstream cis-acting regulatory elements of the 
bovine counterpart of human keratin 10 i.e., BKVIb was acquired from Dr. Jose Jorcano 
(Madrid, Spain). Use of the same promoter (BKVIb) has been shown to successfully 
direct suprabasal keratinocyte-specific expression of a mutant H-ras gene (Bailleul et al.,
1990) and of mutant TGFpi (Cui et al., 1994), in transgenic mice. In this project, the use 
of the BKVIb promoter to target expression of human clotting factor IX in a 
keratinocyte-specific fashion was investigated.
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1.10.4 HaCaT CELLS AS THE KERATINOCYTE TARGET
As described previously, epidermal keratinocytes in culture switch off the 
differentiation-specific keratins and induce expression of a set of smaller keratins (K6 and 
K16) in addition to the basally-expressed keratins (K5 and K14). It is however possible to 
achieve the expression of differentiation-specific keratins, K1 and K10, by modifying the 
culture conditions. High calcium concentration (>0.10 mM; Yuspa et al., 1989), vitamin 
A depletion (Fuchs and Green, 1981; Kopan et al., 1987) and culturing at an air-liquid 
interface (Asselineau et al., 1986) or transfer to an in vivo site serve to stimulate cultured 
primary keratinocytes to synthesise K1 and K10.
The HaCaT cell line is a spontaneously transformed human epithelial cell line 
derived from normal adult skin (Boukamp et al., 1988). HaCaT cells are non-tumorigenic 
and maintain a full epidermal differentiation capacity. When transplanted onto nude mice, 
like normal keratinocytes, they reform an orderly structured and differentiated epidermal 
tissue.
HaCaT cells are a particularly attractive model to study the expression of 
differentiation-specific keratins because of their largely preserved normal epidermal 
characteristics (including a normal capacity to differentiate) and due to their unusual 
capacity to synthesise a broad spectrum of keratins including the differentiation-specific 
keratins under conventional culture conditions and low calcium levels (0.05 mM) (Ryle et 
al., 1989). At low cell densities they express K5, K6, K7, K8, K14, K16, K17, K18 and 
K19. With increasing cell densities they express more of K5, K6, K14, and K16 and begin 
to express K4, K13 and K15. At very high cell densities (at and after confluence) HaCaT 
cells begin to express the differentiation-specific keratins, K1 and K10. While K1 is 
detectable at confluence, there is a significant delay in the expression of K10. Moreover, 
K10 is expressed at considerably lower quantities than Kl.
The expression of these keratins is strongly modulated by environmental 
conditions including cell density (Ryle et al., 1989). As witnessed by en face 
immunofluoresence, the increase of Kl and K10 expression is due to the increasing 
numbers of positively-stained cells and not due to a gradual increase of expression in all
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cells. K1 and K10 expression in HaCaT cells is shown not to be related to stratification 
and is largely not affected by passage number.
Clearly, primary keratinocytes and other known keratinocyte cell lines would not 
be appropriate to assess the expression of the K10 promoter (in a tissue-specific manner) 
in conventional cultures. The HaCaT cell line was therefore used as the model to test the 
ability of the K10 promoter to drive expression of human factor IX in vitro in a 
keratinocyte-specific manner. Bearing in mind that the expression levels obtained would 
be suboptimal, the cell line should still allow the comparison of efficiency of different 
gene constructs in directing expression. The HaCaT cell line was kindly provided by Dr. 
N.E. Fusenig (Heidelberg).
1.11 SPECIFIC AIMS OF THIS PROJECT
The two overall objectives of this project are: (I) to carry out a comprehensive 
search for mutations in the factor VIII gene of patients with haemophilia A and (II) to 
investigate the possibility of keratinocyte-specific expression of factor IX as a potential 
method for somatic cell gene therapy for haemophilia B.
The specific aims of this project are as follows:
1.11.1 Characterisation of mutations in the factor VIII gene
(1) To detect mutations in the entire essential sequence of the factor VIII gene:
(i) Design PCR primers spanning the entire essential sequence of the factor VTII 
gene to enable the amplification, mutation screening and direct sequencing of 
alterations within these regions.
(ii) Detect and characterise gross alterations of the factor VIII mRNA/gene by RT- 
PCR/DNA-PCR followed by direct sequencing, and identify and accurately localise 
small sequence alterations by chemical mismatch cleavage (CCM) analysis followed 
by direct sequencing.
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(iii) Characterise mutations in selected individual exons reported to harbour a 
disproportionately higher number of mutations for their size, using single strand 
conformation polymorphism (SSCP) analysis.
(2) To analyse the mutations detected:
(i) Correlate the genotype with the phenotype by analysis of residues affected by 
mutations. For example, to look for evolutionary conservation and involvement with 
known or predicted functional domains and analyse gross alterations of the factor 
Vni gene/mRNA for their predicted effects on the primary structure of factor VIII.
(ii) Analyse the sequence in the immediate vicinity of mutations to decipher probable 
mechanisms of mutagenesis.
1.11.2 Keratinocyte-specific expression of factor IX
(1) To create the basic cvtokeratin 10 promoter-driven factor IX gene expression 
construct:
Directionally subclone the human factor IX coding sequence (FIX) into a gene 
expression construct containing the cytokeratin 10 (K10) promoter and SV40 viral 
small t-antigen intron and polyadenylation signal (SV40 poly A cassette).
(2) To introduce favourable sequence modifications into the basic K10-F1X construct:
(i) Engineer a favourable sequence context around the "AUG" initiation codon for 
efficient translation initiation (Kozak, 1991a,b) using PCR-mediated site-directed 
mutagenesis.
(ii) Repair the defective 5' untranslated sequence of the K10 promoter in the basic 
construct by insertion of synthetic oligonucleotides with the appropriate sequence 
(partial gene synthesis).
(iii) Replace the SV40 polyA cassette at the 3' end of the K10-FIX construct with 
the natural 3' end of the cytokeratin 10 gene.
(3) To verify the sequence of the various gene constructs before utilising them for gene 
expression studies:
(i) Confirm the successful incorporation of the various sequence manipulations by 
direct sequencing.
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(ii) Detect mutations (if any) in inserts generated by PCR, using CCM analysis and 
direct sequencing.
(4) To transfect keratinocvtes in vitro:
(i) Transfect a spontaneously transformed, non-tumorigenic human keratinocyte cell 
line (HaCaT cells) which is known to express a wide range of cytokeratins 
(including K10) in vitro (Boukamp et al., 1988; Ryle et al., 1989).
(ii) Linearise the gene constructs prior to transfection, to avoid disruption of the 
transcriptional unit during random integration of the constructs into the host cell 
genome.
(iii) Transfect using cationic-liposomes to achieve a high efficiency of transfection 
with minimal disruption of the physiology of the transfected cells.
(iv) Assess the efficiency of transfection using a control lacZ reporter construct.
(v) Co-transfect with a selectable marker to enrich for cells containing the stably 
integrated transgene and to isolate individual clones of stably transfected cells.
(vi) Confirm the successful integration of the transgene.
(5) To analyse the absolute and relative levels of factor IX expression achieved by the 
various gene constructs:
(i) Analyse expression at the transcriptional level by detection of factor IX mRNA 
using RT-PCR and Northern blotting.
(ii) Analyse expression at the translational level by detection of factor IX protein 
secreted into the tissue culture medium using the sensitive and quantitative enzyme 
linked immunosorbent assay (ELISA). Indirectly assess the ability of HaCaT cells to 
produce biologically active factor IX by using the "A7" antibody which detects only 
the y-carboxylated form of factor IX (Smith et al., 1986).
(iv) Comparatively assess the effects of the site-directed sequence modifications 
introduced into the gene constructs using the results of Northern blotting and 
ELISA.
(6) To assess the ability of the K10-FIX construct to achieve keratinocyte-specific
expression in vivo in transgenic mice: (in collaboration with Dr. Y. Alexander).
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CHAPTER: 2 
MATERIALS AND METHODS
2.0 MATERIALS AND METHODS
2.1 INTRODUCTION
All materials used throughout this project were sterilised to prevent contamination 
or degradation of nucleic add samples. Solutions and plasticware used in DNA analysis 
were autoclaved before use. Gloves were worn at all times. Materials employed in 
procedures which involved the use of RNA were treated as follows: (a) glassware was 
washed thoroughly with distilled water and baked for a minimum of four hours at 180°C, 
(b) plasticware was submerged in distilled water containing freshly added 0.01% DEPC 
(diethyl pyrocarbonate; Sigma) for a minimum of four hours and sterilised by autoclaving 
and (c) all solutions, except Tris-based solutions and organic solvents, were treated with 
0.01% DEPC before being autoclaved.
Contamination in PCR due to "carryover" was avoided by diligently separating 
the pre- and post-PCR stages. All procedures involving bacterial cultures and blood 
samples were carried out using aseptic techniques. Tissue culture was also carried out 
under aseptic conditions in a dedicated laboratory and flow hood.
2.2 PATIENT INFORMATION
A total of twenty-five unrelated haemophilia A patients were analysed in this 
project. A total of thirteen patients (group 1) were analysed for mutations in the entire 
essential region of the factor VIII gene and twelve (group 2) were analysed for mutations 
in certain selected exons. Fresh blood samples from the patients in group 1 were acquired 
from the Regional Haemophilia Centres at the Glasgow Royal Infirmary (West of 
Scotland), the Leeds General Infirmary and St. James' University Hospital (Yorkshire, 
England). Analysis of the patients in Group 2 was performed on DNA samples obtained 
from the West of Scotland Regional Genetics Service (Yorkhill Hospital, Glasgow, 
Scotland).
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Of the thirteen patients in group 1, eight had severe haemophilia A and two of the 
ten from whom inhibitor data was available had developed inhibitors to exogenous factor 
VTn. Group 2 consisted of six severely and six mild to moderately affected haemophilia A 
patients.
2.3 EXTRACTION OF DNA AND RNA
2.3.1 EXTRACTION OF DNA
In this project, genomic DNA was extracted from whole blood samples, cultured 
cells and mouse tail-tips. The preparation of small and large scale plasmid DNA from 
bacterial cultures is described in sections 2.6.6 and 2.6.7.
Extraction of DNA from peripheral leukocytes
Genomic DNA was extracted from peripheral blood samples using a variation of 
the method described by Kunkel et al. (1977). Two volumes of ice cold lysis mix (0.32M 
Sucrose, 10 mM Tris-HCl, pH 7.5, 5 mM MgCl2, 1% Triton X-100) were added to the 
blood sample. The mixture was inverted a few times and centrifuged at 2,500 rpm for 10 
minutes at 4°C in an IEC DPR-6000 refrigerated centrifuge. The supernatant was 
discarded and the pellet was dissolved in 3 ml nuclei lysis mix (10 mM Tris-HCl, pH 8, 
0.4M NaCl, 2 mM EDTA), 200 pi 10% SDS, 100 pi proteinase K (Boehringer 
Mannheim; 10 mg/ml), and was incubated overnight at 37°C. 1 ml of 6M NaCl solution 
was added to the overnight digest, and the mixture was vigorously mixed and centrifuged 
at 2,500 rpm for 10 minutes. The supernatant was transferred to a fresh tube where two 
extractions were performed with equal quantities of phenolxhloroform and one with 
chloroform:isoamyl alcohol. DNA was precipitated from the aqueous phase with a tenth 
volume of 3M sodium acetate (pH 5.5) and two volumes of ethanol. The DNA was 
spooled out on a terminally-sealed pasteur pipette, washed in 70% ethanol, air-dried and 
dissolved in a suitable volume of T.E. buffer (10 mM Tris-HCl, pH 8,1 mM EDTA).
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Extraction of DNA from tissue culture cells
Genomic DNA was extracted from cultured cells grown in 80 cm2 flasks by a 
scaled-up version of the method described by Laird et al. (1991). The tissue culture 
medium was aspirated and the cells were washed twice in PBS (Gibco, BRL). 5 ml of 
lysis buffer (100 mM Tris-HCl, pH 8, 5 mM EDTA, 0.2% SDS, 200 mM NaCl, 
Proteinase K 100 pg/ml) was added to the flask, which was followed by a 3 hour 
incubation at 37°C. An equal volume of isopropanol was added and the flask was placed 
on a shaker for 15-20 minutes until the precipitation was complete. The DNA was 
spooled out, washed in 70% ethanol, air-dried and dissolved in a suitable volume of T.E. 
buffer.
Extraction of DNA from tail-tip biopsies
Genomic DNA was extracted from tail biopsies as described by Laird et al. 
(1991), using the same solutions as described above. Tail tip biopsies (~1 cm) were 
transferred to a tube containing 0.5 ml lysis buffer, immediately upon cutting. They were 
then incubated overnight in a 55°C water bath with continuous shaking. Following 
complete lysis, the tubes were vortexed briefly and centrifuged on a bench top centrifuge 
at 12,000 rpm for 10 minutes to obtain a firm pellet. The supernatant was transferred to 
pre-labelled tubes containing 0.5 ml isopropanol. The DNA was spooled out, washed in 
70% ethanol, air-dried and dissolved in a suitable volume of T.E. buffer.
2.3.2 EXTRACTION OF RNA
Total cellular RNA was extracted from peripheral blood lymphocytes and a 
cultured keratinocyte cell line. The acid guanidinium thiocyanate-phenol-chloroform 
extraction method described by Chomczynski and Sacchi (1987) was used. Peripheral 
blood lymphocytes were initially separated from whole blood by centrifugation through 
'Histopaque 1077' (Sigma) followed by rinsing with cold PBS. RNA from cultured cells 
was extracted whilst still in the tissue culture flasks. In both cases, the cells were 
vigorously mixed with solution D (4M guanidinium thiocyanate, 25 mM sodium citrate, 
0.5% sarcosyl and freshly added 0.1 mM (3-mercaptoethanol), and extraction carried out 
by the addition of a tenth volume of 2M sodium acetate (pH 4.0), an equal volume of
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water-saturated phenol and a fifth volume of chloroformrisoamyl alcohol (49:1). The 
contents were mixed by vortexing and incubated on ice for 15 minutes. The aqueous 
phase obtained after centrifuging the mixture at 10,000 g for 20 minutes at 4°C, was 
transferred to a fresh tube, and an equal volume of isopropanol added. The contents were 
mixed, and precipitation was carried out at -20°C for at least an hour. The mixture was 
centrifuged, as before, and the pellet redissolved in 600 pi solution D. The solution was 
reprecipitated with isopropanol and the RNA pellet was dissolved in a suitable volume of 
distilled water that had been treated with DEPC and autoclaved.
The integrity of the extracted RNA was assessed by electrophoresis on a 1.5% 
agarose gel containing 5.2% formaldehyde and lxMOPS buffer (lOx buffer: 200 mM 
MOPS, 50 mM sodium acetate pH 7, 10 mM EDTA). RNA samples were prepared for 
electrophoresis by adding an equal volume of 50% formamide, 5.2% formaldehyde in 
lxMOPS buffer. The samples were heated at 70°C and quenched on ice. A sixth volume 
of loading dye (20% ficoll, 10 mM EDTA, 0.25% bromophenol blue, 0.25% xylene 
cyanol) was added and the samples were loaded on the gel. Electrophoresis was carried 
out (at 100 volts for 4-8 hours) in lxMOPS buffer which was circulated to prevent the 
depletion of ions at the anode. An RNA ladder (Gibco RRL) was run alongside the 
samples for use as a marker.
2.4 PCR TECHNIQUES AND METHODOLOGY
2.4.1 OLIGONUCLEOTIDE DESIGN AND SYNTHESIS
In this project oligonucleotides were designed for use in (i) conventional PCRs,
(ii) allele-specific PCRs, (iii) PCR cloning, (iv) site-directed mutagenesis, (v) recombinant 
PCR or splicing by overlap extension (SOE; Horton et al., 1989) and (vi) partial gene 
synthesis.
In every case, oligonucleotides were synthesised on an ABI 391 automated DNA 
synthesiser. Concentrated ammonia was used to elute the oligonucleotides from the solid 
support and deprotection was carried out at 55°C for 16 hours. A rapid method was
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employed for the purification of deprotected oligonucleotides, using n-butanol 
(Sawadogo and van Dyke, 1991). Briefly, 100 pi of the crude deprotected 
oligonucleotide solution in ammonia was mixed with 1000 pi of n-butanol, vortexed and 
centrifuged for 5 minutes at 12,000 rpm. The pellet obtained was air-dried and 
resuspended in 100 pi distilled water and the n-butanol extraction was repeated once 
more. The pellet was finally dissolved in 100 pi distilled water, quantified and stored at - 
20°C until required.
Oligonucleotides synthesised for PCR were designed using the computer 
program, OLIGO™ version 3.4 (© Wojciech Rychlik; MedProbe). This program allowed 
the design of PCR primers that (i) were not self-complementary i.e., did not form internal 
duplex structures primer-dimers, (ii) would form specific and stable duplexes with the 
template DNA, (iii) as a pair, were compatible in PCR i.e., were not complementary at 
their 3' ends (to avoid primer-dimers) and had similar melting temperatures and duplex 
stabilities.
Oligonucleotides for other specific uses, either PCR related or otherwise, were 
designed to have the appropriate additional sequence features. For example, primers for 
cloning were designed with the sequence of the appropriate restriction enzyme 
recognition sequence incorporated at the 5' ends (e.g. primer F9A was designed to 
introduce a Kpnl site immediately 5' to the "AUG" initiation codon of the factor IX 
coding sequence; section 3.5.2; Scharf et al., 1986). Anchor sequences ( 5 - 6  nucleotides, 
GC-rich) were added 5' to the restriction enzyme recognition sequences in order to 
achieve efficient digestion at the termini of PCR products. Also, the appropriate base 
substitutions were incorporated into the PCR primer in order to facilitate site-directed 
mutagenesis (e.g. primer F9G4 was designed to produce the Q-45V mutation in the 
factor IX coding sequence; section 3.5.3). For SOE, primers were designed so as to 
generate PCR products with complementary sequence at their ends. When SOE was 
required for the joining of two unrelated sequences, then the primers were designed with 
additional sequences at their 5' ends so as to make the unrelated sequences overlap at one 
end (Horton et al., 1989; Higuchi, 1989). An example of this can be seen in figure 31 
(section 3.5.5) where the factor IX coding sequence is spliced to a segment at the 3' end
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of the bovine cytokeratin VIb gene (BKVIb). When SOE was required for parts of the 
same sequence, as in the case of the three segments of the factor IX coding sequence, no 
special sequence modification was required as long as overlapping PCR products were 
generated (figure 21, section 3.5.1). For partial gene synthesis, oligonucleotides were 
designed with the appropriate sequence that needed to be inserted, flanked by appropriate 
restriction enzyme and anchor sequences. An example of this can be seen in section 3.5.4, 
where a pair of complementary oligonucleotides (50 nucleotides long) were used to 
repair the region of the 5'UTR in the recombinant factor IX expression construct.
Primers designed during the course of this project are listed in tables 1, 2, 5 & 6.
2.4.2 DNA-PCR
In general, all PCRs for the amplification of targets in a DNA template were 
performed over 30 cycles, in a final volume of 50 p i PCRs were performed either on a 
PHC I or III automated thermocycler. All reagents were obtained from Boehringer 
Mannheim. A typical PCR mix contained: lxPCR buffer (10 mM Tris-HCl pH 8.3, 50 
mM KC1, 1.5 mM MgCl2, 0.001% gelatin), each primer in a final concentration of 1 pM, 
each dNTP in a final concentration of 250 pM, 250 ng of DNA and 2 units Taq DNA 
polymerase.
PCR mixes were always assembled on ice using a dedicated set of pipettes. 
Buffer, primers and dNTPs were added into pre-labelled 0.5 ml microfuge tubes on ice, 
and the volume was made up to 48 pi with distilled water. The mixture was then UV- 
irradiated for 10 minutes (GRI-Amplirad). After addition of the DNA template (1 pi), the 
contents were briefly mixed by vortexing and centrifuged. Taq polymerase was added and 
after a brief vortex and centrifugation, light mineral oil was layered on top of the reaction 
mix. The tubes were immediately placed on a preheated (>90°C) thermocycler.
The DNA-PCR thermocycle profile was different for the two thermocyclers used. 
Since the PHC I thermal block is cooled by tap water and is much slower than the PHC 
III at temperature variation, longer times had to be set in the program. A typical cycle on 
a PHC I consisted of 94°C for 1 minute (denaturation), 56 - 64°C (depending on the 
primer pair) for 1 minute (primer annealing) and 72°C for 1-2 minutes (primer extension).
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The denaturation and annealing steps were reduced to 30 seconds each, in the case of the 
PHC III thermocycler. A 10 minute final extension step (at 72°C) was performed after 
the 30 cycle PCR was complete.
PCR products were visualised by agarose gel electrophoresis (in lxTBE), 
ethidium bromide staining and transillumination on a UV-lamp (Fotodyne, UV- 
transilluminator). Permanent records of these gels were made using either a polaroid 
camera and film or a gel documentation system (UVP Imagestore 5000) linked to a 
thermal printer.
2.4.3 HIGH FIDELITY PCRs USING Taq POLYMERASE
Due to the lack of 3' to 5' exonuclease activity in Taq polymerase, a high rate of 
random mutagenesis was experienced during the making of the basic construct (section 
3.5.2), using the conventional PCR protocol described in the preceding section (2.4.2). 
Specific measures were taken (in subsequent subcloning experiments) in order to reduce 
the probability of extension at a misincorporated nucleotide, and also to reduce the DNA 
damage errors caused by high temperatures (Eckert and Kunkel, 1992). These included:
(i) reducing the number of cycles to 25; (ii) reducing the final dNTP concentration five 
fold, to 50 pM and (iii) reducing the denaturation temperature and duration to 91°C for 
30 seconds. As seen in section 3.5.3, this seemed to have a beneficial effect.
2.4.4 RT-PCR AND NESTED PCR
1 pg of total cellular RNA was mixed with 10 pM of a suitable reverse primer in a
9 pi volume in DEPC-treated water. This was heated to 90°C for 5 minutes followed by a
10 minute incubation at 65°C. To this mix was added, 4 pi 5X reverse transcriptase 
buffer (Gibco, BRL; 250 mM Tris-HCl, pH 8, 375 mM KC1,15 mM MgCl2), 2 pi 0.1M 
DTT, 250 pM dNTPs and 200 units of Moloney murine leukaemia virus (MMLV) 
reverse transcriptase (Gibco, BRL). The volume was made up to 20 pi and the mixture 
was incubated at 37°C for 45 minutes. Reverse transcriptase was inactivated by heating at 
95°C for 5 minutes (Sellner et al., 1992). Half of this reverse-transcribed mixture was 
used as a template for PCR analysis.
63
When amplifying transcripts in very low abundance, as in the case of ectopic 
transcripts, it was necessary to perform a further PCR amplification using a nested set of 
primers. 2pi of the original PCR product was then used as the template for a subsequent 
nested PCR amplification. This effectively doubled the number of PCR cycles and 
tremendously increased the sensitivity of the assay (Roberts et al., 1990).
2.4.5 GENERATION OF RADIO ACTIVELY-LABELLED PCR PRODUCTS
This was required for the generation of radioactive probe for chemical mismatch 
cleavage analysis (CCM) and prior to single strand conformation polymorphism analysis 
(SSCP). In the former case, primers were initially 5' end-labelled using T4 polynucleotide 
kinase (NBL) and [y-32P] ATP (Amersham). This was performed in a 10 pi volume (for 
each primer) in lx  polynuceotide kinase buffer (lOx buffer: 500 mM Tris-HCl, pH 7.5, 
0.1M DTT, 0.1M MgCl2) by adding: 50 pM primer, 5-10 pCi [y-32P] ATP (3000 
Ci/mmol; 10 Ci/ml) and 10 units of T4 polynucleotide kinase. The mixture was incubated 
at 37°C for 45 minutes. Half of this mixture was used as primer for a PCR reaction, 
which was otherwise performed as in section 2.4.2.
Generation of radiolabelled PCR products suitable for SSCP analysis was 
performed using internal incorporation labelling of [a-32P] dCTP. This was performed by 
preparing the PCR pre-mix in exactly the same way as in section 2.4.2, except for a ten 
fold reduction in the final concentration of cold dCTP. To this was added 0.5 - 1.0 pCi [ 
a -32P] dCTP (3000 Ci/mmol; 10 Ci/ml), and PCR carried out as before.
2.4.6 ALLELE-SPECIFIC PCR AMPLIFICATION
In this method, the fact that the specificity and efficiency of primer extension is 
highly dependent on the 3' terminal 1-2 nucleotides, was exploited (Wu et al., 1989; 
Sarkar et al., 1990). An example of this is illustrated in figure 15, where the two reverse 
primers, 6N and 6M were specific for the normal (A) and mutant base (G) at position +3 
in the 5' splice site of intron 6, respectively. A multiplex reaction was performed, using 
6X and 6Y along with either 6N or 6M in order to have an internal positive control. 6N 
and 6M were designed so as to have similar melting temperatures to 6X and 6Y and so
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that none of the four would form dimers with each other, thus making it possible to use 
them in a multiplex PCR assay.
PCRs were performed as in section 2.4.2, except that three PCR primers were 
added in each reaction (6XNY or 6XMY). At first a low annealing temperature was used. 
The annealing temperature was gradually increased by 1°C at a time, until it was possible 
to achieve the desired discrimination between the two alleles. Satisfactory allele 
specificity was achieved at 65°C, although the PCR products were rather faint at this 
temperature. Due to the variability in the temperature profiles generated from one 
thermocycler to another, the same PCR machine was used during the optimisation. The 
PHC III thermocycler was used, as unlike the PHC I, it was not dependent on tap water 
to cool the thermal block.
2.4.7 ASYMMETRIC PCR
Single stranded templates used for sequencing were generated by asymmetric 
PCR amplifications (Gyllensten and Ehrlich, 1988) as previously described (Mgone et al, 
1992). Approximately 50 ng of gel-purified double-stranded PCR product (obtained by 
passive elution or adsorption to glass milk [geneclean II]; section 2.5.2) was used as a 
template for asymmetric PCR, which was performed by limiting one primer to between 
50 to 100 times less concentration than the other (0.5 to 1.0 pM). As there was only a 
linear accumulation of PCR product generated by a single primer after the limiting primer 
was exhausted, the number of cycles was increased to 40. The single and double stranded 
products were visualised by ethidium bromide staining following agarose gel 
electrophoresis.
2.4.8 RECOMBINANT PCR
Two methods were employed in order to achieve recombination via PCR. These 
included: (i) splicing by overlap extension (SOE; Horton et al., 1989; Higuchi, 1989) and
(ii) ligation followed by PCR. An example of this can be seen in figure 31 (section 3.5.5), 
where the factor IX coding sequence is spliced to a segment of the 3' end of the bovine
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cytokeratin VIb gene (BKVTb). The principle of primer design in the two methods has 
been described in section 2.4.1.
In SOE, 50 ng of each purified PCR segment was combined and used as a 
template for PCR. A PCR performed using primers that amplified across the region of the 
sequence designed to overlap, enabled the joining of the two unrelated sequences. In the 
latter method, equimolar concentrations of digested PCR products (section 2.6.1) were 
initially ligated to each other using T4 DNA ligase (section 2.6.2). 50 to 100 ng of this 
ligation mixture was then used as a template for PCR using primers flanking the ligation 
site.
2.4.9 DIRECT PCR SCREENING FOR RECOMBINANT CLONES
Bacterial colonies that were formed after transfection with ligated recombinant 
plasmids were screened directly for the presence of the desired insert. Primers were 
designed to be specific to the sequence of the insert and to bridge at least one ligation 
site. This helped to prevent amplification from unligated insert present on the plate.
The PCR pre-mix was made in the same way as before. An autoclaved toothpick 
was used to scrape about a third to a sixth of an isolated bacterial colony. The toothpick 
was then dipped into the PCR pre-mix and the same toothpick was also used to grow a 
10 ml culture (L-broth containing ampicillin; section 2.6.6). The mixture was vortexed 
and heated for 10 minutes at 95°C. After chilling on ice, Taq polymerase was added and 
PCR performed as in section 2.4.2. Plasmid DNA was extracted from the corresponding 
10 ml cultures (section 2.6.6) that gave positive PCR results, indicating the presence of 
the desired recombinant plasmid. The preliminary screening result was then confirmed by 
restriction mapping (section 3.5.2), CCM (sections 3.5.2, 3.5.3) and direct sequencing 
(sections 3.5.3, 3.5.4).
2.4.10 PREPARATION OF DOUBLE-STRANDED OLIGONUCLEOTIDES
Double-stranded oligonucleotides were made to repair the sequence of the 5'UTR 
in the KlO-factor IX expression constructs, as described in section 3.5.4. Two 
complementary oligonucleotides, 50 nucleotides long, were designed with the appropriate
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sequence, flanking restriction enzyme sites and anchor sequences (K10A and K10B). 
After purifying them by n-butanol extraction, equimolar proportions were mixed together 
in a solution of lx  One-Phor-All PLUS buffer (Pharmacia; lOx buffer: 100 mM Tris- 
acetate, pH 7.5, 100 mM Magnesium acetate, 500 mM potassium acetate). The mixture 
was heated to 75°C for 5 minutes and then gradually cooled to room temperature over 30 
minutes. The annealed double stranded oligonucleotide in restriction enzyme buffer was 
thus ready for digestion.
2.5 METHODS FOR MUTATION DETECTION
Three methods were used for the screening and eventual characterisation of 
mutations. Single strand conformation polymorphism (SSCP) analysis and chemical 
cleavage of mismatches (COM) were used as mutation screening methods. Positive 
screening results were characterised by direct sequencing of single stranded template 
generated by asymmetric PCR amplifications (section 2.4.7).
2.5.1 SINGLE STRAND CONFORMATION POLYMORPHISM (SSCP) 
ANALYSIS
This method, for the detection of single base substitutions, was described by Orita 
et al. (1989). Incorporation of [a-32P] dCTP during PCR amplification was used to 
obtain radiolabelled PCR products suitable for analysis (section 2.4.5). These were 
diluted 1 in 10 with T.E. buffer and a further 1 in 5 with formamide loading buffer (95% 
formamide, 20 mM EDTA, 0.05% bromophenol blue, 0.05% xylene cyanol). The diluted 
products were denatured at 95°C for 10 minutes, and 10 pi of each sample was applied to 
a native 6% polyacrylamide gel (49:1, bisacrylamide:acrylamide). A 0.4 mm thick gel was 
polymerised in a 40 cm X 20 cm sequencing gel cast (Sequigen; Biorad). The gel was 
prepared and electrophoresed in lxTBE buffer (89mM Tris borate, ImM EDTA buffer, 
pH 8.0).
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Two different electrophoretic conditions were used in order to increase the 
sensitivity of the SSCP analysis. In one method, the 6% native polyacrylamide gel was 
run at 4°C (in a cold room) and electrophoresis carried out for < 6 hours. In the other 
method, a similar gel containing 5% glycerol was electrophoresed at room temperature 
for over 16 hours.
Following the completion of electrophoresis, the gel was transferred to a 3MM 
Whatmann paper and dried under vacuum at 80°C (Biorad 583 gel dryer) for about 30 
minutes. The gel was then exposed to X-ray film (X-Omat AR diagnostic imaging film; 
Kodak) at -70°C for 4 -16 hours.
2.5.2 CHEMICAL CLEAVAGE OF MISMATCHES (CCM)
The CCM protocol involved five separate steps; (i) preparation of labelled probe 
and unlabelled test DNA, (ii) formation of heteroduplexes, (iii) chemical modification, 
(iv) chemical cleavage of mismatches and (v) electrophoresis and autoradiography. 
Preparation of labelled probe and unlabelled test DNA
End-labelled wild-type PCR products that were used as probes in CCM were 
generated as described in section 2.4.5. Unlabelled test PCR products were prepared as 
described in section 2.4.2. The PCR products were purified (i.e. separated from 
unincorporated cold and radiolabelled nucleotides and primers) by adsorption to 
glassmilk, using a Geneclean II kit (BIO 101). Unlabelled PCR products were initially 
electrophoresed on a low melting point agarose gel (NuSieve; FMC) and the required 
products were excised from it. The gel slice, containing the DNA to be eluted, was 
melted in 3 volumes of 6M Nal solution (at 45-55°C). The DNA was then adsorbed to 10 
pi of glassmilk. The glassmilk-DNA complex was washed three times with the 
commercially supplied "new wash buffer'1 to remove any agarose. DNA was eluted in 15 
pi T.E. buffer at 65°C over 10 minutes. The radiolabelled wild-type PCR product was 
mixed directly with 3 volumes of the 6M Nal solution and the same method was 
followed. The elution of a typical PCR product yielded a concentration of approximately 
100 ng/pl DNA.
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Formation of heteroduplexes
15 ng of labelled probe (10^ cpm) was mixed with 150-200 ng of each test DNA 
in a 20 pi volume of lx  annealing buffer (lOx buffer: 1M Tris-HCl, pH 8, 3M NaCl). 
Heteroduplex formation was carried out in 0.5 ml microfuge tubes. 50 pi mineral oil was 
layered on to the mixture and it was heated to 99°C for 10 minutes and then placed in a 
65°C water bath for two hours. The heteroduplexes were transferred to 1.5 ml siliconised 
microfuge tubes to be precipitated. To each tube was added, 3 pi of glycogen 
(Boehringer Mannheim; 20 mg/ml) and 750 pi of precipitation mix (63 mM sodium 
acetate, 20 pM EDTA, 80% ethanol) and the mixture was incubated at -70°C for 15 
minutes. The tubes were centrifuged at 12,000 rpm for 10 minutes, the pellet was rinsed 
with 70% ethanol, air dried and resuspended in 14 pi T.E. buffer.
Chemical modification using hydroxylamine and osmium tetroxide
Each heteroduplex was split between two tubes (7pl each) i.e. one tube each for 
the hydroxylamine and osmium tetroxide reactions. For the hydroxylamine reaction, 1.39 
G of hydroxylamine hydrochloride was mixed in 1.6 ml of pre-warmed (37°C) distilled 
water. The pH of the solution was adjusted to 6.0 by the addition of diethylamine (about
1.5 ml) and the solution was stored at 4°C for up to 7-10 days. 20 pi of this solution was 
added to the heteroduplex and incubation carried out at 37°C for 2 hours.
For the osmium tetroxide (OSO4) reaction, a commercially available 4% OSO4 solution 
(Aldrich; which was stored at 4°C for up to 3 months) was used. A lOx reaction mix was 
prepared by mixing 1.5 pi osmium tetroxide, 6.75 pi pyridine and 154 pi T.E. buffer on 
ice. 18 pi of this mix was then added to 7 pi of the heteroduplex. The mixture was 
incubated at 37°C for 1 - 2 hours.
Both the hydroxylamine and osmium tetroxide reactions were stopped by 
transferring the tubes onto ice which was followed by the addition of 750 pi of 
precipitation mix (63 mM sodium acetate, 20 pM EDTA, 80% ethanol). The DNA was 
precipitated at -70°C for 15 minutes and centrifuged at 12,000 rpm to obtain a pellet, 
which was rinsed and briefly air dried.
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Piperidine cleavage of the chemically modified mismatch
50 pi of a 10% piperidine solution was added to each pellet and the tubes were 
vortexed for up to one minute. They were then incubated at 90°C for 30 minutes. The 
tubes were chilled on ice and the DNA was precipitated as before and the pellet was 
resuspended in 15 pi formamide loading buffer (95% formamide, 20 mM EDTA, 0.05% 
bromophenol blue, 0.05% xylene cyanol).
Gel electrophoresis and autoradiography
The resuspended pellet was heated to 95°C for 10 minutes and applied to an 8% 
denaturing polyacrylamide gel containing 7M urea. The gel mixture was prepared and 
polymerised in a sequencing gel apparatus (Sequigen; Biorad) as previously described. A 
labelled 1 kb DNA ladder (Gibco, BRL) was also denatured and electrophoresed on the 
gel in order to permit accurate size estimation of the cleavage products. Electrophoresis 
was carried out at 35 watts constant power till the bromophenol blue reached the end of 
the gel. The gel was transferred onto a pre-cut piece of 3MM Whatmann paper and 
autoradiographed using Kodak X-Omat AR film for a period of 12-16 hours.
2.5.3 SEQUENCING OF PCR PRODUCTS
All sequencing reactions performed in this project involved a prior PCR 
amplification. The PCR product was used as a template for asymmetric PCR 
amplification to generate single stranded DNA suitable for direct sequencing, as described 
in section 2.4.7. Sequencing was carried out by the dideoxy chain termination method 
(Sanger et al., 1977) using the Sequenase version 2.0 sequencing kit (USB). Products of 
the asymmetric PCR were precipitated using a final concentration of 2M ammonium 
acetate and an equal volume of isopropanol, in order to preferentially precipitate the PCR 
products and remove the unincorporated dNTPs and primers. The DNA pellet was 
washed in 70% ethanol and dissolved in 14 pi distilled water. 7 pi was used for each 
sequencing reaction.
The samples were treated exactly according to the protocol provided by the 
manufacturers of the Sequenase kit. 1 pM of the appropriate sequencing primer and 2 pi 
of 5x Sequenase reaction buffer (to give a final concentration of 40 mM Tris-HCl pH 7.5,
70
20 mM MgCl2, 50 mM NaCl) were added to the DNA template (in a final volume of 10 
pi). The sample was incubated at 65°C for 2 minutes and then allowed to cool slowly to 
< 35°C over 20 to 30 minutes. 1 pi of 0.1M DTT, 2 pi of diluted labelling mix (diluted 
1:5 in distilled water), 0.5 pi of [a-35S] dATP (1000 Ci/mmol; 10 pCi/pl) and 2 pi (3.25 
units) of diluted Sequenase enzyme (T7 DNA polymerase; 13 units/pl; diluted 1:8 in 
enzyme dilution buffer [lOmM Tris-HCl, pH 7.5, 5mM DTT, 0.5 mg/ml BSA]) were 
added to the mixture and this was kept at room temperature for 2-5 minutes. Meanwhile 
the four termination mixes (containing 80 pM of each dNTP and 8 pM of each ddNTP) 
were prewarmed at 37°C, to which 3.5 pi of the labelling reaction was added. The 
reaction was allowed to continue for 5 minutes before being terminated by the addition of 
formamide dye stop solution (95% formamide, 20 mM EDTA, 0.05% bromophenol blue, 
0.05% xylene cyanol).
The samples were heated at 75°C for 2 minutes before applying them to an 8% 
denaturing polyacrylamide gel containing 7M urea and which had been preheated to 50° 
C. The gel was electrophoresed at constant power in order to maintain the gel 
temperature at 50°C. The sequencing gel was fixed in a solution of 10% methanol: 10% 
acetic acid for 10 minutes before drying in a vacuum gel dryer (Biorad) at 80°C for 30 
minutes. The dried gel was exposed for 16-18 hours to Kodak X-Omat AR film in a 
cassette using intensifying screens. The sequence was analysed manually.
2.6 RECOMBINANT DNA METHODS
2.6.1 RESTRICTION ENDONUCLEASE DIGESTS OF dsDNA
All restriction enzymes were obtained from Pharmacia, because of the 
compatibility of almost all their enzymes with one reaction buffer, One-Phor-All PLUS 
(lOx buffer: 100 mM Tris-acetate, pH 7.5, 100 mM Magnesium acetate, 500 mM 
potassium acetate). All digestions were performed according to the manufacturer's 
recommendations. Digestion at internal sites in plasmids or PCR products were
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performed using 1-2 units/pg of DNA for 1 hour. Digestion at termini of PCR products 
was performed using at least 3 units/pg of DNA for a minimum of 3-5 hours.
2.6.2 LIGATION OF DNA FRAGMENTS
As all ligations were performed at unique cohesive ends on either end of the 
insert, no end-filling or treatment with phosphatase was necessary. DNA fragments to be 
ligated were simply precipitated prior to the ligation reaction. Restriction-digested PCR 
products were purified by agarose gel electrophoresis followed by elution with adsorption 
to glassmilk (Geneclean II; as in section 2.5.2), in order to remove the digested termini 
and unincorporated primers and dNTPs.
Ligations were performed with a 3-5:1 molar excess of insert to vector. The 
ligation reaction consisted of 50-100 ng of linearised vector mixed with approximately 
one tenth of the purified digested PCR product (insert), 1 unit of T4 DNA ligase (1 unit/p 
1; Boehringer Mannheim) in 10 pi of lx  ligase buffer (lOx buffer: Tris-HCl 660 mM, pH 
7.5, 50 mM DTT, 10 mM ATP). Ligation was performed for 16 hours at room 
temperature (22°C), as recommended by the supplier.
2.6.3 PREPARATION OF COMPETENT E. Coli CELLS
A glycerol stock of E.Coli LE392 was used to inoculate 10 ml L-broth (1% 
bactotryptone, 0.5% yeast extract, 1% NaCl pH 7.0, antibiotic free) which was incubated 
at 37°C overnight with orbital shaking (at 225 rpm). 1 ml of this overnight culture was 
used to inoculate 50 ml of L-broth and incubation was carried out at 37°C for 
approximately 2 hours. When the optical density at 600nm was approximately 0.3, the 
culture was transferred to a 50 ml Falcon centrifuge tube and the cells were pelleted by 
centrifugation at 2,500 rpm for 10 minutes at 4°C in an IEC DPR-6000 centrifuge. The 
cell pellet was resuspended in 10 ml 10 mM MgSC>4 and incubated on ice for 20 minutes. 
The cells were again pelleted as before and resuspended in 5 ml chilled 50 mM CaCl2, 
incubated on ice for at least 30 minutes, and were then ready for use in the transformation 
protocol.
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2.6.4 TRANSFORMATION OF COMPETENT CELLS
Plasmids were transformed into KColi LE392. Half the ligation mixture was 
added to 100 |xl of ice-cold competent LE392 cells in a 1.5 ml microfuge tube. The cells 
and DNA mixture were incubated on ice for 30 minutes after which, they were given a 
heat-shock of 1 minute at 42°C. The cells were allowed to recover for 2 minutes at 20°C 
before adding 800 pi of L-broth (prewarmed to room temperature) and incubating at 37° 
C for 45 minutes. The cells were briefly pelleted for 20 seconds, and all but -100 pi of 
medium was poured off. The cell pellet was resuspended in this residual 100 pi of 
medium and spread on L-agar plates (L-broth, 1.5% agar) containing 100 pg/ml 
ampicillin. The culture was allowed to dry on the agar and the plates were inverted and 
incubated overnight at 37°C. Colonies were visible the following morning.
2.6.5 SCREENING FOR PUTATIVE RECOMBINANTS
L-agar plates were poured containing ampicillin (100 pg/ml), which only allowed 
the selection of those clones containing closed circular plasmid DNA with an intact 
ampicillin resistance gene. Analysis of recombinant colonies was initially performed by 
direct PCR screening as described in section 2.4.9. Plasmid DNA extracted from cultures 
(containing ampicillin) of the various positive colonies (by PCR) was used to perform 
detailed restriction mapping.
As all the inserts were generated by PCR using the proof-reading deficient Taq 
polymerase, it was necessary to rule out the presence of random mutagenesis in the 
selected clones (see section 3.5.2). A CCM analysis was therefore performed on at least 
5-6 positive clones. Furthermore, for the confirmation of the site-directed mutagenesis 
(Q-45V; section 3.5.3) and the repair of the K10 5'UTR sequence (section 3.5.4) it was 
necessary to confirm these small sequence alterations by direct sequencing. For this 
purpose, flanking PCR primers were designed and direct sequencing of asymmetric PCR 
products was performed as described in section 2.5.3.
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2.6.6 SMALL SCALE PREPARATION OF PLASMID DNA
Small scale plasmid DNA was prepared by the alkali-lysis method (Sambrook et 
al., 1989). An isolated bacterial clone was picked with a sterile toothpick and used to 
inoculate a 10 ml L-broth culture (containing 100 pg/ml ampicillin), which was incubated 
at 37°C overnight with orbital shaking. 1.5 ml of this overnight culture was briefly 
pelleted in a 1.5 ml microfuge tube. The supernatant was removed, and the pellet 
resuspended in 100 pi of solution A (50 mM glucose, 25 mM Tris-HCl, pH 8, 10 mM 
EDTA), to which 2 mg/ml lysozyme was freshly added. 200 pi of solution B (0.2 M 
NaOH, 1% SDS) was added and the tube mixed by rocking. A clear but viscous solution 
was obtained after incubating for 5 minutes on ice. 150 pi of solution C (5 M potassium 
acetate, 11.5% glacial acetic acid to get pH 4.8) was then added, followed by inversion 
and a quick vortex to mix the contents. The tube was held on ice for 5 minutes to allow 
the DNA and protein to precipitate, then centrifuged at 12,000 rpm for a minute. The 
supernatant was transferred to a fresh 1.5 ml tube and phenol:chloroform extraction was 
performed. The solution was then treated with RNase at a final concentration of 10 pg/ml 
at 37°C for 30 minutes. The plasmid DNA was then precipitated with ammonium acetate 
and ethanol and the pellet was dissolved in 50 pi T.E. buffer.
2.6.7 LARGE SCALE PREPARATION OF PLASMID DNA
Large scale plasmid DNA was prepared using Qiagen™ columns. DNA produced 
by this method was suitable for eukaryotic cell transfection without further purification. A 
single transformed bacterial colony was used to inoculate a 10 ml L-broth culture 
containing 100 pg/ml ampicillin. After overnight incubation, 1 ml was used to inoculate a 
500 ml culture which was incubated at 37°C overnight by shaking (225 rpm). Bacterial 
cells were harvested by centrifugation at 4,000 rpm for 10 minutes at 4°C in a Sorvall 
rotor. The supernatant was gently resuspended in solution I (50 mM glucose, 25 mM 
Tris-HCl, pH 8, 10 mM EDTA; 2 ml / 50 ml culture) to which 2 mg/ml lysozyme had 
freshly been added. The cell suspension was incubated on ice for 5 minutes. Freshly-made 
solution II (0.4 M NaOH, 1% SDS) was added (4 ml / 50 ml culture) and the mixture 
was gently inverted until it turned clear. This mixture was incubated on ice for a further 5
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minutes. Solution III (5 M potassium acetate, 11.5% glacial acetic acid to get pH 4.8; 6 
ml / 50 ml culture) was added and the solution mixed gently until a heavy white protein 
precipitate was formed. The solution was incubated on ice for 30 minutes and then 
centrifuged at 5,000 rpm for 10 minutes at 4°C to pellet the white precipitate (bacterial 
chromosomal DNA). The supernatant was added to a Qiagen™ column, equilibrated with 
10 ml QBT (750 mM NaCl, 50 mM MOPS, 15% ethanol, pH 7, 0.015% Triton-X), and 
was allowed to flow by gravity. 30 ml buffer QC (1 M NaCl, 50 mM MOPS, 15% 
ethanol, pH 7) was added and allowed to flow through by gravity. The plasmid DNA was 
eluted with buffer QF (1.25 M NaCl, 50 mM MOPS, 15% ethanol, pH 7) and the eluant 
mixed with 0.7 volumes of isopropanol to precipitate the plasmid DNA. The mixture was 
centrifuged at 5,000 rpm for 30 minutes followed by one wash in 70% ethanol. The 
plasmid DNA pellet was resuspended in 500 pi of T.E. buffer.
2.7 GENES AND VECTORS
The factor IX coding sequence used in the construction of the various K10-factor 
IX expression vectors was obtained from the retroviral vector pLXSN5'G3'cVI 
(pLIXSNL-2 in Gerrard et al., 1993). This was constructed by Dr. Ann Gerrard by 
inserting the factor IX cDNA from p5'G3'cVT (Anson et al., 1985) into the polylinker site 
(X) of the retroviral vector pLXSN (Miller and Rossman, 1989), and kindly provided by 
Professor G.G. Brownlee (Oxford University). In this project, primers were designed to 
amplify the entire factor IX coding sequence from the "AUG" initiation codon to 9 
nucleotides downstream of the "UAA" translation termination codon (1.4 kb).
A cloned DNA segment containing 5 kb of upstream sequence of the bovine 
cytokeratin VI gene (BKVIb; from the genomic clone XKBVTb; Lehnert et al., 1984; 
Reiger et al., 1985), just short (eight nucleotides) of the natural BKVIb cap site (Blessing 
et al., 1989; called the K10 promoter because it is the bovine counterpart of the human 
cytokeratin 10 gene [K10]; Bailleul et al., 1990) was obtained from Jose Jorcano 
(Madrid, Spain). A 0.85 kb, SV40 polyadenylation cassette (SV40 poly A) containing the 
SV40 small-t antigen intron (66 nucleotides) and polyadenylation signal sequence was 
obtained from pRSV|3globin (Mulligan et al., 1979). The K10 promoter and SV40 polyA
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sequence were directionally subcloned into the multiple cloning site (MCS) of pIC20H 
leaving a few restriction enzyme sites of the MCS for insertion of cDNAs. This 
expression vector (KlO-polyA cassette) was constructed by Dr. D. Fowlis in our 
department. This was used as the backbone for the various K10-factor IX expression 
constructs made in this project. The genomic BKVIb clone (XKBVTb; Lehnert et al., 
1984; Reiger et al., 1985) was used as a template for PCR, in order to obtain sequences 
at the 3' end of the gene (see section 3.5.5).
The plasmid pIRV-Neo-Act-lac Z, which contains the E.Coli lacZ gene under the 
control of the rat p-actin promoter (Beddington et al., 1989), was used to optimise 
liposome-mediated transfection of linearised DNA fragments into a transformed human 
keratinocyte (HaCaT) cell line (Boukamp et al., 1988). This plasmid was linearised (9.6 
kb) at a Noil site in the vector and used for transfection (see section 3.6.1).
The various K10-factor IX constructs were co-transfected with pSV2Neo 
(Southern and Berg, 1982) to confer G418 (a neomycin analogue) resistance as a 
selective marker. pSV2Neo contains the coding sequence of the neomycin resistance gene 
driven by a SV40 viral promoter. Prior to its use in co-transfection, pSV2Neo was 
linearised (using EcoRI) and used in a 20 fold reduced concentration, in order to increase 
the probability of successful co-selection.
2.8 RNA ANALYSIS
The extraction of total cellular RNA and confirmation of its structural integrity by 
denaturing agarose gel electrophoresis have been described in section 2.3.2.
2.8.1 TRANSFER OF RNA TO NYLON MEMBRANES
For Northern analysis, RNA samples (10 pg) were prepared and electrophoresed 
as described in section 2.3.2. When the gel had run a sufficient distance (as judged from 
the migration of the loading dye) it was washed in 2-3 changes of distilled water for 30 
minutes each, in order to remove the formaldehyde. The marker lanes were then cut from
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the rest of the gel. The gel strip containing the marker lane was then stained in ethidium 
bromide (5 pg/ml) for 1 hour, followed by destaining in distilled water over 16 hours, 
viewed on a UV-transilluminator and photographed alongside a scale.
The main gel was placed on two sheets of 3MM Whatmann paper on a platform, 
which were pre-wetted in 2xSSC and made to function as a wick by dipping into a 
reservoir containing lOxSSC (1.5 mM NaCl, 150 mM sodium citrate). The edges of the 
gel were shrouded by plastic film in order to prevent the lOxSSC solution bypassing the 
gel into the blotting materials. A piece of the nylon membrane (Hybond-N; Amersham) 
and two sheets of 3MM Whatmann paper were cut to the size of the gel. The blotting 
membrane was carefully placed over the gel avoiding the trapping of any air bubbles 
between them. The two sheets of filter paper were soaked in 2xSSC and similarly placed 
over the nylon membrane. A pack of dry paper towels was laid on top of the filter paper. 
Finally, a weight (-1 Kg) was placed over the towels. Transfer was carried out overnight 
at room temperature. The transferred RNA was cross-linked onto the nylon membrane by 
placing it on a UV-transilluminator for 4 minutes.
2.8.2 RANDOM PRIMED LABELLING OF DNA
DNA segments to be used as a probe were labelled with [a-32P] dCTP 
(Amersham) using a random primer labelling kit (Boehringer Mannheim). 100 ng of the 
double stranded DNA segment was denatured by heating, and to it were added 2 pi of 
(0.5mM solution) each dNTP (except dCTP), 4 \il of the reaction mix (containing 
reaction buffer and random hexanucleotides), 2 units of Klenow enzyme and 50 pCi of [a 
-32P] dCTP (3000 Ci/mmol; 10 Ci/ml). The mixture was incubated at 37°C for 30 
minutes. Unincorporated nucleotides were removed by passing the sample through a Nick 
column (Pharmacia). The specific activity of the probe was measured and it was used in a 
concentration of 2 X 106 counts/ml after heating at 100°C for 10 minutes.
2.8.3 NORTHERN HYBRIDISATION
The nylon membrane and a suitably sized mesh were pre-wet in 2xSSC. The two 
were rolled together and placed inside a Hybaid hybridisation bottle. To the bottle, 10-15
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ml (5-10 ml for a small bottle) prehybridisation solution (5xSSC, lxDenhardt's solution, 
100 pg/ml salmon sperm DNA, 0.5% SDS, 50% formamide) was added, and incubation 
carried out in a Hybaid rotating oven at 42°C for at least 1 hour. The prehybridisation 
solution was then replaced by a similar quantity of hybridisation solution (5xSSC, 
lxDenhardt's solution, 100 p.g/ml salmon sperm DNA, 0.5% SDS, 50% formamide, 10% 
dextran sulphate, 2 X 106 counts/ml denatured probe) and incubation carried out 
overnight at 42°C in a rotating oven.
2.8.4 POST-HYBRIDISATION WASHES
The hybridisation solution was replaced by 2xSSC, 0.1% SDS and the first wash 
was carried out in the hybaid bottle in the 42°C oven. The washing procedure after this 
was dependent on the counts read on the membrane. In most cases a 15 minute wash with 
0.2xSSC, 0.1% SDS at 65°C in a shaking water bath, followed by one or two such 
washes at room temperature on a shaker, were adequate to get the counts down to < 10 
cpm. The hybridised membrane was then exposed to Kodak X-Omat autoradiographic 
film.
2.9 TISSUE CULTURE
2.9.1 INTRODUCTION
Cells were maintained at 37°C in a humidified atmosphere containing 5% CO2, in 
80cm2 tissue culture flasks. Cells were grown in "Special Liquid Medium" (formulated 
for keratinocyte cultures by Dr. Ian Freshney; supplied by Gibco, BRL), supplemented 
with 10% foetal calf serum (FCS; Gibco, BRL; Cat. No. 10099-075), 10 mM L- 
glutamine, 100 units/ml penicillin and 100 (ig/ml streptomycin. Cultures were usually split 
every 3-4 days by washing cells once each in 10 ml PBS (Gibco, BRL; Cat. No. 14040- 
091) and versene (1:5000; Gibco, BRL; Cat. No. 15040-033), followed by incubation in
2.5 ml trypsin solution (0.25%; Gibco, BRL; Cat. No. 25050-022) for 5-10 minutes at 37 
°C. Cells were observed under low magnification to determine if trypsinisation was
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complete before the addition of 7.5 ml fresh tissue culture medium containing 10% FCS 
to inactivate trypsin. Cell numbers were estimated using an improved "Neubauer" 
haemocytometer (BDH) and fresh tissue culture flasks were seeded with 5 X105 cells per 
80 cm2.
2.9.2 CRYOPRESERVATION OF EUKARYOTIC CELLS
Cells were grown to 80% confluency and trypsinised as described in 2.9.1. After 
inactivating the trypsin with fresh serum-containing medium, cells were centrifuged at 
1,000 rpm for 5 minutes. The supernatant was discarded and cells were resuspended in 1 
ml of 10% DMSO in tissue culture medium. The cells were slowly cooled by storage in 
Nunc cryostat tubes, wrapped in bubblepak at -70°C for two days and then transferred to 
liquid nitrogen stores. To regrow cells frozen by this method, the tubes were thawed 
quickly at 37°C, added to fresh medium, centrifuged at 1,000 rpm for 5 minutes and 
replated. The following day the media was aspirated off, cells were washed in PBS and 
fresh media added.
2.9.3 LIPOSOME MEDIATED TRANSFECTION OF HaCaT CELLS
For this purpose a commercially available liposome transfection reagent, DOTAP 
(Boehringer Mannheim) was used exactly according to the supplier's recommendations. 
HaCaT cells were transfected at 60-80% confluence in 80cm2 tissue culture flasks. For 
each flask of cells, 70 p i of DOTAP was made up to 250 p i with the Hepes-buffered 
saline (Sigma; HBS; 20 mmM Hepes, 150 mM NaCl) in a polystyrene reaction vial. To 
avoid contact with air the DOTAP solution was aspirated through the rubber seal using a 
sterile cannula. The DNA to be transfected was diluted up to a final volume of 250 pi 
with HBS in another polystyrene reaction vial. For optimisation of transfection of 
linearised plasmids into HaCaT cells, a lac Z  reporter construct (pIRV-Neo-Act-lac Z; 
Beddington et al., 1989) was used in concentrations of 1 pg , 5 p g  and 10 pg  and
cU p l.c ^
transfections were carried out in , As seen in section 3.6.1, 10 p g  DNA showed
the maximum transfection efficiency and therefore 10 p g  was used for the transfection of 
all K10-factor IX constructs. Both the solutions were mixed and incubated at room
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temperature for 10 minutes. Meanwhile, the cells were washed twice in PBS and 12 ml 
tissue culture medium was added to the flask containing cells to be transfected. The 
liposome-DNA solution was then added to the flask. Cells were incubated at 37°C for 24 
hours in 5% CO2. The medium was then replaced with fresh medium and incubated for a 
further 48 hours.
2.9.4 DETERMINATION OF THE EFFICIENCY OF TRANSFECTION
The plasmid pIRV-Neo-Act-lac Z (Beddington et al., 1989), containing the 
E. Coli lac Z  gene driven by the rat p-actin promoter was used to determine the efficiency 
of transfection. Transfection was carried out in duplicate as described in 2.9.3. 
Transfected cells were rinsed twice in PBS and fixed in 0.2% glutaraldehyde, 2 mM 
MgC^, 5 mM EGTA in PBS for 5 minutes at 4°C. The fix was aspirated from the flasks 
and cells washed twice in 2 mM MgCl2, 0.1% sodium desoxycholate, 0.02% NP40, 
0.05% BSA in PBS. The reaction mix (1 mg/ml X-Gal, 5 mM potassium ferricyanide, 5 
mM potassium ferrocyanide, 2 mM MgCl2 in PBS) was then added to the flask and 
incubation carried out at 37°C for 24 hours. The number of blue-stained cells were 
counted.
2.9.5 SELECTION OF STABLE CLONES
In order to have a selectable marker for identifying transfected cells, they were 
co-transfected with pSV2Neo (Southern and Berg, 1982) to confer G418 (a neomycin 
analogue) resistance. pSV2Neo contains the neomycin resistance gene driven by a SV40 
viral promoter. Prior to its use in transfection, pSV2Neo was also linearised (using 
EcoRI). As the selectable marker was not linked to the expression vectors, in order to 
increase the probability of co-selection with the factor IX constructs, the latter were used 
in a 20 fold excess concentration over that of pSV2Neo.
A protocol identical to that used for the transfection of the linearised lacZ 
reporter construct (as described in 2.9.4) was used for the factor IX expression 
constructs. Transfections were carried out using 10 pg of the appropriate factor IX
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construct along with 0.5 |ug of pSV2Neo. Control transfections were also performed 
using only pSV2Neo, K10-FIXII and liposomes without DNA.
72 hours after transfection the confluent flasks were split 1 in 5. Two parts, were 
stored in liquid nitrogen (in 10% DMSO) and two plated on to fresh 80 cm2 tissue 
culture flasks. The fifth part was plated onto 10 tissue culture petridishes (100 x 20 mm). 
Cells were grown in medium containing 400yfcg/ml G418 sulphate (Geneticin®; Gibco, 
BRL). Flasks and petridishes were thoroughly washed (to remove dead cells) and fresh, 
G418-containing tissue culture medium was replaced every 3-4 days. After about 20 days 
(5-6 washes), individual clones of cells were observed in those that had been transfected 
with pSV2Neo. Cells that were transfected with only K10-FIX II or liposome without 
DNA had all died by this stage.
Cells in the petridishes were grown till the average clone contained about 50 cells 
when they were ready for picking. Clones in 80 cm2 flasks were grown in 400 ng/ml 
G418-containing medium until they overlapped and reached subconfluency. They were 
then trypsinised and split into fresh 80 cm2 flasks, and maintained in 200 ng/ml G418 for 
a further 2-3 passages. At this stage they were used for analysis of factor IX gene 
expression and the G418 selection was withdrawn. These cells were used for analysis as 
"pools" of transfected clones.
Individual stably-transfected clones were isolated for each KlO-factor IX 
construct. The method involved the use of cloning rings and the protocol described by 
Malcolm et al. (1987) was followed. Clones in petridishes that had approximately 50 cells 
each and were adequately separated from other clones, were selected for the cloning 
procedure. They were first identified under low power magnification on an inverted 
microscope and were encircled (-0.5 cm diameter) on the underside of the dish using a 
marker pen, by inserting the pen tip between the underside of the dish and the objective. 
A total of 10-15 suitable clones were selected for each transfected factor IX expression 
construct (not more than 3-5 per dish).
The wide ends of plastic pipette tips (blue) were excised and used as cloning 
rings. After suitable clones had been selected, cells in the petridishes were washed once 
each with PBS and versene. The flat (uncut) open surface of the ring was coated with
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autoclaved silicone grease. Cloning rings were placed on each clone using the marked 
circles to identify exact positions and tapped firmly in place. About 3-5 clones were 
selected per dish and all were treated promptly and simultaneously to avoid cells from 
drying. A drop of trypsin (-100 pi) was added to each ring (using plugged pipette tips) 
and incubation carried out for about 5 minutes at 37°C. 200 pi of fresh serum containing 
medium was added to each ring and the total solution was flushed up and down a few 
times to free cells. These were transferred to individual wells in a 24-multiwell dish. Cells 
were incubated at 37°C in 5% CO2 in a combination of conditioned and fresh medium (1 
part:2 parts), containing G418 at a final concentration of 200 ng/ml. Cells were not 
disturbed for a period of one week. After that, the cells were washed and fresh medium 
containing 200 ng/ml G418 was replaced. Clones in wells that reached subconfluency, 
were trypsinised and transferred to individual petridishes (35 x 10 mm). Culture volumes 
were gradually scaled up from these petridishes to 25 cm2 flasks and finally to 80 cm2 
flasks. Throughout the scaling up process, cells were grown in medium containing 200 
ng/ml G418. This selection was finally withdrawn at the 80 cm2 flask stage, when the 
cells were ready for gene expression analysis.
2.9.6 COLLECTION OF CONDITIONED MEDIA
Transfected HaCaT cells (pools or individual clones) were grown in media 
containing 500 ng/ml vitamin K (Sigma). For the collection of conditioned media, 
transfected HaCaT cells were washed four times in PBS and incubated in serum-free 
"Special Liquid Medium" for 24 hours at 37°C. The conditioned medium was cleared by 
centrifugation at 1,000 rpm for 10 minutes and stored on ice until being loaded on to 
microtitre plates for ELISA (usually within an hour).
2.10 ENZYME LINKED IMMUNOSORBENT ASSAY OF FACTOR IX
Enzyme Linked Immunosorbent Assay (ELISA) was used to detect secreted 
factor IX protein in conditioned media. Two monoclonal antibodies were used in a
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"sandwich" ELISA for the detection of factor IX antigen. The two antibodies used were 
A5 (anti-heavy chain of factor IXa) and A7 (anti-light chain of factor IXa) (Smith and 
Ono, 1984; Smith, 1988) which were generously supplied to us by Dr. K. Smith 
(University of New Mexico, USA). The A7 antibody detects the calcium-dependent 
epitope in the light chain igla region) of factor IX and distinguishes between biologically- 
active factor IX that contains 7-carboxyglutamic acids and non-activated factor IX, which 
does not (Smith et al., 1986; Smith, 1988). The protocol used in this study was essentially 
as described by Smith (1988). The A7 antibody was biotinylated and detected using 
avidin-peroxidase. As this assay detects the active form of factor IX it was used as an 
indirect measure of biological activity of the factor IX produced by the expression 
constructs (Gerrard et al., 1993).
Polystyrene flat bottom microtitre plates (Nunc) were used in the assay. All 
additions were made in 100 pi volumes using an 8-channel multipipette. The plates were 
coated with the A5 antibody at a concentration of 0.01 mg/ml in 0.05 M NaHCC>3 buffer 
at pH 8.6 (made by adding a small amount of dilute NaOH). The plates were incubated 
for 4 hours at 37°C or overnight at 4°C. The plates were washed three times in wash 
buffer I (0.1 M NaCl, 0.05 M Tris-HCl, pH 7.5, 0.1% Tween 20). The concentration of 
Tween 20 was ten fold more than that recommended by Smith (1988), in order to reduce 
the background due to non-specific binding (Smith, personal communication). Washing 
was performed using two different methods. One included the immersion of the plate in a 
container that was placed on a shaker, followed by tapping the plates to empty the 
contents of the wells. The other involved the use of a plastic squeezable bottle, with the 
water jet washing individual wells. The plates were blocked with 5% BSA (Fatty Acid 
free; Boehringer Mannheim) in 0.1 M NaCl, 0.05 M Tris-HCl, pH 7.5 with 0.05% azide 
for 2 hours at room temperature or overnight at 4°C. Plates were washed three times in 
wash buffer I.
Serial dilutions of conditioned media collected from the various transfected cells 
(and an untransfected negative control) were added in triplicate. To make a standard 
curve, serial dilutions of commercially available pure factor IX (Dakopatts) to yield 
concentrations between 0-50 ng/ml were also loaded in triplicate. Dilutions were made in
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a buffer containing 0.1 M NaCl, 0.05 M Tris-HCl, pH 7.5, 1 mg/ml BSA. Incubation was 
carried out for 3 hours at 37°C or overnight at 4°C. Plates were then washed six times in 
wash buffer H (0.1 M NaCl, 0.05 M Tris-HCl, pH 7.5, 0.01 M CaCl2, 0.1% Tween 20).
Antibody A7 was diluted to 1 nM (1:6667 for a 1 mg/ml solution) in 0.1 M NaCl, 
0.05 M Tris-HCl, pH 7.5, 0.005 M CaCl2, 1 mg/ml BSA and 100 pi was added to each 
well. Incubation was carried out for 2-5 hours at 37°C or overnight at 4°C. Plates were 
then washed six times with wash buffer II. To each well was added, avidin-peroxidase 
(Boehringer Mannheim) diluted 1:10,000 in buffer containing 0.1 M NaCl, 0.05 M Tris- 
HCl, pH 7.5, 0.005 M CaCl2, 1 mg/ml BSA, 0.05% Tween 20. Incubation was carried 
out for 45 minutes at room temperature. Plates were washed six times in wash buffer II. 
A solution of 0.1 M sodium citrate (pH 4.5) with 1 mg/ml OPD (1,2-Phenylenediamine; 
Dakopatts) and 0.033% hydrogen peroxide was added to each well. The solution and 
plates were shielded from light with an aluminium foil cover. Usually in about 5 minutes 
the colour development was adequate and the reaction was stopped by the addition of 2.5 
M H2S04- Optical densities (OD) were recorded on a microtitre plate reader at 490 nm.
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CHAPTER: 3 
RESULTS
3.0 RESULTS
3.1. AMPLIFICATION OF THE SEQUENCE OF THE FACTOR VIII GENE
The sequence of the factor VIII gene was amplified using both, genomic DNA 
and total cellular RNA as templates obtained from peripheral blood lymphocytes. All 26 
exons except the large, central exon 14, were amplified by RT-PCR followed by nested 
PCR of the ectopic factor VTII mRNA transcripts. Selected individual exons (including 
exon 14) were amplified using flanking intronic primers and genomic DNA as the 
template. The putative promoter and polyadenylation signal sequence of the factor VIII 
gene were also amplified using appropriate flanking primers.
3.1.1. AMPLIFICATION OF THE ENTIRE ESSENTIAL SEQUENCE
The entire coding sequence, putative promoter and polyadenylation/cleavage 
sequence, representing the entire essential sequence of the factor VIII gene (figure 3), 
was amplified in 13 unrelated and randomly selected haemophilia A patients. Twenty-five 
of the twenty-six exons were amplified in four overlapping PCR fragments. These were 
obtained by RT-PCR followed by nested PCR amplification of ectopic factor VIII 
transcripts. The four RT-PCR segments (as seen in figure 3) are named R1 to R4 ('R' 
indicating the use of RNA as template) from 5' to 3' of the factor VIII cDNA and spanned 
the following factor VIII nucleotide numbers, Rl: -50 to 1223; R2: 1114 to 2282; R3: 
5000 to 6171 and R4: 6071 to 7143 (numbering according to Wood et al., 1984). Primer 
sequences for the amplification of all segments except R3 were as described by Naylor et 
al. (1991) and obtained from Professor F. Giannelli (personal communication; appendix 
I). Primers for the amplification of segment R3 were designed using OLIGO™ version
3.4 (section 2.4.1; table 1).
The entire exon 14 was initially amplified from genomic DNA in a single PCR 
product of 3.2 kb, using flanking intronic primers. This large PCR fragment was then 
amplified in two segments using nested primers. The two segments were named D1 and
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Table 1: Prim er sequences spanning the entire factor VIII coding sequence
Name Orientation Sequence (5' - 3’) mRNA Position3
Rl-E
Rl-G
Rl-F
Rl-H
Forward
Forward
Reverse
Reverse
ATC ACC TTT TC A ACA TCG CT 
CCA GTC AAA GGG AGA AAG AA 
CCA ACT TTT CCC TTC ATC AA 
CTG TCC AAG GTC CAT C AA GA
224 - 244 
410 - 430 
662 - 682 
953 - 973
R2-E
R2-G
R2-F
R2-H
Forward
Forward
Reverse
Reverse
CAG CGG ATT GGT AGG AAG TA 
TTC AAG GAG ATT ACC AAA AG 
TTG GGG AGA AAG CGT TGT AT 
AGA ATG GGA ATA GGG TGA GT
1306 -1326 
1518 -1538 
1828 -1848 
2058 - 2078
R3-A
R3-B
R3-C
R3-D
R3-E
R3-G
R3-F
R3-H
Forward
Reverse
Forward
Reverse
Forward
Forward
Reverse
Reverse
ACC CAC CAG TCT TGA AAC GC 
TGT CCT GAA GCT GTA ATC TG 
GGG AAA TAA CTC GTA CTA CT 
GTA ATC TGA AAA TCT CTA AT 
GGC TCT GGG ATT ATG GGA TG 
GCC TCT CGT CCC TAT TCC TT 
GAT GGT GAA AAA CAG AGC AA 
CAA AAA CAC CTG GAT AGA GA
4973 - 4993 
6163 - 6183 
5000 - 5020 
6151 - 6171 
5171 - 5191 
5392 - 5412 
5684 - 5704 
5988 - 6008
R4-E
R4-G
R4-F
22Fd
22Rev
23Fd
23Rev
Forward
Reverse
Forward
Forward
Reverse
Forward
Reverse
CCA GCC TCT ACA TCT CTC AG 
CTG AGA GAT GTA GAG GCT GG 
CAG GTG AAT AAT CCA AAA GA 
TCC ACT GGA ACC TTA ATG GT 
ACC ATT AAG GTT CCA GTG GA 
ATA GCA TTC GCA GCA CTC TT 
AAG AGT GCT GCG AAT GCT AT
6338 - 6358 
6338 - 6358 
6721 - 6741 
6412 - 6432 
6412 - 6432 
6524 - 6544 
6524 - 6544
D2-C
D2-D
D2-E
D2-F
Forward
Reverse
Forward
Reverse
GAA TGT AGT TTT GCC TCA GA 
TTT CAC AAG CGT TCA GGG AC 
CGC AAC GTA GTA AGA GAG CT 
ACC CAT TGC TAG ITT  CCG TA
3678 - 3698 
4854 - 4874 
3980 - 4000 
4578 - 4598
Rl - R4 represent the four segments amplified by RT-PCR and D1 & D2 the two 
halves of exon 14 amplified by DNA-PCR. R l, 2 and 4 were amplified using primer 
sequences described by Naylor et al. (1991,1993a). R3-A, B, C & D were designed for 
the initial RT-PCR amplification of that segment. All other primer sequences listed are 
for the nested PCR amplifications of the named segments. All forward and reverse 
primers within each segment have been specifically designed to be compatible for PCR 
when used in any combination. Primers 22/23-Fd/Rev were used for the detection of 
the characteristic intron 22 mRNA abnormality (Naylor et al., 1992,1993a) along with 
R4-E, F & G (figure 19). aNumbering is according to Wood et al. (1984).
Figure 3: Amplification of the essential sequences of the factor W I  gene
A diagrammatic representation of the factor VTII cDNA amplified in 8 overlapping 
segments is shown. The positions of selected exons are indicated. The segments 
amplified by RT-PCR (R1-R4) followed by nested PCR (indicated by hatched boxes) 
of the ectopic factor VIII transcripts are shown. Exon 14 is amplified in two 
overlapping nested segments (D1 and D2; indicated by hatched boxes) from the full- 
length exon 14 PCR product. Two additional segments amplified by DNA-PCR, one 
around the putative promoter region (Pr) and the other around the polyadenylation 
signal sequence (polyA) are indicated.
The products of amplification resolved by agarose gel electrophoresis are shown. 
Lanes 2-5 show the RT-PCR segments R1-R4 respectively. Lanes 1 and 6 show the 
segments Pr and poly A, respectively. Lane 7 shows the 3.2 kb full-length exon 14 
PCR product and lanes 8 and 9 show segments D1 and D2, respectively.
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D2 ('D' indicating the use of DNA as template). Primer sequences for the amplification of 
exon 14 were as described by Higuchi et al. (1991a) (GC-clamps were excluded) and 
those for segments D1 and D2 were as described by Naylor et al. (1991) and also 
obtained from Professor F. Giannelli (personal communication; appendix I). Segments D1 
and D2 spanned the following factor VIII nucleotide positions, Dl: 2114 to 3692 and 
D2: 3537 to 5219 (numbering according to Wood et al., 1984). Two additional DNA- 
PCRs were performed in order to amplify the putative promoter and polyadenylation 
sequence using primer sequences described by Higuchi et al. (1991b). The nucleotide 
positions spanned by these primers were as follows: -505 to +16 for the promoter and 
8665 to 9056 for the polyadenylation sequence (these numbers are according to Gitschier 
et al., 1984). The amplification of the entire exon 14, segments D l and D2, the additional 
segments for the promoter and polyadenylation sequence, are also shown in figure 3.
All the primer sequences obtained from published data or by personal 
communication have been listed in appendix I.
Additional oligonucleotides were designed (section 2.4.1) for further nested PCR 
amplifications of segments Rl-4 and D2. These were so designed, as to be compatible for 
PCR in any combination of forward and reverse primers, within any one segment. The 
primer sequences, their orientation and nucleotide positions are listed in table 1. They 
have been named according to the segment they map to, followed by an 'E', 'F', 'G' or 'H' 
within Rl-4 and 'C1, 'D1, 'E' or 'F within D2. These oligonucleotides were also used as 
primers for direct sequencing. Primers 22 Fd/Rev and 23 Fd/Rev (table 1) were 
specifically designed to amplify across the junction of exons 22 and 23, for the diagnosis 
of the common intron 22 mRNA abnormality (Naylor et al., 1992; 1993a) seen in about 
half of all severe haemophilia A cases.
3.1.2. AMPLIFICATION OF SELECTED INDIVIDUAL EXONS
Exons 4, 7, 8, 11, 12 and 16 of the factor VIII gene were amplified in 12 
unrelated haemophilia A patients selected at random. These exons ranged in size from 
151 bp (exon 12) to 262 bp (exon 8) and were all amplified as PCR products of <400 bp 
in length, thus being amenable for PCR-SSCP analysis (Orita et al., 1989). Other
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individual exons were also amplified as required for the sequencing and confirmation of 
mutations detected in the ectopic factor VIII transcripts. Flanking intronic primers 
described by Higuchi et al. (1991a), but excluding the GC-clamps, were used for this 
purpose (appendix I).
3.2. CHARACTERISATION OF MUTATIONS IN THE FACTOR VIII GENE
Two distinct strategies were employed for the identification of mutations in the 
factor VIII gene. The choice depended on whether an RNA sample was available from 
the patient. Twelve unrelated haemophilia A patients were screened for mutations by 
PCR-SSCP of six exons, four of which were selected for their reported non-random 
concentration of mutations (Tuddenham et al. 1991). Thirteen other unrelated patients 
were screened by chemical mismatch cleavage (CCM) analysis of the entire essential 
sequence of the factor VIII gene. This comprehensive search for mutations was possible 
due to the availability of fresh blood samples and thus RNA samples from these 
individuals. All positive results obtained from the initial mutation screening method 
(SSCP/CCM), were eventually characterised by direct sequencing of asymmetrically 
amplified PCR products. The mutations characterised, are described in separate sub­
sections, depending on the initial screening method used.
3.2.1. PCR-SSCP OF SELECTED EXONS
Exons 4, 7, 8, 11, 12 and 16 of the factor VIII gene were screened by PCR- 
SSCP. Twelve unrelated haemophilia A patients were screened by this method. Two 
different electrophoretic conditions were used (as described in section 2.5.1), in order to 
maximise the sensitivity of SSCP.
Mobility shifts on SSCP analysis
In the twelve unrelated individuals screened, two positive mobility shifts were 
detected. Both of these involved exon 4. Lane 4 in figure 4A shows altered 
electrophoretic mobilities at the level of both, single and double stranded DNA. The
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Figure 4: SSCP analysis of exon 4
4A. SSCP analysis of exon 4 showing altered mobility of both the single (SS) and 
double (DS) strands in lane 4 (GLA14).
4B. SSCP analysis of exon 4 showing altered mobility of the single strands in lane 4, 
in another patient (GLA15). The altered mobility is indicated by arrows.
J
presence of a faster moving double stranded band suggested the presence of a small 
deletion. Lane 4 in figure 4B reveals a mobility shift in the single strands of the exon 4 
PCR product of another patient. Samples in figure 4A were electrophoresed on a non­
denaturing polyacrylamide gel at 4°C (in a cold room) whereas samples in figure 4B were 
electrophoresed at room temperature for >16 hours on a similar gel, containing 5% 
glycerol.
Characterisation of a 5 bp deletion in exon 4
The cause of the mobility shift seen in figure 4A was characterised by the direct 
sequencing of exon 4 in that individual (GLA14). Figure 5 reveals a 5 bp deletion of 
"TACCT" involving nucleotide positions 519 to 523 in exon 4 of the factor VIII gene. 
This involved amino acid positions 154,155 and 156.
Segregation of the deletion for genetic diagnosis
The 5 bp deletion was resolved on a 10% denaturing polyacrylamide gel. This 
enabled the detection of individuals with the deletion and thus offered an unequivocal 
means of carrier diagnosis in female relatives. Figure 6 demonstrates the segregation of 
the deletion for this purpose.
3.2.2. CCM ANALYSIS OF THE ENTIRE ESSENTIAL SEQUENCE
The entire essential sequence was amplified in thirteen unrelated haemophilia A 
patients. Those individuals who had normal sized PCR products for each of the eight 
segments were assumed to have point mutations or other smaller gene alterations and 
subjected to chemical mismatch cleavage (CCM) analysis (Cotton et al., 1988).
The products of Chemical Mismatch Cleavage analysis
Nine of the thirteen patients analysed by this strategy revealed normal sized PCR 
products spanning the entire essential sequence (all except GLA3, 8,11 and 12). All eight 
segments (Rl-4, Dl-2, promoter and polyadenylation sequences) from each of the nine 
patients and seven (normal) segments from those four who had one segment grossly 
abnormal, were subjected to CCM analysis. A total of thirteen cleavage products were 
detected. All the normal sized segments detected in patients that had a segment grossly 
altered, showed no cleavage products. At least one cleavage product was detected in
Figure 5: Partial sequence analysis of exon 4 showing del519TACCT
Partial sequence analysis of exon 4 identifying the cause of the abnormal SSCP result 
in lane 4 in figure 4A, to be a 5 bp deletion (TACCT) involving amino acid residues 
154,155 and 156. The position of the deleted bases is indicated alongside a normal 
control sequence (C) and by an arrow against the patient's sequence (P). The 
alteration in the translational reading frame resulting from the 5 base deletion is also 
shown.
Figure 6: Segregation analysis of del519TACCT
Resolution of the 5 base pair deletion on a 10% denaturing polyacrylamide gel for 
direct detection of carriers of this mutation. The results of the resolution on a 
denaturing polyacrylamide gel are shown for the various family members. All the 
female relatives possess the patients deleted allele (Del) in addition to the normal 
allele (N) indicating their haemophilia A carrier status.
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Figure 7 (A to G): CCM analysis of the factor VTII cDNA
Results of the chemical cleavage analysis of the various indicated segments of the 
factor V in coding sequence. The modifying chemical used to obtain the cleavage is 
mentioned. The position and mutation responsible for each cleavage product are 
shown by arrows. In those cases where the cleavage product has not been completely 
characterised, the exonic location is mentioned within parentheses. Note that in lane 1 
in 7B, two cleavage products in segment R3 are seen in the same individual (GLA1), 
only one of which has been characterised by sequencing (A1834T). Lane 3 in 7G, 
shows two cleavage products in patient GLA6, who also showed a cleavage product 
seen in lane 3 of 7B (5697delC). The cleavage products mapping to exon 14 and 21 
seen in lane 4 of 7C and lane 5 of 7G were both identified in patient GLA10.
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Figure 7 (E, F, G): CCM analysis of the factor VIII cDNA (continued)

each of the other nine patients. Three patients had more than one cleavage product, with 
two each in GLA1 and 10 and three in GLA6. GLA6 and GLA10 had an identical sized 
cleavage product that mapped to exon 21. Figure 7 shows each of the thirteen cleavage 
products.
Fine mapping of the cleavage site
The probe for CCM analysis was generated by radiolabelling both the 5' ends with 
[«y-32p] ATP and T4 polynucleotide kinase. This meant that the cleavage product could 
represent the radiolabel on either end of the probe. The mutation therefore mapped to any 
of two possible locations, assuming either end to be labelled. In order to avoid the 
possible need to perform two sequencing reactions to characterise the mutation, a second 
CCM analysis was performed in each case. For this, nested PCR primers were used to 
generate two internal and overlapping fragments spanning the originally cleaved PCR 
fragment. As seen in figure 8, a CCM reaction using these internal PCR fragments 
mapped the location of the cleavage site to within a 20-30 bp region. This necessitated 
only one sequencing reaction in order to characterise the mutation responsible for the 
cleavage product. This exercise of fine-mapping of the initial cleavage product was 
performed for all the 13 results obtained. In this way all thirteen cleavage products were 
mapped to specific regions in exons of the factor VIII gene. The cleavage products are 
denoted according to their exonic locations in figure 7 and table 4. Those that have not 
yet been characterised by sequencing are marked within parentheses.
Direct sequencing of the sites of cleavage
The mutations responsible for the cleavage products were characterised by direct 
sequencing of the exonic region (amplified by DNA-PCR) to which it had been mapped. 
This served to confirm that the mutation that existed in the ectopic factor VIII transcript 
also existed in the factor VIII gene itself. Furthermore, it served to also rule out the 
likelihood of a misincorporation error introduced during the early cycles of PCR by Taq 
DNA polymerase.
Asymmetric PCRs were performed to generate single stranded DNA template for 
direct sequencing, using flanking intron-specific primers for each exon shown to be 
carrying a mutation. The cause of each of seven cleavage products was completely
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Figure 8: Fine mapping of cleavage sites
This figure shows a diagrammatic representation and a CCM analysis using nested 
primers within segment R3 (position 5000-6171) to precisely localise the two 
cleavage products seen in lane |  of figure 7B. The position and orientation of the 
nested primers R3-E (E) and R3-F (F) are indicated. The hatched box represents 
exon 16 (position 5374-5586).
The cleavage products obtained for R3-CF and R3-ED and their sizes are indicated 
by arrows. L=radiolabelled 1 kb ladder. Localisation of the cleavage site depends on 
the size of the cleavage product and can be at any of two sites assuming either end of 
the product to be labelled. The uninterrupted and dotted lines seen above and below 
segment R3, represent the two possible positions calculated for each of the two 
nested segments, R3-ED and R3-CF. The uninterrupted lines precisely localise the 
cleavage product to two sites in exon 16. One site is in the vicinity of positions 5501- 
5520 and the other is between positions 5554-5561. Only one of these mutations has 
been characterised which is a missense mutation (A1834T) at position 5557.
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Figure 9 (A to G): Characterisation of cleavage products by direct sequencing
The results of direct sequencing of the various mutations detected as cleavage 
products on CCM analysis in Figure 7 are shown. T' and 'C' represent patient and 
control sequences, respectively. The mutation and the order of loading (T, C, G, A) 
are indicated along the top of each sequence. The mutation is indicated by the change 
(in the codon) shown at the appropriate position along the patient's sequence.
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Figure 9 (E, F, G): Characterisation of cleavage products by direct sequencing 
(continued)
The T—>A mutation (D56E) is not very clear, but due to (i) its position 
exactly at the site where the cleavage product mapped, (ii) the modifying 
chemical being osmium tetroxide (see figure 7D), which detects T/A—»N 
substitutions and (iii) the presence of no other change in the vicinity, it is 
beleived that it is the change responsible for the cleavage product in 
segment R1 of patient GLA13.
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characterised, in seven different haemophilia A patients. The mutations thus characterised 
include, six single base substitutions and a single base pair deletion. The single base 
substitutions detected were, five missense mutations: D56E, V162M, G701D, A1834T 
and R1869I and one nonsense mutation: R-5X. The deletion was that of a single "C" 
nucleotide at position 5697 (5697delC), in exon 17 of the factor VIII gene. The 
sequences of all the point mutations characterised, along with some surrounding normal 
sequence, are illustrated in figure 9. The details regarding the base substitutions, 
predicted amino acid changes, nucleotide and codon numbers involved, are listed in table 
4.
3.2.3. GROSS ABNORMALITIES OF THE FACTOR VIII mRNA
Following the initial PCR amplification spanning the entire factor VIII cDNA, 
three patients (GLA3, 8 & 11) consistently showed products of abnormal size in one RT- 
PCR segment each. In addition, one repeatedly resisted the amplification of segment R4 
(GLA12). These were subsequently investigated and the underlying causes for the mRNA 
abnormalities determined
An identical error of splicing resulting in shortening of the factor VIII cDNA in the 
region comprising segment 'Rl' in two patients
Of the three patients who showed products of abnormal size on amplification, two 
patients (GLA3 and 8) seemed to have an identical shortening of segment Rl. As seen in 
figure 10, RT-PCR of segment Rl showed an approximately 200 bp shortening in both 
patients compared with the normal. The altered sized transcripts in both patients were 
identical and reproducible (on three separate amplifications). No normal or other 
transcripts of aberrant size were co-amplified.
Since GLA3 had an affected brother and two affected maternal uncles, his mother 
was an obligate carrier. GLA8 on the other hand, was a sporadic case and so a sample of 
RNA from his mother (MP1) was investigated similarly. As seen in figure 10, she also 
showed the altered transcript in addition to the normal one from her normal X- 
chromosome, indicating that she was a carrier.
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Figure 10: RT-PCR of segment R l showing loss of 200 bp
The figure shows the products of RT-PCR of the factor VIII mRNA between 
positions -50 and 1223, resolved by agarose gel electrophoresis. The normal control 
(N) shows the expected size of 1.3 kb, whereas both patients PI (GLA3) and P2 
(GLA8) show a shorter 1.1 kb product. The mother of patient PI, MP1 shows the 
normal and altered transcripts identifying her as a carrier.
Figure 11: Sequence analysis of segment Rl showing skipping of exons 5 and 6
Partial sequence of the altered size transcript reveals the exclusion of sequence 
between mRNA positions 602 and 787 and the consequent splicing together of exons 
4 and 7. The arrow indicates the abnormal splice junction.
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Table 2: Primers used in the characterisation of the intron 6 splice donor 
mutation
Primer Orientation Sequence (5’ to 3')
6X Forward CAT GAG ACA CCA TGC TTA GCT GAC TCT A
6Y Reverse AAC TCT GGT GCT GAA TTT GGA AGA CCC T
6N Reverse AGA TTG TTG AGC AGG TGT GTA CAT
6M Reverse AGA TTG TTG AGC AGG TGT GTA CAC
5Hyb Forward GCC AAG GAA AAG ACA CAG AC
6Hyb Forward GGC ACT CAG AAA CAA AGA AC
6X and 6Y are intron-based primers for the amplification of exon 6. 6N and 6M are 
allele-specific primers for the mutant and normal alleles of 787+3A to G. 5Hyb and 
6Hyb are primers used for the identification of some normally spliced factor VIII 
transcripts in GLA3 and GLA8. The nucleotide positions of 5Hyb and 6Hyb are 610 
(exon 5-specific) and 680 (exon 6-specific), respectively.
The altered transcript was sequenced following an asymmetric PCR amplification. 
As seen in figure 11, this revealed a missing 186 bp between nucleotide positions 602 and 
787 of the mature factor VIII mRNA. This corresponded to an exon skipping event 
involving exons 5 and 6, with the consequent perfect splicing together of exons 4 and 7.
Exons 5 and 6 amplified normally from the DNA of both patients, GLA3 and 8 
and corresponded in size to those from a normal control, indicating that they were not 
deleted from the factor VIII gene (figure 12).
The splice sites flanking exons 5 and 6 were sequenced following asymmetric 
PCR amplifications of these exons. This revealed an A—>G substitution at position +3 in 
the splice donor site of intron 6. As seen in figure 13, both patients were hemizygous for 
the base substitution and the mother of GLA8 (MP1) was heterozygous for the mutation, 
confirming her carrier status.
Additional nested PCRs were performed using primers complementary to exons 5 
and 6 (5Hyb and 6Hyb, table 2). The RT-PCR product of segment Rl (which is itself a 
product of a nested PCR) was used as the template for this reaction. As seen in figure 14, 
this enabled the detection of transcripts containing sequences from both of these exons, 
i.e. a small fraction of full-length transcripts. These were not seen after the initial PCR 
amplification, even when the number of cycles were increased from 30 to 40.
As no restriction site was either lost or created by this splice mutation, allele 
specific primers (Wu et al., 1989; Sarkar et al., 1990) were designed that were specific 
for either the normal or mutant allele, in order to screen normal males for this mutation. 
For this purpose, a base substitution was made at the 3' end of the primers so that they 
would then be specific for either the normal or mutant allele (6N & 6M, respectively, 
table 2). As depicted in figure 15, both these primers were used in a reverse orientation 
along with a common forward primer in intron 5, just flanking exon 6 (6X). Multiplex 
PCR amplifications were carried out using three primers in each reaction. Either 6N or 
6M was used along with 6X and 6Y (6X & 6Y are intronic primers flanking exon 6, table 
2). 6X and 6Y produced a PCR product in every individual and was used as an internal 
positive control. 6N or 6M along with 6X produced an amplification in only those who 
were hemizygous for the normal (A) or mutant (G) base at +3 in the intron 6 splice donor
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Figure 12: Genomic amplification of exons 5 and 6
This figure shows the successful amplification of exons 4, 5 and 6 by DNA-PCR in 
patients PI (GLA3) and P2 (GLA8) using flanking intronic primers.
Figure 13: Sequence analysis of the intron 6 splice donor site
This figure shows the sequence of the splice donor site of intron 6. A hemizygous A 
to G substitution at position +3 is seen in both patients, PI (GLA3) and P2 (GLA8), 
and the mother of patient PI (MP1) shows a heterozygous A to G change at the same 
position, confirming her carrier status. The boundary between exon 6 and intron 6 is 
indicated along the sequence.
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Figure 14: Demonstration of a small fraction of full-length factor VIII mRNA by 
nested PGR
The diagrammatic representation of the RT-PCR segment Rl is shown, with the 
hatched boxes representing exons 5 and 6. 5Hyb and 6Hyb are two forward primers 
specific to exons 5 and 6, respectively, and are used in a nested PCR along with the 
reverse primer Rl-D. Both patients, PI (GLA3) and P2 (GLA8) show the expected 
normal sized product for the two PCRs, indicating the presence of some full-length 
factor VIII mRNA.
Figure 15: Screening of 787+3A to G by allele-specific PCR amplification
A diagrammatic representation of the allele specific PCR amplification for the 
787+3A to G mutation, and the results obtained on agarose gel electrophoresis are 
shown. 6N and 6M represent allele-specific primers for amplification of the normal 
(N) and mutant (M) alleles, respectively. 6X and 6Y are flanking intronic primers for 
the amplification of exon 6. The mutant allele-specific reaction (6XMY) reveals the 
presence of the mutant allele in both patients PI (GLA3) and P2 (GLA8). The normal 
allele-specific reaction (6XNY) shows the presence of two bands in the normal lane 
(N) and the expected single exon 6 band in the two patients PI and P2.
Fi
gu
re
 
15 
Fi
gu
re
 
14
-Q
X
CD
XI 
>  
X  
ID
o
tcc
cr
CD
X
LU
IDX
LU
®l
2 2
(D  CD
CD
LU
®l
CD
CO
ID
site, respectively. After optimising the multiplex allele-specific PCR (figure 15), a total of 
24 other haemophilia A patients and 60 unrelated, normal male controls were screened 
for the presence of the mutation. All showed the absence of this mutation.
Gross deletion of an exon resulting in shortening of the factor VIII cDNA in the 
region comprising segment 'R3'
Patient GLA11 consistently showed a shortening of segment R3 (three separate 
amplifications). As seen in figure 16, electrophoresis on a 1% agarose gel revealed an 
approximately 200 bp shortening of segment R3. The altered transcript was not 
accompanied by either normal or other aberrantly sized products.
Detailed restriction mapping of segment R3 was carried out. This revealed that 
the sequence originating from exon 16 was deleted from the RT-PCR product. A partial 
map depicting this is shown in figure 17.
In order to determine the cause of this exclusion of exon 16 from the mature 
factor VIII mRNA, an attempt was made to amplify exon 16 from the factor VIII gene, 
using flanking intronic primers and genomic DNA as the template. As seen in figure 18, it 
was not possible to amplify exon 16 in patient GLA11. It was, however, possible to 
amplify exons 14, 15, 17, 18, 19 and 20, the other exons contributing to the RT-PCR 
segment R3. These findings were consistent with a gross deletion of exon 16 from the 
factor VIII gene, and indicates that the proximal and distal breakpoints are likely to be in 
introns 15 and 16, respectively. This deletion is therefore predicted to be at least 0.35 kb 
up to a maximum of 1.8 kb.
The characteristic intron 22 mRNA abnormality
One of the severe cases, GLA12, repeatedly resisted the RT-PCR amplification of 
segment R4. Since this segment spans the junction of exons 22 and 23, it was therefore 
suggestive of the presence of the intron 22-mediated inversion, that is known to affect 
half of all severe haemophilia A cases. Using the same method described by Naylor et al. 
(1992, 1993a) (but using different primer sequences, table 1), successful RT-PCR 
amplifications on either side of the exon 22-23 junction and a failure of amplification 
across it, was demonstrated (figure 19). This was consistent with the diagnosis of the 
commonly occurring DNA inversion that disrupts the factor VIII mRNA in this region.
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Figure 16: RT-PCR of segment R3 showing loss of 200 bp
The diagrammatic representation of the RT-PCR segment R3 and its exonic 
composition is shown. The position of primers R3-C (C), R3-E (E), R3-F (F), and 
R3-D (D) and their orientation, is shown with respect to exon 16 (5374-5586). The 
PCRs performed using the nested primers show the loss of approximately 200 bp 
(Del; indicated by arrows) that maps between primers R3-E and R3-F (positions 
5171-5704).
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Figure 17: Restriction mapping of segment R3 showing loss of exon 16
17A. The diagrammatic representation of the RT-PCR segment R3 and its exonic 
composition is shown. The position of primers R3-C (C), R3-E (E), R3-F (F), and 
R3-D (D) and their orientation, is shown with respect to exon 16 (5374-5586). The 
expected cleavage sites for the seven restriction enzymes used for digestion are 
shown.
17B. The figure shows the results of the restriction mapping of the shortened 
segment R3 in patient GLA11, using enzymes Hinf I, Stu I, Ban I, Hinc II, Ava II, 
Alu I and Taq I in lanes 1 to 7, respectively. L=1 kb ladder. Ban I and Hinc II are 
expected to cut only in exon 16 {Hinc II is expected to cut near the 5' end of exon 16 
at position 5579), and have not resulted in cleavage of this segment (lanes 3 and 4). 
Stu I is expected to cut near the 5' end of exon 16 (position 5396), and digestion with 
this enzyme (lane 2) indicates the abolition of this site. The digest in lane 1 indicates 
that the Hinf I site (position 5327) near the 3' end of exon 15 is intact. The digest in 
lane 5 indicates that the Ava II restriction site (position 5615) near the 5' end of exon 
17 is also intact. The results of this restriction mapping along with the results in 
figure 16 (R3-EF) indicate that the shortening of segment R3 is likely to be due to a 
missing exon 16 (213 bp).
Figure 18: Deletion of exon 16.
The amplification of exon 16 by DNA-PCR using flanking intronic primers is shown. 
Lanes 1 and 3 represent the amplification products from normal controls and lane 2 
shows non-amplification of exon 16 in GLA11.
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F ig u re  1 9 A : Diagrammatic representation of the intron 22-mediated inversion 
(adapted from Lakich et al., 1993)
tel & cen = telomere and centromere of the X-chromosome; Int22=intron 22; F8A (hatched box) 
and F8B (crossed box) are the two genes embedded in intron 22 (orientations are shown); Nested 
primers 22F and 23R (along with their orientations) are indicated. (I) The genomic organisation of 
the factor VIII gene. The two F8A copies situated 500 kb 5' to the factor VIII gene are shown. (II) 
The intrachromosomal recombination mediated by the homologous sequences inside and outside of 
the factor VUI gene is shown (the commoner recombination, mediated by the distal copy of F8A is 
shown in this figure). ( I l l )  The product of the inversion after the homologous recombination. The 
separation of the previously juxtaposed primers, 22F and 23R, is depicted.
F ig u re  1 9 B : Detection of the characteristic intron 22-mediated mRNA abnormality 
A diagrammatic representation of segment R4 with its exonic composition is shown. The positions 
and orientations of the various nested primers are indicated. The agarose gel to the left shows the 
optimisation of the PCRs using various forward nested primers (R4-C, R4-E, 22F, 23F, R4-F) 
with R4-D, multiplexed with R4-C and R4-G, which acts as the internal positive control. The 
agarose gel to the right shows the various PCRs used to diagnose the intron 22-mediated mRNA 
abnormality. The control (C) and patient (P) lanes, and the various forward primers used, are 
indicated along the top of the gel. In all reactions the reverse primer used was R4-D. The use of 
forward primers R4-C and 22F, 5' to the junction of exons 22 and 23, demonstrate non­
amplification in the patient, whereas the use of 23F shows amplification in both patient and 
control. This demonstrates the inability to amplify across the junction of exons 22 and 23. The 
constant amplification using primers R4-C with R4-G (indicated by the arrow) and 23F with R4- 
D, demonstrate the ability to amplify on either side of the junction of exons 22 and 23.
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At least six different studies have shown that this inversion is responsible for 
about 45% of all severe haemophilia A cases (Lakich et al, 1993; Naylor et al, 1993a; 
Goodeve et al, 1994; Collins et al, 1994; Ljung, 1994; Tizzano et al, 1994). In the present 
study, this abnormality was detected in only one of eight severe cases. This discrepancy is 
most likely to have arisen due to the small number of patients analysed and the 
consequent misrepresentation of its frequency. It has not yet been determined if the 
inversion in this patient involves the proximal or distal homologous sequence (Lakich et 
al, 1993).
3.3. ANALYSIS OF THE MUTATIONS DETECTED IN THE FACTOR VIII 
GENE
The five missense mutations detected in this study were analysed for their 
potential role in the pathogenesis of haemophilia A, especially in the context of the 
observed clinical and biochemical severity. Two attributes were tested, viz. evolutionary 
sequence conservation and the involvement with consensus sequence patterns catalogued 
in the PROSITE dictionary of protein sites and patterns (Release 10.1; Bairoch, 1993). 
Two computer programs, namely, "PileUp" and "MOTIFS" (Smith et al., 1990) were 
used for this purpose. Both are part of the GCG (Genetics Computers Group; Devereux 
et al., 1984) package of sequence analysis programs, and were used on a V A X /V M S  
computer.
Furthermore, an attempt was made to objectively analyse the relevant splice donor 
sites, by assigning "consensus values" and to study in general their base composition in 
order to understand the mechanism of the double exon skipping event resulting from the 
intron 6 splice donor mutation. The results obtained from the sequence analyses are 
illustrated in this section and a detailed discussion is presented in sections 4.1.1 and 4.1.2.
Finally, in order to discover clues to the possible mechanisms for the origin of the 
two small deletions and six point mutations (excluding the splice site mutation) detected, 
the sequence at the site of the mutation and in the immediate vicinity was analysed. The 
observations and their implications are discussed in section 4.1.2.
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3.3.1. MISSENSE MUTATIONS: ANALYSIS FOR EVOLUTIONARY 
SEQUENCE CONSERVATION
Computer-aided analysis of the factor VIII amino acid sequence has revealed the 
presence of a triplicated homologous segment about 330 residues in length, called the 
"A" domains. Similar triplicated "A" domains have been demonstrated in factor V and 
ceruloplasmin. There is between 30-40% sequence identity amongst the various "A" 
domains of these three proteins (Vehar et al., 1984; Kochinsky et al., 1986; Kane and 
Davie, 1988). Since all five missense mutations affected only the three "A" domains of 
factor VIII, these were aligned with the other homologous "A" domains of human factor 
VIII, clotting factor V and ceruloplasmin. Murine factor VIII, the only other factor VIII 
sequence in the GenBank/EMBL database was also included in the analysis.
The program "PileUp" from the GCG package was used to align the three "A" 
domains of the four proteins i.e. twelve in all. Figure 20 shows that three of the missense 
mutations (D56E, V162M, G701D) are very highly conserved, occurring in at least 9 of 
the 12 "A" domains analysed. R1869 on the other hand occurred in 3 of the 12 domains, 
being conserved only in the "A3" domains of human factor VIII, ceruloplasmin and 
murine factor VIII. Interestingly, the A1834T mutation occurred as an Alanine in 4/12 
and Threonine in 7/12 of the "A" domains (see discussion).
3.3.2. MISSENSE MUTATIONS: ANALYSIS FOR THEIR PRESENCE IN 
CONSENSUS SEQUENCES
The five missense mutations were also analysed for their involvement of common 
functional domains, mapped on the human factor VIII sequence, using the "MOTIFS" 
sequence analysis program (Smith et al., 1990). This program scans through a protein 
sequence for patterns catalogued and defined in the PROSITE dictionary of protein sites 
and patterns (Release 10.1; Bairoch, 1993). This analysis revealed that the V162M 
mutation involved a casein kinase II phosphorylation site "SHVD" spanning amino acid 
positions 160 through to 163. The G701D mutation was seen to affect a multicopper 
oxidase I signature sequence "GLWILGCHNSDFRNR(jrMTALL" spanning amino acid 
positions 686 through to 706 (see discussion).
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Figure 20: Analysis of missense mutations for evolutionary sequence conservation
This figure shows the partial depiction of a "PileUp" analysis of the homologous "A" 
domains (three each) of human (F8) and murine (Mf8) factor VIII, factor V (Fv) and 
ceruloplasmin (Cp) (12 "A" domains in total). The coding sequence of these proteins 
were obtained from GenBank/EMBL using the accession numbers X01179, L05573, 
M14335 and M13699, respectively. Each missense mutation is denoted by an arrow 
pointing at the appropriate position above the aligned sequences. The position of the 
highly conserved cysteine residue at 1832 is also shown (see discussion). The amino 
acid position in the three "A" domains of human factor VIII (F8al, a2 & a3) are 
denoted at the end of the respective aligned sequence of the domain. The domain in 
which the indicated mutations lie is marked by underlining the corresponding amino 
acid number at the end of the aligned sequence. Numbering is according to Wood et al 
(1984).
D56E G7Q1D
t  ♦
F8al PFNTSW.YK KTLFVEFTDH 12 CHISSHQHDG 319
Mf 8al PFNTSIM.YK KTVFVEYKDQ CHISSHKHDG
Fval SLNLSVTSFK KIVYREY.EP SLTPKHLQAG
F8a2 GPQRIGRKYK KVRFMAYTDE 434 CHNSDFRNRG 701
Mf 8a2 GPHRIGRKYK KVRFIAYTDE CHNSDFRKRG
Fva2 FSNQIGKHYK KVMYTQYEDE SMNSSPRSKK
Cpa2 GTTRIGGSYK KLVYREYTDA CLTTDHYTGG
Cpa3 GEFYIGSKYK KWYRQYTDS CHVTDHIHAG
Cpal GPDRIGRLYK KALYLQYTDE CQNLNHLKAG
F8a3 ....... FK KWFQEFTDG 1741 CLIGEHLHAG 2009
Mf 8a3 ....... FK KWFQEFTDG CLIGEHLQAG
Fva3 ....... YK KWFRKYLDS TEVGENQRAG
Rl8691
♦
F8al EGSLAKEKTQ 190 
Mf8al EGSLSKERTQ 
Fval KGTLTEGGTQ 
F8a2 KESVDQRGNQ 565 
Mf8a2 KESVDQRGNQ 
Fva2 SRSLDRRGIQ 
Cpa2 KGSLHANGRQ 
Cpa3 RPYLKVFNPR 
Cpal KDSLDK.EKE 
F8a3 TNTLNPAHGR 1869 
Mf8a3 ANTLNPAHGR 
Fva3 KGILHKDSNM
Cys
m i  A1834X M62M
♦
PLCLTYSYLS
PPCLTYSYMS
PPCLTHIYYS
PRCLTRYYSS
PRCLTRYYSS
AQCLTRPYYS
PVCLAKMYYS
SACIPWAYYS
GNCVTRIYHS
FDCKAWAYFS
FDCKAWAYFS
SACRAWAYYS
HVDLVKDLNS 1211
HVDLVKDLNS
HENLIEDFNS
FVNMERDLAS 54 5
FINPERDLAS
DVDIMRDIAS
AVDPTKDIFT
TVDQVKDLYS
HIDAPKDIAS
DVDLEKDVHS 1849
DVDLERDMHS
AVNPEKDIHS
3.3.3 ANALYSIS O F T H E  INTRON 6 SPLICE DONOR MUTATION
Consensus values were calculated for the splice donor sites of introns 4, 5, 6 and 
mutant 6, according to the method described by Shapiro and Senapathy (1987). This was 
based on the conservation of bases at the 8 positions most likely to contribute 5' splice 
recognition determinants i.e. position -2 through to +6. These values ranging from 0 to 
100%, were used as relative indicators of the efficacy of splice sites. Briefly, the formula 
used that gives a score between 0 and 100 was:
CV = 100 (t - min t) /  (max t - min t) 
where "min t" and "max t" are the sums of the lowest and highest possible total of 
percentages in each of the eight positions (-2 to +6) at the splice donor site, "t" is the 
total of percentages for the same eight positions observed in the splice donor sequence in 
question. Instead of using the "min t" and "max t" values for the various GenBank files 
used by Shapiro and Senapathy (1987), these were calculated for the factor VIII gene 
from the published splice donor sequences of its 25 introns (Gitschier et al., 1984). The 
values used in the above calculation were therefore, min t = 12 and max t = 624. As seen 
in table 3, the consensus value of the mutant intron 6 splice donor site showed a 9% 
reduction from that of the normal sequence. Perhaps also of significance was the 
observation of a consensus value of 100 for the intron 4 splice donor compared to 90.84 
for the intron 5 counterpart. Evaluation of the intron 5 splice donor sequence also 
revealed a "T" at position +3 which is only observed in 2% of all primate 5' splice sites. In 
addition to the reduction in efficiency of the intron 6 splice donor site caused by the splice 
mutation, these findings also suggest that the intron 5 splice donor site may be less 
effective than that of intron 4 (see discussion).
3.4 SUMMARY O F M UTATIONS DETECTED IN TH E FACTOR V III GENE
Table 4 summarises all the factor VIII mutations that were detected in this study. 
A total of 4 gross mRNA abnormalities, 13 positive CCM and 2 positive SSCP results 
were detected while screening for mutations within the factor VRI gene during the course 
of this project. A total of 11 different and potentially pathogenic mutations have been
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Table 3. Evaluation of the splice donor sites of introns 4, 5, 6 and mutant 6
5' SS Percentages at the 5' SS positions t CV
-2-1 +1 +2 +3 +4 +5 +6
Intron 4 A G  G T A A G T
52 88 100 100 68 84 76 56 624 100
Intron 5 A G  G T T A G T
52 88 100 100 12 84 76 56 568 90.84
Intron 6 normal A G  G T A T G T
52 88 100 100 68 16 76 56 556 88.88
Intron 6 mutant A G  G T G T G T
52 88 100 100 20 16 76 56 508 81.04
5' SS = 5' splice site or splice donor site; t = the sum total of the 
percentages observed for the various bases occuring at the eight 
positions in the splice donor site, most likely to contribute 5' splice 
recognition determinants; CV = consensus value of Shapiro and 
Senapathy (1987).
fully characterised. These include 7 single base substitutions, 3 deletions and 1 gross 
mRNA abnormality due to the intron 22-mediated inversion (Naylor et al., 1992, 1993a; 
Lakich et al., 1993). The 7 single base substitutions include 5 missense (D56E, V162M, 
G701D, A1834T and R1869I), 1 nonsense (R-5X) and 1 splice donor site mutation in 
intron 6 (787+3A—»G). The 3 deletions include a single base deletion in exon 17 
(5697delC), a five base pair deletion in exon 4 (519delTACCT) and a gross deletion of 
exon 16. A further seven mutations have been mapped to specific exons of the factor VIII 
gene using CCM/SSCP analysis, but not yet characterised by sequencing (shown within 
parentheses).
Eight of these are novel changes affecting the factor VIII gene. Of the recurrent 
mutations, both V162M (Tuddenham et al., 1991; Diamond et al., 1992) and R-5X 
(Pattinson et al., 1990a; Reiner and Thompson, 1992) have each been reported twice 
before. The same intron 6 splice donor mutation (787+3A—>G) was seen in two patients 
in this series (GLA3 and GLA8) and as discussed in section 4.1.2, it is unlikely that this 
represents a true recurrence. Of the eight severe haemophilia A cases in whom a complete 
ascertainment of mutations was carried out, only one showed the characteristic intron 22 
mRNA abnormality. Only one of the seven different single base substitutions detected, 
occurred in a hypermutable CpG dinucleotide. The findings of only 1 in 8 severe case 
with the intron 22 mutation and 1 of 7 single base substitutions involving a CpG 
dinucleotide, go in favour of this small group of patients not being representative of the 
population. The distribution of mutations among the various exons was not totally 
random. If the tentatively mapped mutations are also included, exons 4, 16, 17 and 21 
were seen to be affected by two mutations each. Three mutations were mapped to exon 
14. Since GLA6 had a single base deletion in exon 17, it is very likely that the cleavage 
product in exon 21 is silent/conservative. Interestingly, both GLA6 and GLA10 have an 
identical cleavage product that maps to exon 21 (GLA10 also has another CCM result 
that maps to exon 14) where there are no known factor VIII polymorphisms (Tuddenham 
et al., 1991; Lin et al., 1993).
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The eleven potentially pathogenic mutations that were characterised in this study 
have been listed in table 10, along with their effect on the phenotype and the predicted 
deleterious effects on the factor VIII polypeptide.
3.5. FACTOR IX EXPRESSION CONSTRUCTS
The second objective of the project was to investigate the use of keratinocytes as 
a delivery system for ectopically expressed therapeutic gene products. An attempt was 
made to target the expression of clotting factor IX in a keratinocyte-specific fashion with 
the use of a cytokeratin gene promoter. With this aim, a variety of bovine cytokeratin VI 
promoter (BKVIb; Blessing et al., 1989; Bailleul et al., 1990) driven, human factor IX 
cDNA expression constructs were made. It was known that the -acting elements 
located in a 5 kb region upstream of the translation initiation site would be required to 
achieve expression in a tissue and differentiation-specific manner, in suprabasal 
keratinocytes (Bailleul et al., 1990), and it was hoped that levels high enough to be of 
therapeutic value might be obtained. BKVIb is the bovine counterpart of human 
cytokeratin 10 (K10) gene (Reiger et al., 1988). The two genes share a high level of 
sequence homology and have an identical expression pattern (in suprabasal 
keratinocytes). The expression constructs created in the present study, have been named 
with the prefix "K10" since the human nomenclature is the most widely used and 
accepted (Moll et al., 1982).
A "basic construct" was first created which was followed by various sequence 
manipulations that were facilitated by PCR and synthetic oligonucleotides.
3.5.1. SEQUENCE VERIFICATION OF THE HUMAN FACTOR IX cDNA 
CLONE
A possibility existed that the available human factor IX cDNA clone, 
pLXSN5'G3'cVI (Gift from Professor Brownlee at Oxford University; Anson et al., 
1985), might contain point mutations introduced during the propagation of the bacterial
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host. This would be critical for recombinant factor IX protein expression studies. Thus, a 
CCM analysis was performed in order to compare the sequence of the human factor IX 
cDNA clone with that of the wild-type sequence. Ectopic factor IX transcripts amplified 
from total human peripheral lymphocytic RNA was used as the wild-type sequence. The 
factor IX coding sequence was amplified using RT-PCR followed by nested PCR. As 
seen in figure 21, the entire factor IX coding sequence was initially amplified in three 
segments. The PCR primers used are listed in table 5 (A/B are primers used in the 
external reaction and C/D for the nested PCR). This initial amplification was followed by 
"splicing by overlap extension" (SOE; Horton et al., 1989), in order to combine the three 
individual segments and achieve the amplification of the full length factor IX coding 
sequence (figure 21B).
This full-length, wild-type factor IX coding sequence was used as the probe in a 
CCM analysis against the human factor IX cDNA insert in plasmid pLXSN5'G3'cVI. As 
seen in figure 22, no cleavage product was obtained, confirming that the sequence of the 
factor IX cDNA clone was identical to the wild type sequence. Furthermore, no cleavage 
product was observed that would correspond to the junctions of the SOE. These might 
be predicted to arise from the non template-directed addition of a deoxyadenosine (A) 
residue at the 3' ends of duplex PCR products by Taq DNA polymerase (Clarke, 1988). 
The high annealing temperatures and low concentration of dNTPs used during the SOE 
may have prevented the priming with those strands that had the non-complementary base 
at their 3' ends (as in allele-specific amplifications; Wu et al., 1989; Sarkar et al., 1990). 
Also analysis of the predicted mismatches resulting from the added adenosine residues at 
the 3' end of the primers in SOE revealed that they were either A-G or A-A, both of 
which are inefficiently extended by Taq polymerase (Kwok et al., 1990).
3.5.2. THE BASIC KIO-FACTORIX cDNA CONSTRUCT
A cloned DNA segment containing 5 kb of upstream sequence of the bovine 
cytokeratin VI gene (BKVIb), just short (eight nucleotides) of the natural BKVIb cap site 
(K10 promoter; Blessing et al., 1989; Bailleul et al., 1990) was obtained from Jose 
Jorcano (Madrid, Spain). A 0.85 kb, SV40 polyadenylation cassette (SV40 poly A)
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Table 5: Prim er sequences for the amplification of ectopic factor IX transcripts
Name Orientation Sequence (5' - 3') Positiona
F9IA
F9IB
F9IC
F9ID
Forward
Reverse
Forward
Reverse
GCT AGC AAA GGT TAT GCA GCG CGT 
TGA TTG GGT GCT TTG AGT GAT GTT 
AAA GGT TAT GCA GCG CGT GAA CAT 
CAT CAG GAA AAA CAG TCT CAG CAC
-13-11 
637 - 660 
-7-17 
572 - 595
F9DA
F9IIB
F9IIC
F9IID
Forward
Reverse
Forward
Reverse
AAA ATA GTG CTG ATA ACA AGG TGG 
TTC CCC AGC CAC TTA CAT AGC CAG 
TGA ACC AGC AGT GCC ATT TCC ATG 
GAT GTT CGT GTA TTC CTT GTC AGC
437 - 460 
1049 -1072 
510 - 533 
1009 -1032
F9IDA
F9DIB
F9MC
F9HID
Forward
Reverse
Forward
Reverse
GGA GAC AGA ACA TAC AGA GCA AAA 
CTA ACA AAA GAT GGG AAA GTG ATT 
GAA CAT ACA GAG CAA AAG CGA AAT 
AAA GAT GGG AAA GTG ATT AGT TAG
855 - 878 
1450 -1473 
862 - 885 
1444 -1467
Primers named I, II and in  are for the amplification of segments A, B and C, in figure 
21, respectively. Primers that end with B were used for reverse transcription. Primers 
ending with A and B were used for the initial PCR reaction and those ending with C 
and D for the nested PCR. aNumbering is according to GenBank/EMBL accession 
number J00136.
Figure 21: Amplification of the full-length ectopic human factor IX transcript by 
SOE-PCR
21A. This figure shows the diagrammatic representation of the factor IX cDNA and 
the positions of the primers used to amplify the factor IX ectopic transcript in three 
overlapping segments (A, B and C). The position and orientation of the primers F9A 
and F9B, spanning the entire factor IX coding sequence, are also indicated.
21B. The three overlapping RT-PCR segments (A, B and C) spanning the entire factor 
IX coding sequence are resolved by agarose gel electrophoresis. "Ct", represents the 
control PCR performed using primers F9A and F9B to amplify the cloned factor IX 
cDNA. "Sp", indicates the product of SOE-PCR using primers F9A and F9B, and 
segments A, B and C as templates. Lane "Sp" indicates a product similar in size to that 
of the control PCR (Ct). Faint bands at the level of segments "B" and "C" are also 
noted in the lane marked "Sp".
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Figure 22: CCM analysis of the cloned factor IX cDNA
The figure shows the CCM analysis of the human factor IX coding sequence in 
pLXSN5'G3'cVI (pLIXSNL-2 in Gerrard et al., 1993). The normal human factor IX 
coding sequence was obtained by RT-PCR of ectopic factor IX transcripts (figure 21). 
The modifying chemicals are indicated as Hy=hydroxylamine and Os=osmium 
tetroxide. The lane marked "+" is a positive control (cleavage product indicated by an 
arrow). The control (C) and test (T) lanes are indicated along the top margin.
Table 6: Oligonucleotides used in cloning / sequence modifications:
Name Orientation Sequence (5f - 3')
F9A
F9B
F9G4
Forward
Reverse
Forward
CTC GGG GTA CCA TGC AGC GCG TGA ACA TGA T 
AAC CTT GGA AAT CCA TCT TTC ATT AAG TGA G 
CTC GGG GTA CCA TGG TCC GCG TGA ACA TGA T
3'K10
5'FIX
K10SCR
Forward
Reverse
Forward
GCA AAA AGA AAA CCA AGC AAG TAA G 
AAT TTT GTT GGC GTT TTC ATG ATC A 
ACT CCC TGA GCT AAA CAG CAT CAC
K10A
K10B
Forward
Reverse
CAC GGG GGA TCC CAC TCC CTG AGC TAA ACA 
GCA TCA CCG GTA CCG GGC AC 
GTG CCC CCT CTT GTG AGG GAC TCG ATT TGT CGT 
AGT GGC CAT GGC CCG TG
3'MAN-A
3'MAN-B
3'MAN-C
3'MAN-D
K10X
Forward
Reverse
Forward
Reverse
Forward
CAC GGG GGA TCC CAC TCC CTG AGC TAA ACA G 
CTA GTT TCT GCT GAC CTT GGT TTA AGT GAG GAA 
ACA AAA AAG GAA
CTT TTT TGT TTC CTC ACT TAA ACC AAG GTC AGC 
AGA AAC TAG CTG
GAA GCC TCG CGA GAA TTC GAC TTA ATT CAA 
AGC CAG AGA A
GCT GGG ATC GAT ACC AAG GTC AGC AGA AAC 
TAG CTG
containing an SV40 polyadenylation signal sequence and small-t intron (66 nucleotides) 
was obtained from pRSV(3globin (Mulligan et al., 1979). The K10 promoter and SV40 
polyA sequence were subcloned into the multiple cloning site (MCS) of pIC20H in the 
correct orientation with a few restriction enzyme sites of the MCS left in between them 
(figure 23A). This expression vector (KlO-polyA cassette) was constructed by Dr. D. 
Fowlis in our department. The chance presence of a consensus cap sequence 24 
nucleotides downstream of the BKVIb TATA box (as part of the MCS; instead of 26 
nucleotides as in the normal BKVIb gene) and its functional capacity were demonstrated 
following the use of the same K10 promoter/enhancer to drive the expression of mutant 
H-ras and TGFpl in transgenic mice (Bailleul et al., 1990; Cui et al., 1994). Cw-acting 
elements required for suprabasal keratinocyte-specific expression are present in a 3.4 kb 
segment of this promoter (with the same 3' end as the promoter used here; Bailleul et al., 
1990) but absent in a 1.2 kb segment of immediate upstream sequence in the human K10 
gene (Jiang et al., 1991). The small t-intron in the SV40 polyA cassette was included to 
provide the non-specific effect of efficient mRNA processing and transport attributable to 
the presence of heterologous introns in expression vectors (Hamer and Lader, 1979; 
Gruss and Khoury, 1980; Mulligan and Berg, 1980; Villarreal and White, 1983) and for 
transcriptional enhancement in transgenic mice (Brinster et al., 1988).
Two oligonucleotide primers were designed to facilitate the amplification and 
cloning of the entire human factor IX coding sequence (figure 23B). Kpnl and Clal 
recognition sequences were incorporated into the forward (F9A) and reverse (F9B) 
primers respectively (table 6), because these were unique sites available for cloning 
between the K10 promoter and SV40 polyA sequence. The Kpnl recognition sequence 
was incorporated into the upstream primer, immediately flanking the 'ATG' translation 
initiation codon. A single base substitution (C-*G) was introduced into the downstream 
primer, nine nucleotides downstream of the 'UAA' translation termination codon, so as to 
produce a Clal recognition sequence. GC-rich anchor sequences were also incorporated 
into the primer design to allow efficient digestion at the termini. The plasmid 
pLXSN5'G3'cVT was used as a template for PCR. A 1.4 kb PCR product was obtained 
(figure 23C), and the Kpnl /  Clal restriction-digested PCR product was gel purified and
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Figure 23: Construction design of the basic K10-FIX gene construct
23A. The figure shows a diagrammatic representation of the K10 polyA cassette. The 
relative positions and sizes of the K10 promoter and SV40 polyA cassette (SV40 
polyA) are indicated. The restriction enzyme recognition sites as part of the multiple 
cloning site (MCS) of the pIC20H plasmid are also shown.
23B. This figure demonstrates the design of the primers (F9A and F9B) use to 
facilitate the cloning of the human factor IX coding sequence into the K10 polyA 
cassette. F9A, which primes at the 5' end, has a Kpnl recognition site immediately 
flanking the " ATG" initiation codon. F9B, which primes at the 3' end, has a single base 
substitution (C—>G) situated 9 nucleotides 3' to the translation termination codon 
(TAA) to create a Clal recognition site. Both primers have sufficient sequence 
flanking the restriction enzyme sites to facilitate efficient digestion at the termini of the 
resultant PCR product.
23C. This figure shows the amplification of the complete factor IX coding sequence 
(1.4 kb) using primers F9A and F9B.
(A)
S a i l
”M C S ”
B a m H I / S m a l / K p n l / S a c l / E c o R I / C l a l / E c o R V / X b a l / B g l l l
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S V 4 0
p o l y A
( 0 . 8 5  K b )
K10 polyA c a s s e t t e  
(in plC20H)
(B)
5 ’ C T C G G
Kpnl
”F 9 A ”
AT G CAG CG CGT G A ACAT G AT
—  CTCACT TAA TGAAAG  
3 ’ GAGTGA ATT ACT TTC
”F 9 B ”
AT G G AT 
TACCTA
T T C C A A G G T T  3 ’ 
A A G G T T C C A A  5 ’
I
G
( C la l )
(C)
F9A/ B PCR
ligated into the MCS of the KlO-polyA cassette. After transformation into E. Coli 
LE392, six out of twenty-five colonies picked, were found to contain the desired insert by 
direct PCR screening, which was then confirmed by restriction mapping (figure 24). 
These subclones were named K10-FIX-I to VI.
As Taq polymerase was used for PCR and no specific measures were taken to 
minimise the infidelity of the polymerisation, it was imperative to verify the sequence of 
the individual clones. A CCM analysis was performed, using the factor IX cDNA clone in 
pLXSN5'G3'cVI as the wild-type probe. Figure 25 shows cleavage products in two of the 
six clones analysed, one each by osmium tetroxide and hydroxylamine modification 
respectively. K10-FIX-I and VI therefore represent examples of PCR-induced 
mutagenesis. It was important to analyse the mutation in K10-FIX-I, since this construct 
had already been used for generation of transgenic mice (in collaboration with Dr. Y. 
Alexander). Following a precise localisation of the mutation in K10-FIX-I by an 
overlapping nested CCM analysis (as in section 3.2.2), it was characterised by direct 
sequencing of the products of an asymmetric PCR. As seen in figure 26, clone I had a 
single base substitution, T—»A (nucleotide 575; numbering according to Anson et al., 
1984), which changes a serine to threonine at position 136 (amino acid numbering is 
according to Anson et al., 1984) in exon VI of the factor IX gene, mapping within the 
activation domain of the factor IX polypeptide. Over 70% of mutations resulting from the 
lack of 3'—>5' exonuclease activity are T-»C substitutions resulting from efficient 
extension at T-dGTP mispairs (Tindall and Kunkel, 1988; Bebenek et al., 1990; Eckert 
and Kunkel, 1992). Another cause for mutagenesis in PCR includes heat damage causing 
cytosine deamination that result in C—»T /  G—>A mutations (Eckert and Kunkel, 1992). 
None of these mechanisms explain the error observed in K10-FIX-I. For generation of 
further gene constructs K10-FIX-II was selected for use as the basic construct, since this 
was shown not to contain mutations.
The following observations can be made about the basic construct from figure 28: 
(a) The "AUG" initiation codon of the factor IX coding sequence is the first in the leader 
sequence, but is not in an appropriate "context" (Kozak, 1991a,b); (b) There is no natural 
cap site, either from the K10 or the factor IX gene, though a consensus cap site is
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Figure 24: Restriction analysis of the basic K10-FIX gene construct
24A. This figure shows a diagrammatic representation of the K10 polyA cassette and 
the restriction enzyme recognition sites available in the MCS. K10=K10 promoter; 
polyA=SV40 polyA cassette.
24B. This figure shows a diagrammatic representation of the basic K10-FIX gene 
construct and the restriction enzyme sites used to confirm the subcloning of the factor 
IX coding sequence into the K10 polyA cassette.
24C. Partial restriction mapping of the basic K10-FIX gene construct to confirm the 
successful subcloning of the factor IX coding sequence. Lanes 1, 3, 5 and ^  are digests 
of the K10 polyA cassette. Lanes 2, 4, 6 and 8 are digestions of the K10-FIX-II gene 
construct. The restriction enzymes used include, Kpnl/Nrul (lanes 1, 2); ZTcoRV (lanes 
3, 4); Sacl (lanes 5, 6) and ZTcoRI (lanes 7, 8). The Kpnl/Nrul double digest 
demonstrates the expansion due to a 1.4 kb insert. The EcoRV digest demonstrates 
that the expansion is due to the subcloning of the factor IX coding sequence and 
serves to confirm the orientation of the insert. Lanes 5-8 demonstrate the abolition of 
the recognition sites in the MCS as a result of the insertion between the Kpnl and Clal 
site.
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Figure 25: CCM analysis of the basic K10-FIX gene constructs
This figure shows the result of the CCM analysis of the six positive constructs (I-VI) 
isolated after the subcloning of the human factor IX coding sequence into the K10 
polyA cassette (K10-FIX-I to VI). The modifying chemical used in each reaction is 
indicated. C=Negative control; L=radiolabelled 1 kb ladder. Cleavage products 
(indicated by arrows) are seen in K10-FIX-I (A) and K10-FIX-VI (B), detected by 
osmium tetroxide and hydroxylamine modifications, respectively.
Osmium te t rox ide  
C I II III IV V VI
Hydroxylamine
Figure 26: Sequence analysis of the K10-FIX-I construct showing the S136T 
mutation
This figure shows partial sequence analysis surrounding the cleavage site (detected in 
figure 25A) in the factor IX coding sequence of K10-FIX-I. Mt=mutant sequence; 
N=normal sequence. Analysis of the sequence shows a T—»A transversion at mRNA 
position 575, which results in a serine to threonine missense mutation at amino acid 
136 in exon VI of the factor IX gene (numbering according to Anson et al., 1984).
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provided within the MCS; (c) The 5'UTR (leader) which is formed by the pIC20H 
polylinker sequence, is only 14 nucleotides long and has a GC content of -71% (10/14). 
All of these features would contribute in considerably reducing the efficiency of 
translational initiation by interfering with scanning of the leader sequence (by the 40S 
ribosomal subunit/initiation complex) and the efficient recognition of the "AUG" initiator 
(Kozak, 1991a,b). Sequence modifications were therefore designed to minimise, as much 
as possible, the apparently negative effects of these unfavourable sequence contexts.
3.5.3. ENGINEERING OF A FAVOURABLE CONSENSUS SEQUENCE FOR 
TRANSLATION INITIATION
Kozak (1986a, 1987, 1989a,c) demonstrated that for the most efficient initiation 
of translation, the consensus sequence GCCA/rTCCAUGG. must exist around the 
initiation codon in eukaryotic mRNAs. Two positions were found to be most critical, 
namely: a purine (usually an 'A') at -3 and a 'G' at +4 (where the 'A' of AUG is +1) and, in 
fact, most vertebrate RNAs conform to the consensus sequence A/nNNAUGG. As seen 
in figure 27, the sequence surrounding the initiation codon in the basic construct 
(ACCAUGC) does not have a 'G' at position +4. The choice of Kpnl as the enzyme 
recognition sequence immediately upstream from the AUG codon, provided a purine (A) 
at position -3.
In order to theoretically increase the translational efficiency of the factor IX basic 
construct, a 'C' nucleotide at position +4 was replaced by a 'G'. To avoid altering the 
amino acid charge at position 2 (Gin to Glu) it was decided to cause a more conservative 
change by altering the entire sequence of the second codon (position -45 according to 
Anson et al., 1984), so that it would read as GUC (Val) instead of the normal CAG (Gin) 
(Q-45V). A forward primer that was otherwise identical to F9A (used for the basic 
construct), except for the 'CAG—>GUC' change at positions 44, 4-5 and +6 in the coding 
sequence (positions 15-17 in the primer), was designed for this purpose (F9G4, table 6). 
This altered factor IX coding sequence was amplified and cloned into the KlO-polyA 
cassette in the same way as for the basic construct. Seven out of twenty-five colonies
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Figure 27: Site-directed mutagenesis to introduce a favourable sequence context for 
translational initiation
27A. This figure shows a Kpnl/Nrul double restriction digest to demonstrate the 
expansion of the K10 polyA cassette due to a 1.4 kb insert (as in figure 24). Lane 1 
contains DNA from the K10 polyA cassette and lanes 2 and 3 contain DNA from K10- 
FIX-I and II, respectively. Lane 4 contains DNA from the K10-FIX-G4 construct 
which shows a similar pattern to those of the two latter constructs.
27B & C. These figures show the sequence surrounding the junction of the K10- 
promoter and the factor IX coding sequence and confirm the incorporation of the site- 
directed mutagenesis involving the second codon of the factor IX cDNA in the K10- 
FIX-G4 construct. The order of loading of the sequence is indicated along the top 
margin. The restriction enzyme recognition sequences in the MCS are shown. The 
"TATA” box in the K10 promoter and the translation initiation site of the factor IX 
cDNA are indicated. Figure 27C shows the change in the sequence of the second 
codon from CAG (Gin; in K10-FIX-II) to GTC (Val; in K10-FIX-G4) (Q-45V) and 
the attainment of a favourable consensus sequence (described by Kozak, 1991a,b) for 
translation initiation (^/qCCATGG).
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screened by PCR were positive and on restriction mapping revealed the presence of the 
correct insert.
In order to confirm that PCR mediated, site-directed mutagenesis had been 
successful, the region surrounding the AUG initiation codon was sequenced. A forward 
primer (3'KIO, table 6) near the 3' end of the truncated K10 promoter (59 bp upstream 
from the BKVIb TATA box) and a reverse primer at position 96 in the factor IX cDNA 
(5'FIX) were synthesised. Asymmetric PCR was followed by direct sequencing. Figure 27 
demonstrates the successful modification of the sequence at the second codon of the 
factor IX cDNA and the consequent attainment of a 'G1 at +4 and therefore a favourable 
translation initiation consensus sequence (ANNAUGG). To signify the mutagenesis of 'C 
—»G' at position +4, this construct was named K10-FIX-G4.
Due to the high mutability rate encountered during the making of the basic 
construct, conditions for PCR were modified so as to permit a higher fidelity of 
polymerisation (section 2.4.3). The number of cycles were curtailed to 25, a five-fold 
reduced concentration of dNTPs was used (50 pM) and the duration and temperature of 
the denaturation step at the beginning of each cycle were reduced. A subsequent chemical 
mismatch cleavage analysis revealed no mutations in the coding sequence of all seven 
positive clones. The polymerase error rate was calculated as described by Eckert and 
Kunkel (1992). In the making of the basic construct, the error frequency (f) after 30 
cycles (n) was 1/4194 nucleotides synthesised (2 mutations in 6 X 1398 nucleotides 
screened). Using the formula f = np/2 the error rate was estimated as 1/63,000 per 
nucleotide synthesised per PCR cycle. In the case of K10-FIX-G4, it was estimated to be 
<1/147,000 (error rate <1/9786 nucleotides), which represents a 2.3 fold reduction in 
polymerase infidelity.
3.5.4. ENGINEERING THE 5' UNTRANSLATED SEQUENCE
A moderately long and unstructured leader sequence is ideal for efficient 
translational initiation (Kozak, 1991a,b,c,d, 1992,1994). Recognition of the first "AUG” 
is impaired if it is positioned too close to the cap site (<12 nucleotides) and a 
proportional imrovement takes place when it is elongated (with sequences of low GC
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content) over a range of 17-80 nucleotides. The leader sequence of K10-FTX-II and K10- 
FIX-G4 is 14 nucleotides long with a high GC content of -71% (10/14) and is 
theoretically not an optimal leader sequence. The normal BKVIb/HKlO leader sequence 
is 26 nucleotides long and has a GC content of -54% (14/26) as would be expected for a 
highly expressed gene (Kozak, 1991a,b). Furthermore, the leader sequence of BKVIb and 
HK10 are very highly conserved and are virtually identical (25/26, except for an A—»G 
transition at -17). The high level of sequence conservation may also indicate the presence 
of primary sequences that could enhance gene expression (Reiger et al., 1988).
In order to theoretically improve the translational efficiency of the K10-FIX-II 
and K10-FIX-G4 constructs, by altering the ribosomal binding site to that of BKVIb, the 
natural cap site and 5'UTR sequence of the BKVIb gene (K10CAP and K105'UTR) was 
inserted into the MCS, between the BamHl and Kpnl sites (figure 28 A & B). Two 
complementary oligonucleotides (K10A and K10B, table 6) were synthesised with the 
appropriate sequence (figure 28B) i.e. the K10 CAP site and 5'UTR sequence flanked by 
the recognition sequence for BamHl and Kpnl (table 6). Suitable anchor sequences were 
also included to enable efficient restriction digestion.
Equimolar concentrations of the two oligonucleotides were annealed together, 
digested and ligated into suitably-linearised K10-FIX-II and K10-FIX-G4 constructs. 
Individual colonies were screened directly by PCR. A forward primer specific to the 
inserted sequence (K10SCR, table 6) was synthesised for this purpose (underlined in 
figure 28B). In order to confirm the oligonucleotide-mediated partial gene synthesis, PCR 
primers flanking the region (3'K10 and 5'FIX, table 6) were used to sequence clones that 
were positive for the insert. Figures 29 and 30 show the successful incorporation of the 
required sequence between the BamHI and Kpnl sites. Figure 29 also shows the sequence 
of one of the (seven positive) clones (RB15) that had the anchor sequence incorporated 
into the construct, immediately upstream of the translation start site. This was due to 
incomplete restriction digestion and illustrates the importance of using excess enzyme and 
prolonged duration for digestion at termini of DNA segments (Clackson et al., 1992). As 
the clones K10-FIX-II and K10-FIX-G4 were previously shown not to have any 
mutations in the factor IX coding sequence, no further analysis was necessary.
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Figure 28: Construction design for repair of the 5' untranslated region (5'UTR)
28A. This figure shows a diagrammatic representation of the junction between the 
K10 promoter and the factor IX coding sequence in the basic K10-FIX gene construct. 
The enzyme recognition sequences in the MCS are shown. A consensus cap site 
sequence is underlined in the MCS.
28B. This figure shows the two complementary synthetic oligonucleotides designed to 
repair the 5'UTR of the basic K10-FIX and K10-FIX-G4 gene constructs. The 
sequence of the K10 cap site and K10 5'UTR are shown. The sequence was flanked by 
recognition sites for BamHl and Kpnl to facilitate the directional cloning of this 
synthetic DNA segment into the MCS of K10-FIX-II and K10-FIX-G4. GC-rich 
anchor sequences are incorporated in the oligonuleotide design to enable efficient 
digestion at the termini. The underlined sequence represents a forward PCR primer 
(K10SCR) used for screening bacterial colonies that contained plasmids with the 
synthetic insert.
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BamHl
”MCS”
Smal Kpnl
CTAGA GGATCC CCGGGTACC ATGC
K10 Promoter consensus cap FIX cDNA
5 ’UTR of K 10 -F IX -I/ I I
(B)
Anchor BamHl K10 Cap K10 5'UTR Kpnl Anchor
CACGGG GGATCC CACTCCC TGAGCTAAACAGCATCACC GGTACCGGGCAC
GTGCCC CCTAGG GTGAGGGACTCGATTTGTCGTAGTGGCCATGGCCCGTG
K10 A /  B
Figure 29: Sequence analysis confirming the repair of the 5'UTR in K10-FIX-II
29A. This figure shows the product of PCR using primers 3K10 and 5FIX, which span 
the junction between the (3' end of the) K10 promoter and (5' end of the) factor IX 
cDNA. The product in lane 1 is from K10-FIX-II and in lane 2 is from K10RB-FIX. 
The arrows demonstrate the resolution of the expansion seen due to the insertion of 
the 26 bp synthetic sequence.
29B. This figure demonstrates the sequence across the junctions of the K10 promoter 
and the factor IX cDNA. The order of loading in each track is indicated along the top 
margin. K10RB=K10RB-FIX gene construct; K10-G4=K10-FIX-G4 gene construct. 
The TATA box in the K10 promoter and the translational initiation site of the factor 
IX cDNA are indicated. Analysis of the sequence demonstrates the successful 
incorporation of the synthetic DNA segment (representing the natural K10 cap site and 
5'UTR) between the BamHl and Kpnl recognition sites (and are indicated alongside 
the sequence).
29C. This figure shows the sequence of the same region of one of seven positive 
K10RB-FIX clones (RB15). Analysis of the sequence demonstrates the incorporation 
of the anchor sequence (just prior to the start of the factor IX coding sequence) into 
the construct, due to poor digestion at the terminus (indicated alongside the 
sequence).
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Figure 30: Sequence analysis confirming the repair of the 5'UTR in K10-FIX-G4
This figure demonstrates the sequence across the junctions of the K10 promoter and 
the factor IX cDNA. The order of loading in each track is indicated along the top 
margin. K10RB=K10RB-FIX gene construct; K10RB-G4=K10RB-F1X-G4 gene 
construct. The TATA box in the K10 promoter and the translational initiation site of 
the factor IX cDNA are indicated. Analysis of the sequence demonstrates the 
successful incorporation of the synthetic DNA segment (representing the natural K10 
cap site and 5'UTR) between the Bamftl and Kpnl recognition sites (and are indicated 
alongside the sequence). The site-directed mutagenesis to achieve a favourable 
translation initiation sequence context surrounding the "AUG" initiation codon is also 
seen in the K10RB-FIX-G4 construct (Q-45V).
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To signify the intended enhanced ribosomal binding capacity of the K10-FTX-II 
and K10-FIX-G4 constructs, these constructs were named K10RB-FIX and K10RB-FIX- 
G4 respectively. These engineered constructs would now express mRNAs with a natural 
K10 cap site and a leader sequence 32 nucleotides long with a GC content of ~56% 
(18/32).
3.5.5. ENGINEERING THE 3' UNTRANSLATED SEQUENCE
The C-terminal codon of the natural BKVIb gene encodes a tyrosine. In the 
BKVIb gene, this codon (Tyr) is separated from the preceding codons by intron 7 (also 
seen in the corresponding human and murine genes; Reiger et al., 1988). The 
polyadenylation sequence is present 356 bases downstream from the translation 
termination codon and the cleavage site is a further 18 bases downstream. It has been 
suggested that the 3' end of some keratin genes are essential for efficient transcription (D. 
Roop, personal communication). In order to mimic the natural 3' end of the BKVIb gene, 
the SV40 polyA cassette was replaced with a segment of genomic DNA including intron 
7 (along with its splicing determinants) and 285 bp of sequence distal to the BKVIb 
polyadenylation signal. In some gene constructs, use of the SV40 polyA cassette has 
resulted in abberant splicing (Huang and Gorman, 1990) and its replacement would 
obviate this variable. In this construct therefore, intron 7 of the BKVIb gene would serve 
to enhance mRNA processing and transport (Hamer and Lader, 1979; Gruss and Khoury, 
1980; Mulligan and Berg, 1980; Villarreal and White, 1983; Brinster et al., 1988). The 
required sequences were amplified using the cloned BKVIb gene (in XKBVIb; Lehnert et 
al., 1984) as the template for PCR and termed the K10int7 cassette.
Two recombinant PCR strategies were used to facilitate the joining of the factor 
IX coding sequence to the K10int7 cassette. One method involved an initial ligation step 
followed by a second PCR in order to generate one PCR fragment. The other method 
involved PCR amplification using primers that resulted in SOE (Horton et al., 1989). 
Both methods involved the initial PCR amplification of the two segments to be joined viz. 
the complete factor IX coding sequence (with the previously engineered K10 CAP and 
5'UTR sequences) and the K10int7 cassette.
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Figure 31: Construction design and manipulation of the 3'UTR
31 A. This figure shows a diagrammatic representation of the factor IX cDNA and he 
3' end of the K10 gene. The regions of the K10 gene shown in this figure inclule 
intron 7, the translation termination signal in exon 8 (which has only 4 codiig 
nucleotides) and the polyadenylation signal. Together these comprise the 1 kb segmeit 
named the K10int7 cassette. The primers used to amplify the factor IX cDNA and he 
K10int7 cassette and to achieve the sequence manipulation are indicated. A, B, C aid 
D are the 3'MAN primers listed in table 6. The Clal recognition sites incorporated in 
the primers F9B and K10X are indicated. The solid triangles on primers B and C 
represent the complementarity of sequence to facilitate SOE.
3IB. This figure shows a diagrammatic representation of the joining of the factor X 
coding sequence with the K10int7 cassette, using primers 3'MAN A and D. This was 
achieved in two ways, (i) ligation of the two PCR fragments at the Clal sites in F© 
and K10X and (ii) SOE using the complementary sequences in primers 3'MAN B aid 
C (described in section 3.5.5). The recognition sequence for BamHl (in A) and Nnl 
(in D) and the presence or absence of the Kozak consensus sequence (in K10RB-FX 
and K10RB-FIX-G4, respectively) are indicated.
31C. This figure shows the PCR-based manipulations performed to join the tvo 
segments illustrated in 31 A. L=1 kb ladder. Lanes 1 and 2 are PCR amplifications Df 
the K10RB-FIX and K10RB-FIX-G4 constructs respectively (1.4 kb) . Lane 3 
demonstrates the PCR amplification of the K10int7 cassette (-1 kb). Lanes 4 and 5 
show products of PCR amplification (-2.4 kb) using primers 3'MAN A and D. Tie 
template used in lane 4 was obtained by ligation at the Clal sites in F9B and K10C 
The template used in lane 5 was obtained by SOE using the primers 3'MAN A-B aid 
C-D followed by a second amplification using 3'MAN A-D.
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Five new primers were designed. Four were called 3'MAN (for 3' manipulation) 
primers 'A' to 'D' (labelled as A, B, C & D in figure 31) and the fifth was named K10X. 
The primer F9B, designed for cloning of the basic construct, was also used. The 
sequences of these primers are listed in table 6. 3'MAN A and D, which were common to 
both the methods and as seen in figure 31, were used for the final amplification of the 
combined PCR product. They were designed with restriction enzyme sequences 
incorporated in their sequence (SawHI in 'A' and ZfcoRI and Nrul in 'D') in order to 
facilitate the subcloning of the final product.
In the first method (figure 31), two PCRs were performed; (i) primers 3'MAN A 
and F9B were used to amplify the factor IX coding sequence (1.4 kb) using either 
K10RB-FIX or K10RB-FIX-G4 as templates and (ii) primers K10X and 3'MAN D were 
used to amplify the K10int7 cassette (1.0 kb) using the cloned BKVIb gene (XKBVIb; 
Lehnert et al., 1984; Reiger et al., 1985) as the template. Primers F9B and K10X had 
Clal recognition sequences incorporated in their sequence so that both PCR products 
would have a Clal recognition sequence at one end (3' end of the former and 5' end of the 
latter). The PCR products were digested, gel purified and ligated at their Clal ends. This 
ligation mixture was then used as the template for a second PCR, using primers 3'MAN A 
and D to achieve the joining into one DNA fragment (2.4 kb).
In the second method (figure 31), the same two initial PCRs were performed on 
identical plasmid templates, except for the replacement of primers F9B and K10X with 
3'MAN B and C, respectively. Primers 3'MAN C & D were designed in such a way that 
they would achieve complementarity of the two PCR products at their ends, thus enabling 
SOE. Both PCR products were purified following a gel electrophoresis and mixed in 
equal quantities. The mixture was denatured and allowed to reanneal slowly. Due to the 
sequence of 3'MAN B and C, the otherwise unrelated PCR products would overlap at 
their ends. This was used as a template for PCR using the same external primers, 3'MAN 
A and D, which resulted in the desired product by SOE.
At the conclusion of this work, the K10int7 cassette had been successfully 
engineered 3' to the factor IX coding sequence, but not yet cloned into a plasmid vector.
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Figure 32: Summary of the various K10-FIX gene expression constructs
This figure shows a diagrammatic representation of the various K10 promoter-based 
factor IX gene expression constructs. The K10 promoter, factor IX cDNA, SV40 
polyA cassette and K10int7 cassette are depicted as green, purple, red and yellow 
filled boxes, respectively. The repaired 5'UTR is represented by a green hatched box 
and the manipulation to achieve a favourable translation initiation sequence by a pink 
box. The transcription start sites are indicated.
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3.5.6 SUMMARY OF THE VARIOUS KIO-FACTORIX GENE CONSTRUCTS
Figure 32 shows all the constructs containing the factor IX coding sequence 
driven by the K10 promoter/enhancer element
3.6. CATIONIC LIPOSOME-MEDIATED TRANSFECTION OF HaCaT CELLS
Cationic liposomes have been used for the transfection of a wide variety of 
established cell lines and primary cells either transiently or permanently (Loeffler and 
Behr, 1993). These newer cationic-lipid vectors have overcome most of the drawbacks 
associated with the earlier liposomal preparations (Nabel and Feigner, 1993). There are 
several advantages to this system of gene transfer: (i) it is highly efficient; (ii) no upper 
limit exists for the size of DNA; (iii) it is non-toxic; (iv) the cells do not have to be 
actively dividing; (v) it is applicable to a wide variety of cell types and (v) it is an effective 
method of gene transfer in vivo (approved for clinical trials; Nabel and Feigner, 1993) 
and a particularly attractive method to directly target keratinocytes.
3.6.1. OPTIMISATION OF THE TRANSFECTION PROTOCOL WITH A 
LINEARISED lacZ REPORTER CONSTRUCT
Even though better transfection efficiencies are obtained using supercoiled 
plasmids, to minimise the possibility of interruption of the transcriptional unit of the 
recombinant expression constructs during random integration into the genomes of the 
transfected cells, all the constructs were initially linearised. To ascertain the optimum 
quantity of linearised plasmid DNA and the expected efficiency of transfection obtained 
for the HaCaT cell line, a lacZ reporter construct pIRV-Neo-Act-lac Z (Beddington et 
al., 1989) was used. In this construct, the expression of lacZ was driven by the (3-actin 
promoter. Digestion with Notl released a 9.6 kb linearised DNA fragment which was 
extensively dialysed against T.E. buffer prior to its use in transfection.
1 pg, 5 pg and 10 pg of linearised plasmid DNA were transfected into 
subconfluent HaCaT cells in individual 80 cm2 tissue culture flasks (in duplicate). The
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Figure 33: Optimisation of liposome-mediated transfection of HaCaT cells using a 
LacZ reporter construct
33A-D. These figures show the results of the staining for (3-galactosidase activity 
following transfection with a reporter LacZ construct (pIRV-Neo-Act-LacZ) to 
estimate the transfection efficiency achieved using a cationic liposome preparation 
(DOTAP). 33 A was the negative control and was exposed to liposomes without DNA. 
1 pg, 5 pg and 10 pg of DNA was used for transfections in 33B, C and D, 
respectively. The transfection efficiency was estimated at -1% in 33ft, -3% in 33C 
and 5-6% in 33D.
(A) (B)
(C) (D)
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transfected cells were stained for (3-galactosidase activity, 72 hours after the transfection 
(48 hours after the withdrawal of the DNA-liposome mixture). The results of a negative 
control (which was exposed to liposomes without DNA) and the three different 
concentrations of DNA transfected, are shown in figure 33. Transfection efficiencies were 
estimated for the various transfections. A linear increase in the percentage of blue cells 
with increasing concentrations of DNA was observed. Transfection of 10 pg of linearised 
plasmid DNA gave a maximum transfection efficiency of 5-6%, whereas 1 pg gave an 
efficiency of 1-2%. Loeffler and Behr reported an average transfection efficiency of 15% 
using cationic liposomes for a wide variety of cells. The lower transfection efficiency 
observed in this study is likely to be due to the use of linearised plasmids (Kriegler, 
1990a).
3.6.2. TRANSFECTION OF HaCaT CELLS WITH THE VARIOUS FACTOR IX 
EXPRESSION CONSTRUCTS
The various K10 promoter-factor IX cDNA constructs included: K10-FIX-I 
(which had a missense S136T mutation in the factor IX coding sequence), K10-FIX-II 
(the basic construct), K10-FIX-G4, K10RB-FIX and K10RB-FIX-G4. All five constructs 
were linearised at the Sail site at the 5' end of the K10 promoter and extensively dialysed 
against T.E. buffer prior to use in the transfection protocol (section 2.9.3). In order to 
have a selectable marker for identifying transfected cells, they were co-transfected with 
pSV2Neo (also linearised; Southern and Berg, 1982) to confer G418 resistance (section 
2.9.5). Transfections were carried out in duplicate using 10 pg of the appropriate factor 
IX construct (section 3.6.1) along with 0.5 pg of pSV2Neo. Immediately after the 
transfection protocol, selection was applied using G418 (see section 2.9.5). Two separate 
pooled samples of clones were thus obtained for each transfected factor IX expression 
construct.
3.6.3. CLONING OF INDIVIDUAL STABLE TRANSFECTANTS
Clones in petridishes that had approximately 50 cells each and were adequately 
separated from other clones, were used for the cloning procedure. The method using
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"cloning rings" is described in detail in section 2.9.5 (Malcolm et al., 1987). Selected 
clones that survived, were gradually scaled up from small multiwelled plates to 80 cm2 
flasks maintaining the G418 selective pressure throughout. Table 7 summarises the 
number of clones picked for each factor IX construct and the numbers that survived the 
procedure. On average, the success rate of the cloning procedure was -26%. Both 
individual transfected clones and pools were used for further analysis.
3.6.4. ASSESSMENT OF STABLE INTEGRATION OF THE TRANSFECTED 
DNA
Genomic DNA was extracted from the various transfected clones and pools of 
HaCaT cells (table 7) and from control (untransfected) HaCaT cells. Primers F9A and 
F9B, which amplify the entire factor IX coding sequence were used to test for the 
successful integration of the transfected constructs (figure 34). These primers would fail 
to amplify the endogenous human factor IX sequences as the corresponding genomic 
fragment (>30 kb), would be far beyond the size range for conventional PCR 
amplifications. As cells used for the DNA extraction had been passaged at least five 
generations for pools and three for individual stable clones, this was a reliable indication 
of stable integration. The presence of an amplified 1.4 kb PCR product indicated that at 
least some intact copies of the complete factor IX coding sequence had been integrated 
per pool of transfected clones and at least one copy per cell for the individual stable 
clones. All the pools and a total of fifteen stably transfected (G418 resistant) clones were 
found to be positive (table 7). As seen in figure 34, DNA from untransfected HaCaT cells 
failed to show a PCR product.
3.7. ASSESSMENT OF FACTOR IX EXPRESSION: RNA ANALYSIS
Total cellular RNA was extracted from fully confluent flasks of the transfected 
and control HaCaT cells using the acid guanidinium thiocyanate-phenol-chloroform
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Table 7: Summary of transfected HaCaT cells
EXPRESSION CONSTRUCT POOLS CLONES3 CLONESb CLONES0
K10-FIX-I 2 12 3 2
K10-FIX-II 2 15 4 3
K10-FIX-G4 2 11 3 2
K10RB-FIX 2 10 2 0
K10RB-FIX-G4 2 12 3 2
aNumber of clones picked for analysis; bNumber of clones that survived the cloning 
procedure. All tested positive with the F9A/B PCR (figure 34); cNumber of clones 
analysed by RT-PCR (all positive; figure 35) and ELISA.
Figure 34: PCR analysis of transfected cells showing integration of the transgene
34A. This shows a diagrammatic representation of the primers used for the screening 
PCR to assess for integration of the transgene. The expected product of amplification 
is 1.4 kb.
34B & C. These figures show the results of the screening of the various transfected 
HaCaT cell lines (pools and individual clones). L=1 kb ladder; +=positive control 
DNA (cloned factor IX cDNA); H=DNA from untransfected HaCaT cells. In 34B, 
I=K10-FIX-I (pool); n=K10-FIX-n (pool); G4=K10-FIX-G4 (pool). In 34C, lane 
1=K10RB-FIX (pool); lane 2=K10RB-FIX-G4 (pool); Lanes 3-5=K10-FIX-I clones 
1-3; Lanes 6-9=K10-FTX-II clones 1-4; Lanes 10-12=K10-FIX-G4 clones 1-3; Lanes 
13& 14=K1 ORB-FIX clones 1 and 2; Lanes 15-17=K10RB-FIX-G4 clones 1-3.

method (Chomczynski and Sacchi, 1987). Two methods were used to assess the 
expression of factor IX mRNA in the transfected cells.
3.7.1. FACTOR IX mRNA DETECTION BY RT-PCR ANALYSIS
I
Total cellular RNA (0.5 pg) extracted from the transfected HaCaT cells were 
used as a template for RT-PCR analysis. Primers previously designed for the 
amplification of the human factor IX cDNA were used for this purpose (table 5). Primer 
F9IIB was used for reverse transcription followed thereafter by PCR using F9IIC and 
F9IID, to give an expected product of 523 bp (figure 35). As opposed to the nested PCR 
amplifications required for the detection of ectopic factor IX transcripts in peripheral 
lymphocytic RNA, in this analysis no second (nested) round of amplification was 
performed. Untransfected HaCaT cells and HaCaT cells transfected with pSV2Neo were 
used as negative controls. Primers specific for the actin cDNA were used for RT-PCR 
amplification, in order to confirm the integrity of the RNA extracted from the 
untransfected HaCaT cells. Factor IX mRNA was detected by RT-PCR, in all tested 
pools and individual transfected clones containing a factor IX construct (table 7), but was 
not detected in untransfected (or transfected with pSV2Neo) HaCaT cellular RNA 
(figure 35). To confirm that the expected PCR product arose from the factor IX mRNA 
expressed in these cells and not from contaminating DNA in the RNA preparation, PCRs 
using F9DC and F9IID were simultaneously carried out without a prior reverse 
transcription stage. None of the RNA samples tested were positive for this PCR (figure 
35).
These results also confirm the stable integration of the transgene and the integity 
of the coding sequence. In addition, the RT-PCR results indicate the integrity of the 
essential sequences outside the coding sequence and it can be concluded that the 
"transcriptional unit" was intact in each case. These results do not quantify the factor IX 
expression from the transfected cell lines for which Northern blot analysis and ELISAs 
were performed.
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Figure 35: Analysis of factor IX mRNA expression by RT-PCR
35A. This shows a diagrammatic representation of the primers used for the RT-PCR 
to detect factor IX mRNA. F9IIB (IIB) was used for reverse transcription and F9IIC 
(HC) and F9IID (IID) for the PCR. The expected product of amplification is 523 bp.
35B. This figure shows the result of the screening of three pools of transfected HaCaT 
clones. L=1 kb ladder; H=RNA from untransfected HaCaT cells; A=RT-PCR to detect 
actin mRNA in the untransfected HaCaT RNA sample used in lane H; +=plasmid DNA 
from the cloned factor IX cDNA. In the upper panel labelled "RT-PCR F9IICD", the 
RNA samples were subjected to reverse transcription prior to PCR. In the lower panel 
(indicated by an arrow; marked "PCR F9IICD") the same samples were subjected to 
PCR without prior reverse transcription. I=K10-FIX-I (pool); n=K10-FIX-II (pool); 
G4 (K10-FIX-G4 (pool). The first lane in the lower panel (after the size marker; 
marked by the arrow) is a positive control (cloned factor IX cDNA). The pooled 
samples in the lower panel show no products of amplification, indicating the absence 
of contaminating DNA.
35C. This figure shows the results of the screening of the various transfected HaCaT 
cell lines (pools and individual clones) by RT-PCR. L=1 kb ladder; H=RNA from 
untransfected HaCaT cells; N=RNA from HaCaT cells transfected with pSV2Neo; 
lane 1=K10RB-FIX (pool); lane 2=K10RB-FIX-G4 (pool); Lanes 3&4=K10-FIX-I 
clones 1 and 2; Lanes 5-7=K10-FIX-II clones 2-4; Lanes 8&9=K10-FIX-G4 clones 1 
and 3; Lanes 10&11=K10RB-FIX-G4 clones 1 and 3.
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3.7.2. FACTOR IX mRNA DETECTION BY NORTHERN BLOT ANALYSIS
Total cellular RNA (10 ng) from the five pools of transfected factor IX constructs 
was used for Northern blot analysis. An RNA sample from untransfected HaCaT cells 
was used as a negative control. In order to specifically detect the mRNA expressed by the 
transfected constructs, the SV40 polyA cassette was used to probe the Northern blot. 
Transcripts from a ubiquitiously transcribed gene, GAPDH, were analysed in order to 
assess the relative quantities loaded and the structural integrity of the RNA samples used 
in the Northern analysis.
Figure 36 demonstrates the detection of a -2.5 kb recombinant human factor IX 
transcript in total cellular RNA extracted from pools of clones transfected with the five 
constructs. The GAPDH probe revealed that RNA in the lane not showing factor IX 
transcripts was intact and that similar quantities of RNA were loaded in all lanes. K10- 
FIX-I and K10-FIX-II gave very faint, though detectable, factor IX bands on Northern 
analysis, compared with K10-FTX-G4, K10RB-FIX and K10RB-FIX-G4, which in turn 
were similar to each other. All constructs produced a transcript of the same size (-2.5 kb) 
and no alternative transcripts were seen. The results with the SV40 polyA probe were 
obtained after a five day exposure compared with the GAPDH probe which was obtained 
after 24 hours, indicating low levels of factor IX expression.
RNA extracted from the epidermis of transgenic mice created using the K10-FIX- 
I construct, in collaboration with Dr. Y. Alexander, also gave the same result. The 
presence of only one band indicates that there were no alternate transcripts and that 
within the limited resolution of the agarose gel, the factor IX expression from the various 
constructs utilised one site each for transcriptional initiation and termination. All the 
constructs used for transfection had almost identical sequences in all regions except in the 
5'UTR. The 5'UTR of the K10-FIX-I, K10-FIX-H and K10-FIX-G4 constructs is 
predicted to be 14 nucleotides and that of K10RB-FIX and K10RB-FIX-G4 constructs to 
be 32 nucleotides long. The factor IX coding sequence in the various constructs is 1398 
nucleotides (of which, 9 nucleotides are from the factor IX 3'UTR) and the 3'UTR 
sequence contributed by the SV40 polyA cassette is predicted to be 761 nucleotides 
(assuming the 66 nucleotide small t-intron to be normally spliced out). The total length of
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Figure 36: Analysis of factor IX mRNA expression by Northern blotting
This figure shows the detection of factor IX mRNA by Northern blot analysis of the 
pools of transfected HaCaT cells. Lane 1=RNA from untransfected HaCaT cells; Lane 
2=K10-FIX-I; Lane 3=K10-FIX-II; Lane 4=K10-FIX-G4; Lane 5=K10RB-FIX; Lane 
6=K10RB-FIX-G4. The individual lanes can be distinguished by the loading dye 
shown by the arrow. Probing the Northern transfer with the SV40 polyA cassette 
reveals a -2.5 kb transcript (indicated by an arrow) in all transfected samples (faint 
signals in lanes 2 and 3). The same filters were re-probed with a GAPDH probe to 
determine the integrity and relative loading in the lanes.
S V 4 0  polyA 
GAPDH
the factor IX mRNA transcript from the two types of constructs is therefore predicted to 
be 2174 and 2191 nucleotides in addition to the poly A tail, respectively. As the Northern 
blot revealed a single band of -2.5 kb, it indicates that the poly A tail is approximately 
300 nucleotides long. It is noteworthy that due to the low resolution of the agarose gel it 
is not possible to detect the predicted 17 nucleotide difference among the two classes of 
transcript, nor is it possible to determine if the small t-intron (66 nucleotides long) in the 
SV40 polyA cassette was successfully spliced out
3.8. ASSESSMENT OF FACTOR IX EXPRESSION: TRANSLATIONAL 
ANALYSIS.
Enzyme Linked Immunosorbent Assay (ELISA) was used to detect secreted 
factor IX protein secreted into conditioned media by HaCaT cells transfected with the 
various gene expression constructs. The same assay was also used to estimate the levels 
of factor IX in the plasma of transgenic mice (created with the K10-FTX-I construct).
3.8.1. ENZYME LINKED IMMUNOSORBENT ASSAY OF SECRETED 
FACTORIX
Two monoclonal antibodies, namely 'A5' and A71 were used in a "sandwich’' 
ELISA for the detection of factor IX antigen. The antibodies and protocol for the ELISA 
were provided by Dr. Kenneth Smith (University of New Mexico, USA) and are 
described in section 2.10. For factor IX to be biologically active, the y-carboxylation of 
12 glutamyl residues near the N-terminus is essential (reviewed by Vermeer et al., 1990). 
Since Vitamin K is required for this post-translational modification, it was supplemented 
in the tissue culture medium. The antibody (A7) used in the ELISA detected a calcium- 
dependent epitope in the light chain and was used to specifically estimate y-carboxylated 
factor IX (Smith and Ono, 1984; Smith, 1988) and thus determine the capacity of 
keratinocytes to secrete the biologically active protein. Transfected cells were made to 
condition serum-free medium (for 24 hours) for the assay. Even though this may have
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had some depressing effect on the metabolism of the cells (probably slightly affecting the 
factor IX synthesis and/or secretion), this was done to avoid any cross-reaction with 
bovine factor IX present in the supplementing serum. Furthermore, Smith et al. (1993) 
observed a 40% suppression of the ELISA values due to the presence of (some factors 
in) mouse plasma. This effect would also be avoided by use of serum-free medium for 
sample collection.
Cells in fully confluent 80 cm2 flasks were incubated for 24 hours in serum-free, 
vitamin K containing tissue culture medium. Serial dilutions of conditioned media (in 
triplicate) were used in the ELISA. Serial dilutions of commercially available pure factor 
IX antigen (Dakopatts) was used to plot a standard curve between 0 to 50 ng/ml. The 
biotinylated 'A7' antibody bound to factor IX was detected by a chromogenic assay, and 
the optical densities (at 490 nm) obtained for the conditioned media were plotted on the 
standard curve obtained with serial dilutions of pure factor IX.
To plot a standard curve, serial dilutions of pure factor IX were made in the 
recommended dilution buffer (section 2.10). A control experiment was performed to rule 
out any inhibition/enhancement of the optical densities (OD) due to die high proportion 
of tissue culture medium in the undiluted, 1 in 2 and 1 in 4 diluted conditioned media 
samples. Figure 37 shows the standard curves plotted for the serial dilutions of pure 
factor IX in tissue culture medium (serum free) and in the recommended dilution buffer. 
No significant difference in the curve profile was apparent
Figures 38-41 show the plotting of OD (490) readings obtained from the secreted 
factor IX in conditioned media from the various transfected cell lines (pools and clones; 
tables 7 and 8). In addition, figures 38 and 39 also show the curves obtained for dilutions 
of conditioned media obtained from the pooled samples of K10-FIX-G4, K10-FIX-II and 
K10-FIX-I. These curves indicate that serial dilutions of the conditioned media showed 
the expected reductions in factor IX concentrations (figure 38) and although dilutions of 
up to 1 in 4 plotted in the linear portion of the standard curve in the case of K10-FIX-G4, 
this was only possible up to a 1 in 2 dilution for K10-FIX-I and K10-FIX-II (figure 38, 
39). The OD readings used for the estimation of factor IX secreted by all transfected 
pooled clones plotted in the linear portion of the standard curve (figures 38-41). While
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Figure 37: Effect of tissue culture medium on ELISA
X-axis (logarithmic scale), factor IX concentration (ng/ml); Y-axis, optical density at 
490 nm (OD 490). Serial dilutions of pure factor IX (50 ng/ml to 3.125 ng/ml) were 
made in tissue culture medium and sample dilution buffer (Smith, 1988), and the two 
curves obtained on plotting the optical densitometric readings are seen. The error bars 
represent variation of ±2 standard deviations.
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each of the ELISAs seen in figures 38-41 had different sensitivities, in general it was 
always possible to detect factor IX levels above 1.5-3 ng/ml. Conditioned media collected 
from imtransfected HaCaT cells consistently gave OD readings that were below the 
background.
Figure 40 demonstrates the effect of confluency and storage of conditioned 
media, on the factor IX levels measured. G4-80 represents the same K10-FTX-G4/Pool in 
this figure (including the generation), except that the flask was 80% confluent at the time 
of sampling. Also in figure 40, G4-5D represents the same K10-FIX-G4/Pool sample 
assayed in figure 38 that had been stored at 4°C for 5 days. Bearing in mind the relative 
inaccuracy of the readings in this region of the standard curve, they both nevertheless 
represent a significant drop from the K10-FIX-G4/Pool readings in figures 38 and 40.
The actual OD (490) readings, factor IX concentrations in the various conditioned 
media samples and the factor IX secretion calculated as ng/million cells/24 hours are 
listed in table 8. The measure of variance is indicated by the +2 standard deviations listed 
within parentheses.
In an attempt to assess any difference that may have arisen due to the sequence 
differences in the constructs, a comparative analysis of factor IX expression from the 
various transfected cells was performed (section 4.2.1). In order to avoid errors due to 
possible variations amongst the individual clones, only pooled clones were used for this 
analysis. Figure 42 shows the relative expression levels obtained, along with error bars 
demonstrating the variation of ±2 standard deviations. A student t test was performed to 
estimate the significance of the differences observed in the average expression levels 
(appendix II). Listed in table 9 are, the mean expression levels, ±2 standard deviations 
and the result of the student t test. The rest of the factor IX constructs were compared 
with the expression achieved by the basic (K10-FIX-II) and K10-FIX-G4 constructs. The 
results demonstrate the following: (a) no significant difference existed between the basic 
construct (K10-FIX-II) and that with the S136T mutation (K10-FIX-I); (b) All the three 
manipulated constructs i.e. K10-FIX-G4, K10RB-FIX and K10RB-FIX-G4, showed 
significantly higher expression than the basic construct and (c) No significant difference 
was observed amongst the three manipulated constructs.
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Figure 38: ELISA I
Xl-axis (logarithmic scale), factor IX concentration (ng/ml), used for plotting the 
standard curve of serial dilutions of pine factor IX; X2-axis, dilution factor (1 = 
undiluted, 1/2 = 1:1 dilution, etc.) of conditioned tissue culture medium from 
transfected HaCaT cells; Y-axis, optical density at 490 nm (OD 490). The X2-axis was 
used to plot the densitometric readings of serial dilutions of conditioned medium from 
cells (pooled clones) transfected with K10-FIX-G4 and K10-FIX-II. The OD readings 
(summarised in table 8) were used to calculate the factor IX concentration (ng/ml) 
using the standard curve, and the readings are tabulated in the figure (inset). 
Abbreviations used in the table are, Diln=dilution factor; Obs.=observed reading; 
Exp.=expected reading (from the dilution factor). The readings obtained (Obs.) for the 
conditioned medium from cells transfected with K10-FIX-G4 were above the 
background up to 1 in 8 dilution and correlated with the expected readings (Exp.). 
Similar correlation was seen for K10-FIX-II up to 1 in 4 dilution. It can be seen from 
the curves, that in the case of K10-FIX-G4, serial dilutions up to 1 in 4 plotted in the 
linear portion of the standard curve, whereas for K10-FIX-II this was only possible up 
to a 1 in 2 dilution.
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Figure 39: ELISA II
XI, X2 and Y axes are identical to those in figure 38. The factor IX standard curve 
and curve for serial dilutions of conditioned medium from cells transfected with K10- 
FTX-I, were also plotted as in figure 38. In the case of K10-FIX-I, even though 
dilutions up to 1 in 4 gave readings above background, only the undiluted and 1 in 2 
diluted samples plotted in the linear portion of the standard curve. OD (490) readings 
obtained for the various individual clones of transfected cells (K10-FTX-I/II) are 
plotted on the standard curve and the factor IX concentrations (ng/ml) calculated from 
the Xl-axis, are tabulated (inset). I and II indicate clones of K10-FIX-I and K10-FIX- 
II, respectively. The individual clones are numbered (for example, II/4 is the 4th stably 
transfected clone of K10-FIX-II). All observed OD (490) readings, calculated factor 
IX concentrations (ng/ml) and factor IX expression levels (ng/million cells/24 hours) 
are summarised in table 8.
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Figure 40: ELISA III
The X and Y axes are similar to those in figure 37. OD (490) readings obtained for the 
conditioned media (summarised in table 8) from cells transfected with K10-FIX-G4 
(pools and individual clones) are plotted on the factor IX standard curve. The 
estimated concentration of factor IX (ng/ml) in the various media are tabulated in the 
figure (inset). G4=K10-FIX-G4; G4-5D represents conditioned medium from K10- 
FIX-G4 transfected pool (the same sample used in the ELISA in figure 38) stored for 
5 days at 4°C; G4-80 represents the same K10-FIX-G4 pool of transfected cells used 
in this ELISA, but the conditioned medium was collected from 80% confluent flasks.
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Figure 41: ELISA IV
The X and Y axes are similar to those in figure 37. OD (490) readings obtained for the 
conditioned media (summarised in table 8) from cells transfected with K10RB-FIX-G4 
(pool and individual clones) and K10RB-FIX (pool) are plotted on the factor IX 
standard curve. The reading obtained from a pooled plasma sample of Y-line 
transgenic mice is also plotted in this figure. The estimated concentration of factor IX 
(ng/ml) in the various samples are tabulated in the figure (inset).
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Table 8: Summary of factor IX ELISA results
Factor IX construct 
(Clone /Pool)
OD(490) (±2SD) Factor IX concentration 
ng/ml (±2SD)
Factor IX secretion 
ng/106 cells/24 hours 
(+2SD)
ELISA I:
KlO-FIX-n/Pool
K10-FIX-G4/Pool
0.137 (0.102-0.172) 
0.337 (0.241-0.433)
9.04 (7.66-10.42) 
17.30 (12.46-22.14)
18.1 (15.3-20.8) 
34.6 (24.9-44.3)
ELISA II:
KlO-FIX-I/Pool 
K10-FIX-I/clone 1 
K10-FIX-I/clone 2 
KlO-FIX-H/clone 2 
KlO-FIX-H/clone 3 
KlO-FIX-E/clane 4
0.185 (0.159-0.211) 
0.090 (0.058-0.122) 
0.096(0.062-0.130) 
0.050 (0.026-0.074) 
0.102 (0.062-0.142) 
0.111 (0.081-0.141)
13.70 (10.18-17.22)
7.70 (5.60-9.80) 
8.14 (6.16-10.12) 
5.24 (<3.13-7.10) 
8.96 (6.48-11.44) 
9.13 (7.29-10.97)
22.8 (16.9-28.7)
12.8 (9.3-16.4) 
13.6 (10.3-16.9) 
8.7 (<5.2-11.8)
14.9 (10.8-19.1) 
15.2 (12.2-18.3)
ELISA HI:
K10-FIX-G4/Pool 
K10-FIX-G4/clone 1 
K10-FTX-G4/clone 3
0.065 (0.045-0.085) 
0.050 (0.045-0.055) 
0.058 (0.045-0.071)
14.30 (12.34-16.26) 
13.00 (12.18-13.82) 
13.50 (12.20-14.80)
30.6 (26.4-34.9)
27.9 (26.1-29.6)
28.9 (26.1-31.7)
ELISA IV:
K10RB-FIX/Pool 
K10RB-FlX-G4/Pool 
K10RB-FIX-G4/clone 1 
K10RB-FlX-G4/clone 3
0.110 (0.092-0.128) 
0.100 (0.073-0.128) 
0.081 (0.060-0.102) 
0.060 (0.051-0.069)
13.80 (12.76-14.84) 
13.10 (12.12-14.08) 
11.00 (7.60-14.40) 
8.30 (6.60-10.00)
29.6 (27.3-31.8) 
28.1 (25.9-30.2)
23.6 (16.3-30.9) 
17.8 (14.1-21.5)
Y-line transgenic (plasma) 0.286 (0.254-0.318) 28.1 (22.14-34.06) N/A
ELISA I to IV represent the readings in figures 38 to 41, respectively. Numbers within 
parentheses represent variations by ±2 standard deviations. Y-line transgenic mice were 
created using the K10-FIX-I gene construct.
Figure 42: Comparative analysis of factor IX expression by the various constructs
The relative expression of factor IX resulting from the pools of HaCaT cells 
transfected with the various gene constructs is shown. FIX/I=K10-FIX-I; FIX/II=K;0- 
FIX-D; G4=K10-FIX-G4; RB=K10RB-FTX; RBG4=K10RB-FIX-G4. The error bars 
depict variation of ±2 standard deviations.
Figure 43: PCR screening of tail-tip biopsies from potential transgenic mice
This figure shows the 1.4 kb PCR product (indicated by the arrow) obtained on 
screening DNA samples extracted from tail-tip biopsies of potential transgenic mce. 
L=1 kb ladder; Lane l=positive control; Lanes 3, 9,10 and 11 are DNA samples fom 
mice with the transgene.
Factor IX Expression
ng/106 cells/24 hours
Transfected HaCaT Pools
F9A/B PCR 
L 1 2 3 4 5 6 7 8 9 10 11
Table 9: Comparative analysis of factor IX expression
Factor IX construct Factor IX secretion 
ng/106 cells/24 hours 
(+2SD)
Comparison with 
K10-FIX-n/Pool 
(t test)
Comparison with 
K10-FIX-G4/Pool 
(t test)
K10-FIX-I/Pool 22.8 (16.9-28.7) p < 0.1 p < 0.02
K10-FIX-n/Pool 18.1 (15.3-20.8) N/A p < 0.01
K10-FIX-G4/Pool 34.6 (26.0-45.0) p < 0.01 N/A
KlORB-FIX/Pool 29.6 (27.3-31.8) p < 0.01 p < 0.2
K10RB-FIX-G4/Pool 28.1 (25.9-30.2) p < 0.01 p < 0.1
The factor IX expression achieved by the transfected HaCaT pools of the various 
gene constructs are listed. The results of the t test of significance are shown in the 
third and fourth columns. The mean expression levels obtained for the basic construct 
(K10-FTX-II) and the highest expressing construct (K10-FIX-G4) were compared 
with those of the other constructs. N/A=not applicable.
3.8.2 ASSESSMENT OF SECRETED FACTOR IX IN SERUM FROM 
TRANSGENIC MICE:
Analysis of expression of the K10-factor IX constructs in vivo was performed in 
collaboration with Dr. Y. Alexander in our department. The construct K10-FIX-I was 
used for this purpose. The transcriptional unit (7.3 kb Sail /  Nrul fragment) was 
separated from plasmid sequences and gel-purified for microinjection (as described in 
section 2.5.2). Three lines of transgenic mice (X, Y and Z lines respectively) were created 
by Dr. Y. Alexander. Tail DNA preparations were used to assess the integration of the 
transgene. For this, PCR screening was performed using primers F9A and F9B (Figure 
43). Dr. Alexander performed Southern blot analysis to confirm integration of the 
transgene. A -2.5 kb recombinant factor IX transcript was also obtained from total 
cellular RNA extracted from transgenic mouse epidermis (and not from normal controls) 
and in situ hybridisation confirmed expression in suprabasal epidermal keratinocytes.
Pooled plasma samples from the Y-line transgenic mice were analysed for 
secreted factor IX using ELISA. Samples were obtained by cardiac puncture and supplied 
by Dr. Alexander. Figure 41 shows that the mean concentration of factor IX assayed 
from the plasma of Y-line mice was 28.1 ng/ml (22.1-34.1 ng/ml). These results 
demonstrate the efficacy of the basic construct to express 7-carboxylated factor IX in a 
keratinocyte-specific fashion and perhaps also the ability of keratinocytes to deliver it to 
the systemic circulation.
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CHAPTER: 4 
DISCUSSION
4.0 DISCUSSION
4.1 ANALYSIS OF MUTATIONS IN HAEMOPHILIA A
Haemophilia A is caused by a heterogeneous group of deleterious mutations in the 
factor VIII gene. Besides the mutational hotspot responsible for disease in -20% of 
haemophilia A patients, the vast majority of mutations include single base substitutions. 
The identification of naturally occurring mutations in the factor VIII gene offers an 
insight into the biological properties of this large and complex protein. In a directed 
search for factor VIII mutations, eleven different and potentially pathogenic mutations 
were completely characterised in this study. These have been summarised in table 10. 
Over 150 mutations have now been reported in the factor VIII gene and the spectrum and 
distribution of these is relatively well characterised (Tuddenham et al., 1991). However, a 
relative deficit exists in the knowledge regarding structure-function correlates in factor 
VIII, and in this regard naturally occurring mutations provide a potential source of useful 
information. Analysis of the mutations characterised in this study and the sequence in 
their immediate vicinity, revealed interesting findings regarding phenotypic correlation 
and the mechanism of mutagenesis.
4.1.1 GENOTYPE-PHENOTYPE CORRELATION
For practical purposes the mutations detected in this study can be classified as 
being (i) disruptive i.e., predicted to cause either truncation or internal exclusion of amino 
acids from the mature factor VIII polypeptide and (ii) non-disruptive, which include all 
the missense mutations. In this study, 5 missense and 6 disruptive mutations (of which the 
intron 22-mediated inversion was one) were identified. While it is clear how the 
disruptive mutations and missense mutations affecting sites of established functional 
significance result in a haemophilic phenotype, it is more difficult to explain the role of 
the vast majority of missense mutations in disease causation. The main reason for this 
inability to attribute disease to missense mutations stems from the fact that not much is
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known about structure-function correlates in factor VIII. These have been reviewed 
(Pittman and Kaufman, 1989) and the salient features are described in section 1.3.2.
In this section, a genotype-phenotype correlation is attempted for the two classes 
of mutations detected. By a prediction of the products of translation, the exact extent of 
the loss of amino acid residues or truncation of the factor VIII molecule is estimated. An 
attempt is also made to elucidate the pathogenicity of the missense mutations detected. 
Prediction of the products of translation
In six of the mutations detected, there is predicted to be varying degrees of 
truncation or exclusion of amino acids from the product of translation of the factor VIII 
mRNA. These mutations include two single base substitutions (nonsense mutation: R-5X; 
intron 6 splice donor site mutation: 787+3A—>G), three deletions (5697delC, 
519delTACCT, deletion of exon 16) and the characteristic intron 22-mediated inversion. 
Figure 44 shows a diagrammatic representation of the normal and various abnormal 
products of translation for the disruptive mutations detected. The prediction of the 
products of translation was made assuming that the severely truncated products would be 
stable. It is however likely that the prematurely terminated products may be rapidly 
degraded in the cell (Goldberg and St. John, 1976) thus making some of these predictions 
purely theoretical. The normal factor VIII product of translation is shown with its 
characteristic domain structure, the sites of cleavage, vWF binding and phospholipid 
binding (see section 1.3.2).
The nonsense mutation at codon 15 (Arg) in the signal peptide (R-5X) is 
predicted to result in severe truncation and virtually no circulating normal factor VIII due 
to the termination of translation before the start of the mature factor VIII polypeptide. 
This mutation was detected in a 15 year old severe haemophilia A patient (GLA9). Of the 
seven point mutations, this was the only one that occurred in a hypermutable CpG 
dinucleotide and is likely to be due to a methylation mediated mutagenic event (Cooper 
and Youssoufian, 1988; Cooper and Krawczak, 1990). This is the third independent 
report of the same R-5X mutation (Pattinson et al., 1990a; Reiner and Thompson, 1992). 
This patient has not developed inhibitors to therapeutically administered factor VIII.
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Figure 44: Diagrammatic representation of truncated products of translation due to
factor V m  mutations
This figure shows a diagrammatic representation of the (internally) shortened or 
truncated products of translation caused by five mutations detected in this study. The 
causative mutation is indicated alongside each anomalous product. The normal domain 
structure of factor VIII and the various cleavage and binding sites are shown 
(numbering is according to Wood et al., 1984). The positive results of analysis by 
"MOTIFS" are also indicated at the appropriate location on the normal structure of 
factor VIII. The amino acid sequence of the putative functional domain detected by 
the computer program "MOTIFS", are indicated with the affected residue being 
underlined. APC=Activated protein C; vWF=von Willebrand factor; PL=phospholipid. 
The thrombin (Ha) cleavage sites marked by the asterisks are those that are essential 
for cofactor activation.
100V
1I9P
619
A single base substitution at position +3 in the splice donor site of intron 6 
(787+3A—>G), that caused a skipping of exons 5 and 6 in the mature factor VIII mRNA, 
was detected in two apparently unrelated haemophilia A patients (GLA3 and GLA8) in 
this series (section 3.2.3). Even though nested PCRs using primers specific for exons 5 
and 6 could detect some percentage of full length transcript, it can be assumed from the 
RT-PCR result of segment R1 that >95% of the factor VIII mRNA produced is devoid of 
exon 5 and 6 sequence. This exon skipping event has left the translational frame intact 
and the resultant in-frame "deletion" of 186 bp in the mature mRNA can be predicted to 
cause a shortening of the mature factor VIII polypeptide by 62 amino acid residues 
(figure 45). This shortening will affect the conserved "Al" domain of the factor VIII 
polypeptide (Vehar et al., 1984).
Clinically, both patients with this mutation have disease of moderate severity and 
residual factor VIII activity of 3 IU/dl. It is interesting to note that a patient lacking exons 
5 and 6 in the mature factor VIII mRNA due to a gross DNA deletion has previously 
been reported to have severe haemophilia A with FVIILC <1 IU/dl (Naylor et al., 1993a). 
The relatively higher coagulant activity observed in both patients in the present study is 
probably due to the small component of correctly processed mRNA detected by nested 
PCRs with primers specific for exons 5 and 6. The above predicted alteration in the factor 
VIII protein does not result in a deletion of any known functional site (e.g. thrombin 
cleavage site), or conserved cysteine residues which are known to be important in protein 
folding and maintenance of the three-dimensional structure. This "in-frame" shortening of 
the conserved" Al" domain has therefore resulted in disease of moderate severity, in spite 
of a marked deficiency of normal sized transcripts from the mutant gene.
SSCP analysis and direct sequencing of exon 4 revealed a 5 base pair deletion of 
"TACCT" involving nucleotide positions 519 to 523 and amino acid positions 154, 155 
and 156. The resultant shift in the reading frame is predicted to result in the translation of 
25 altered amino acids followed by a premature stop codon at position 179. This is 
predicted to result in a severely truncated factor VIII polypeptide, 178 amino acids long, 
terminating approximately midway through the conserved "Al" domain (figure 44, Vehar
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Figure 45: Diagrammatic representation of 787+3A to G resulting in skipping of
exons 5 and 6
This figure shows a diagrammatic representation of the splice donor site mutation in 
intron 6 (787+3A to G) resulting in a skipping of exons 5 and 6 from the mature factor 
VIII mRNA. The codons at the junctions of exons 4, 5, 6 and 7 are shown. This 
demonstrates the "in-frame" exclusion of 62 codons (186 nucleotides) from the mature 
factor W I  mRNA. a.a.=amino acid; Ex=exon.
Glu Gly Pro Gly Leu l ie
... AGAAG GG A ... ... CCAG GTCTG AT T.
1*3
E x  4 E x  5 Ex 6 E x  7
- 186bp  
- 62  a.a. A — - G
G lu G ly  Leu lie
A G A A G  G T C T G  AT T
Ex 4  I Ex  7
et al., 1984). The patient is a 10 year old boy of Pakistani descent, with severe 
haemophilia A (FVIII:C = 1 IU/dl) and with no family history of the same.
The frameshift produced by the single base deletion in exon 17 (5697delC) is 
predicted to result in a severe truncation of the factor VIII polypeptide. The deletion of 
C-5697, which is the third base in codon 1880 (Phe), would result in the translation of 44 
altered amino acids before terminating prematurely at a stop codon in the altered reading 
frame at position 1925. This truncated factor VIII of 1924 residues (instead of 2332) if 
stable, will be devoid of the carboxy half of "A3" and the two "C" domains which are 
thought to be essential for phospholipid binding (Arai et al, 1989b; Foster et al, 1990; 
figure 44). This mutation has resulted in a severe phenotype with FVTII:C <1 IU/dl and 
the patient has developed inhibitors to exogenous factor VIII (GLA6, table 10).
One patient (GLA11) showed a gross deletion that resulted in the exclusion of 
exon 16 from the mature factor VIII mRNA. This does not alter the translational reading 
frame and is predicted to result in a factor VIII polypeptide shorter by 71 amino acids 
(1773-1843) within the "A3" domain (figure 44). This mutation has resulted in a severe 
phenotype. The reason for this could be the exclusion of the highly conserved cysteine 
residue at position 1832 (see "pileUp" analysis in figure 20). The characteristic 
distribution of the cysteine residues at similar positions within related domains of factor 
VIII (Vehar et al, 1984), indicates that Cys-1832 plays a crucial role in maintaining the 
conformation of the post-translationally processed factor VIE by disulphide bridging.
The common inversion, mediated by the sequence of F8A in intron 22, causes a 
major disruption of the factor VIII gene (see figure 19) and results in the characteristic 
mRNA abnormality at the junction of exons 22 and 23 (Naylor et al, 1992; 1993a). This 
mutation always results in a severe phenotype and indeed was seen in one of the eight 
severe cases analysed in this study.
Pathogenicity of missense mutations
Missense mutations are readily associated with the disease phenotype when they 
alter an important functional residue, as is seen in the case of recurrent missense 
mutations affecting Arg-372 and Arg-1689, both of which are thrombin activation sites 
and thus critical for factor VIII function. However, such structure-function correlations
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are somewhat limited at present and more information is usually necessary in the case of 
the vast majority of missense mutations. In general, the following information is helpful in 
determining the pathogenicity of missense mutations that do not clearly affect residues 
with well established function: (i) absence of any other change, (ii) a high level of 
evolutionary conservation, (iii) previous independent occurrence of the same mutation in 
an unrelated patient, (iv) failure to observe the same mutation in a sufficiently large 
sample of normal controls, (v) the novel appearance and subsequent cosegregation of the 
mutation with the disease phenotype in the family, and finally, more definitive evidence 
can be had from (vi) functional studies i.e., when recombinant techniques are used to 
show the production of a mutant protein from a mutant clone and correction of the defect 
is achieved by transfer of the normal clone in in vitro experiments.
A total of five missense mutations were characterised in this study. These include 
D56E, V162M, G701D, A1834T and R1869I. Four of these mutations were the only 
sequence alterations detected after screening the entire essential sequence of the factor 
VDI gene and are therefore likely to be the cause of haemophilia A in these patients. Two 
of these have resulted in severe disease (G701D, R1869I) and one each in a moderate 
(D56E) and mild (V162M) phenotype.
Three main attributes were used to assess the significance of the observed 
missense mutations in this study. These included (i) the degree of evolutionary sequence 
conservation of the mutated amino acid residue in both, the genes known to be 
homologous to factor VIII and conservation in factor VIII sequences from other 
mammalian species, (ii) involvement of protein sequence patterns (or motifs) that are 
linked with certain functions or that determine sites of post-translational modification, as 
catalogued in the PROSITE dictionary (Bairoch, 1993), and (iii) the assessment of the 
effect of a particular amino acid substitution, as judged from their chemical properties.
An in-depth study of the phenotypic effect of missense mutations in the factor IX 
gene was reported by Bottema et al. (1991). They noted that mutations at "generic" 
residues (i.e. those conserved in related homologous serine proteases and in the factor IX 
genes of other mammalian species) invariably resulted in disease and mutations in those 
residues that were only homologous to the other factor IX genes were about six-fold less
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likely to cause disease. Mutations at non-conserved residues on the other hand were some 
33-fold less likely to result in disease. They estimated that about 40% of all missense 
mutations would cause disease and the remaining 60% would only affect "spacer" 
regions. In the case of haemophilia B, patients are ascertained only if there is a significant 
loss of factor IX procoagulant activity (Sommer et al., 1992). Haemophilia A and B are 
clinically and genetically alike and, a similar degree of inactivation of the wild-type 
protein is required for the clinical ascertainment of the disease. If it were extrapolated 
from the case of the factor IX gene, determination of the evolutionary sequence 
conservation is likely to be a useful exercise by helping to rule out the affection of 
relatively unimportant "spacer" regions (Bottema et al., 1991). This analysis is especially 
important for missense mutations detected by a screening strategy that has a near total 
ascertainment of mutations (as evidenced from the three patients with two or more 
cleavage products in table 4).
All five missense mutations that were detected in this study occurred in the three 
conserved "A" domains of factor VIII. The "PileUp" program (in the GCG package of 
sequence analysis programs) was therefore used to align the three homologous "A" 
domains of human factor VIII (Vehar et al., 1984) with those of factor V (Kane and 
Davie, 1988), ceruloplasmin (Kochinsky et al., 1986) and murine factor VIII (Elder et al., 
1993) (figure 20). This was done in order to examine the degree of evolutionary sequence 
conservation of the affected residues in the 12 repeated "A" domains of the above named 
proteins. The rationale being that, the more conserved the amino acid, the more likely it is 
to be important for maintaining the structural/functional integrity of factor VIII (Diamond 
et al., 1992).
Since 1988, a compilation of sites and patterns (or motifs) in protein sequences, 
that determine specific and common functions or sites of post-translational modification 
has been developed, called the PROSITE dictionary of sites and patterns in proteins 
(Bairoch, 1993). Release 10.1 (April, 1993) contained 803 different patterns and these 
are periodically reviewed and updated (Bairoch, 1993). The program "MOTIFS" (Smith 
et al., 1990) searches for sequence motifs by scanning through a given amino acid 
sequence for patterns catalogued and defined in the PROSITE dictionary. The five
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missense mutations were thus analysed for their involvement with common functional 
domains, as mapped on the human factor Vin sequence.
The effect of (missense) mutations on protein stability and function has been 
reviewed (Pakula and Sauer, 1989; Alber, 1989) and it is seen that the phenotypic 
consequences of a given mutation depends not only on the nature of the amino acid 
substitution, but also on its location within the protein. Most mutations appear to affect 
activity of the protein indirectly via effects on protein structure or stability. These include 
for example, those that are buried in the protein structure (core residues), those involved 
in disulphide, hydrogen or electrostatic bonding and those amino acids with special 
structural properties such as glycine and proline. This can be appreciated from the 
observation of a wide variety of missense mutations resulting in haemophilia A, where 
only a fraction of these affect known sites of function (e.g. Arg-372 and Arg-1689). Due 
to the lack of knowledge regarding the structure of the factor VIII molecule, the position 
of the mutation in the polypeptide itself is not sufficient to predict the effect of the 
mutation. In the course of this discussion, even though comments are made regarding the 
alteration in chemical attributes (as a result of a missense mutation), the true significance 
of these cannot really be appreciated. Also as many residues could potentially tolerate 
changes better than others, a comprehensive cataloguing and analysis of natural mutations 
in the factor VIII gene (as in Tuddenham et al., 1991) will enable the delineation of such 
"spacer” regions (as was estimated in factor IX, Bottema et al., 1991).
The G701D mutation was the only sequence alteration detected in a patient with 
severe haemophilia A (GLA4). It was shown to affect a highly conserved residue, 
conserved in all but one of the 12 homologous "A" domains (F5A2, figure 20) analysed 
by "PileUp". Analysis using "MOTIFS" revealed that this mutation affected a multicopper 
oxidase I consensus pattern (Messerschmidt and Huber, 1990; Ouzounis and Sander, 
1991; figure 44), spanning factor VIII residues 686 through to 706, with the Gly at 701 
being an invariable determinant of this sequence pattern. There were three multicopper 
oxidase I signatures in the factor VIII amino acid sequence, detected by this method, with 
one occurring in each of the three "A" domains as follows, Al: 304-324, A2: 686-706 
and A3: 1994-2014 (Vehar et al. [1984] used homology to plastocyanin, and
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demonstrated putative ligands for type 1 copper at the same locations, but only in the Al 
and A3 domains). These patterns are observed in a variety of proteins that are known or 
thought to have a copper binding function (laccase, ascorbate oxidase, ceruloplasmin and 
copper resistance protein A) (Messerschmidt and Huber, 1990) and may represent the 
domains responsible for a putative metal binding function of factor VIII (Vehar et al.,
1984; Pittman and Kaufman, 1989). This missense mutation represents a change from a
aci<Lc
neutral to " amino acid. The amino acid glycine, which lacks a (3-carbon can assume 
many backbone dihedral angles, not possible by other amino acids. Due to this, glycine is 
used in certain types of reverse turns where other amino acids are not suitable. Replacing 
glycine in such turns with any other amino acid would be expected to have a destabilising 
effect (Pakula and Sauer, 1989). Due to the lack of structural information for the factor 
VIII protein, it is however not possible to determine if the Gly-701 residue is used in this 
fashion. Missense mutations are not generally associated with the development of 
inhibitors to exogenously administered factor VIII. However, two examples of this have 
been reported, R2209Q and W2229C, and are believed to alter epitopes required for the 
state of immune tolerance (Tuddenham et al., 1991). G701D in patient GLA4 has led to 
the development of inhibitors (9.4 Bethesda units) to therapeutic administration of factor
VIII.
The V162M mutation has been reported twice before and was noted to result in 
mild and moderate haemophilia A in these two cases (Tuddenham et al., 1991; Diamond 
et al., 1992). The patient in this study has a mild phenotype with FVIII:C = 9 IU/dl 
(GLA5, table 10). Analysis using "MOTIFS" revealed the involvement of a casein kinase 
II phosphorylation site (amino acid positions 160-163; figure 44). It is known that acidic 
and basic residues increase and decrease the substrate specificity for this serine/threonine 
kinase, respectively (Pinna, 1990). The significance of the mutation in this respect is 
therefore doubtful, because valine and methionine are both neutral amino acids. This 
mutation was however shown to involve a conserved residue (9 of 12 domains, figure 20) 
and was the only mutation found in this patient
The R1869I mutation was at a much less conserved site, being seen in only the 
"A3" domains of human factor VIII, ceruloplasmin and murine factor VIII (figure 20).
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R1869I represents a change in the class of amino acid from basic to neutral (and 
hydrophobic) and in view of this being the only change detected in this severe 
haemophiliac (GLA2), signifies the biological importance of this residue. Its conservation 
in the three above mentioned "A3M domains may indicate that it plays a specific role in 
that part of the molecule.
Lin et al. (1993) reported a polymorphic conservative change, D56V (GAT-» 
GTT at nucleotide 224), in the Chinese population. This change was also noted between 
the amino acid sequences reported by the first two groups who cloned the factor VIII 
cDNA (Wood et al., 1984; Toole et al., 1984). One of the missense mutations in the 
present study affected a different nucleotide position in the same codon (GAT—>GAA at 
nucleotide 225) and resulted in the replacement of the normally occurring aspartic acid 
residue with glutamic acid (D56E). This mutation affects a very highly conserved residue, 
occurring in 11 of the 12 domains (except F5A1, which in fact has an "E" at this position, 
figure 20). A change from aspartic acid to glutamic acid would normally be considered as 
a conservative change. This mutation was, however, the only sequence change 
encountered in this patient (GLA13) with moderate haemophilia A (FVIII:C = 3 IU/dl).
The fifth missense mutation, A1834T, was one of two chemical cleavage results 
seen in the same patient (GLA1). The second mutation, as yet uncharacterised, has been 
mapped to exon 16 by a further CCM of two overlapping and nested PCRs. Analysis of 
the A1834T mutation by PileUp, interestingly revealed that only 4 of the 12 "A" domains 
normally had an alanine, whereas 7 of the other 8 actually had a threonine at this position 
(figure 20). This can be interpreted as not being a significant mutation, since the modified 
residue is in fact the residue of choice in the sister domains. In this case therefore, the 
uncharacterised mutation mapped to exon 16 may be the cause of the severe haemophilia 
A. An alternate view could be that an alanine at position 1834 in the "A3" domain of 
factor VHI may play a unique role, being crucial for its procoagulant function. There are 
known examples of conservative missense mutations that can result in a disease 
phenotype, if they occupy sites that are key determinants of stability or function (Pakula 
and Sauer, 1989). Furthermore, even though both are neutral amino acids, alanine is polar 
and threonine is hydrophobic.
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The results of the analysis of phenotypic effects of missense mutations detected in 
this study are summarised in table 11.
4.1.2 MECHANISM OF MUTAGENESIS
The frequency and distribution of mutations in eukaryotic genomes is non- 
random. The reason for this is largely due to the strong influence of the local sequence 
environment in the pathogenesis of mutational lesions (Cooper and Krawczak, 1993). 
Single base substitutions are known to result either from chemical (deamination of 5- 
methylcytosine, Coulondre et al., 1978 and depurination, Loeb and Preston, 1986), 
physical (e.g. DNA slippage, Kunkel and Soni, 1988) or enzymatic (e.g. post-replicative 
mismatch repair or exonucleolytic proof-reading, Modrich, 1987; Loeb and Kunkel, 
1982) mechanisms, all of which are known to be sequence-dependent (Cooper and 
Krawczak, 1993). Human gene deletions are also distributed non-randomly, and this is 
evident from their dissimilarity in frequency and distribution in X-linked recessive 
conditions of similar incidence. For example, 2.5% of haemophilia A patients have 
deletions of the factor VIII gene (Millar et al., 1990), whereas 84% of patients with 
steroid sulphatase deficiency have deletions (Ballabio et al., 1989). Moreover, hotspots 
have been demonstrated for deletion breakpoints in several genes, example dystrophin 
(Forrest et al., 1987, 1988; Dunnen et al., 1987) and low density lipoprotein receptor 
(Langlois et al., 1988). Although, Krawczak et al. (1992) demonstrated that single base 
substitutions affecting splice sites did not represent a non-random occurrence, the 
distribution of mutations within the splice sites was shown to have a definite non-random 
distribution. Perhaps the most obvious examples of non-randomness of mutational events 
in the human genome are the recently discovered hotspots namely, the F&4-mediated 
inversion in about half the severe cases of haemophilia A (Naylor et al., 1993a, b; Lakich 
et al., 1993), the CMTlA-REP-mediated 1.5 Mb duplication in 17pll.2 responsible for 
over 90% of Charcot-Marie-Tooth disease type 1A (Lupski et al., 1991; Pentao et al., 
1992; Wise et al., 1993) and the trinucleotide repeat expansions responsible for most 
cases of fragile X syndrome (Fu et al., 1991; Verkerk et al., 1991; Oberle et al., 1991; Yu 
et al., 1991) and myotonic dystrophy (Harley et al., 1992; Buxton et al., 1992).
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In a recent report, it was shown that the common intron 22-mediated inversion 
almost exclusively occurred during male meiosis (Rossiter et al., 1994). The patient in 
this study is the only affected male in his family, but his mother's twin sister 
(monozygotic) showed an abnormal coagulation profile, indicating her carrier status (C. 
Shiach, personal communication). This finding is consistent with those of Rossiter et al. 
(1994), who found that the mothers of all but one of 50 sporadic inversion cases in their 
study were carriers.
The small deletions, splice donor mutation and other single base substitutions 
detected in this study were evaluated for possible mechanistic explanations for the 
mutagenesis. The nucleotide sequence at and in the vicinity of the mutations was analysed 
for possible clues, in order to answer the question (s), "why and how did a particular 
mutation arise in that particular site?" Satisfactory answers were not available for all the 
mutations, but some interesting findings were observed in many.
The small deletions, 519delTACCT AND 5697delC
Analysis of the sequence in the vicinity of the 5 bp deletion in exon 4 
(519delTACCT) revealed the presence of direct repeats of a 3 bp motif "CCT", one copy 
immediately preceding the deleted bases and the other as part of the deleted sequence 
(figure 46). The modified slipped-mispairing model for the generation of deletions at the 
DNA replication fork, as proposed by Krawczak and Cooper (1991), relies on there being 
homology between the sequence flanking a deletion and the neighbouring DNA sequence. 
As seen in figure 46, the underlined sequence would mispair with its displaced homologue 
(shown in the bottom line) if the deleted bases (seen as a hyphenated line under the lower 
case letters) were permitted to loop out during DNA replication and thereby get excised 
by DNA repair enzymes. This deletion is therefore concordant with the modified slipped- 
mispairing model proposed by Krawczak and Cooper (1991).
The sequence surrounding the deleted C-5697 (in exon 17) was similarly analysed 
and showed no evidence of direct or inverted repeats or the presence of quasi- 
palindromic and symmetric sequence elements that could be implicated in the mechanism 
of this deletional mutagenesis (Krawczak and Cooper, 1991).
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Figure 46: "Slipped mispairing at DNA replication" in the pathogenesis of 
519delTACCT
Cys
153
CTGTGCCTtacctACTCATATCTTT 
CCT ACTCATATCTTT
Analysis of the sequence in the vicinity of the 5 base pair deletion in exon 4. The 
normal DNA sequence flanking the deletion is shown in the top line with the 
deleted bases being indicated by lower case letters. The underlined sequence may 
mispair with its displaced homologue, shown in the lower line, if the deleted bases 
indicated by the hyphenated line (under the lower case letters) were to loop out at 
DNA replication. The position in the factor VIII coding sequence is denoted by the 
cysteine residue at 153 (TGC), which is the last normal amino acid residue encoded 
by the deleted allele.
The intron 6 splice donor mutation
The phenotypic effect of mutations affecting splice junctions include either exon 
skipping or activation of cryptic splice sites in the vicinity, with the former being more 
common. Mutations affecting splice donor sites almost invariably cause skipping of the 
preceding exon. In a recent review of 101 splice mutations (Krawczak et al., 1992) it was 
observed that 60% of 5' splice site mutations involve the invariant GT dinucleotide at 
positions +1 and +2. Many examples of 5' splice mutations have been reported that also 
affect positions -3, -1, +3, +5, +6 and +7 (Krawczak et al., 1992; Cooper and Krawczak,
1993). Of these, it was observed that positions -1 and +5 are most commonly affected 
which is perhaps a reflection of these being more highly conserved positions and their 
strong base-pairing with complementary region of U1 snRNA (Krawczak et al., 1992).
A number of mutations putatively affecting factor VIII mRNA splicing have been 
reported (Tuddenham et al., 1991; Higuchi et al., 1991a; Krawczak et al., 1992), but 
confirmation of their phenotypic effects have so far been difficult due to its hepatocyte- 
specific expression. A splice acceptor mutation producing exon skipping was detected 
using RT-PCR of the ectopically transcribed factor VIII mRNA from peripheral 
lymphocytes (Naylor et al., 1991). This method is now being increasingly used, especially 
for large genes transcribed in relatively inaccessible tissues and will result in many more 
splice mutations being reported with the consequent better understanding of splicing 
errors and their role in disease.
In this study, a single base substitution (A-»G) was discovered at position +3 in 
the 5' splice site of intron 6, that caused a skipping of exons 5 and 6 in the mature factor 
VIII mRNA, in two apparently unrelated individuals. The following three questions were 
asked: (i) Is this splice donor mutation (at +3) the cause for the observed error of 
splicing? (ii) Why did exon 5 (with normal splice determinants) get skipped from the 
mature factor VUI transcript, along with exon 6 (with the splice mutation)? and (iii) Does 
the occurrence of the same mutation in two apparently unrelated individuals represent a 
true case of recurrence?
In the 101 splice mutations reviewed by Krawczak et al. (1992), only three 
examples of mutations affecting position +3 of the splice donor site were detected. This is
126
not surprising as the corresponding residue in U1 sriRNA is a pseudouridine rather than a 
cytosine. The same reason accounts for no mutations being found at position +4 although 
the first case of this has recently been reported in the gene for neurofibromatosis type 1 
(Hutter et al., 1994). In order to rule out the possibility of this mutation being a neutral 
polymorphism, a total of 24 other haemophilia A patients and 60 normal controls were 
screened for its presence. As no restriction enzyme site was abolished or created by this 
base substitution, allele-specific PCRs were designed for the normal and mutant alleles 
(Wu et al., 1989; Sarkar et al., 1990). None of those screened showed this mutation. 
Furthermore, consensus values (CV) were calculated for the splice donor sites of introns 
4, 5, 6 and mutant 6, according to the method described by Shapiro and Senapathy 
(1987). These values were estimated on the basis of the conservation of bases at the 8 
positions most likely to contribute 5' splice recognition determinants (position -2 through 
to +6) and were used as relative indicators of the efficacy of splice sites. As seen in table 
3, the single base substitution at +3 results in a 9% reduction of the consensus value of 
the mutant intron 6 splice donor site compared to that of the normal sequence. These 
observations go in favour of this sequence alteration being responsible for the observed 
splicing error.
Direct sequencing of the major transcript showed that exon 5 was consistently 
skipped along with exon 6 in the mature factor VIII mRNA. Why this was so is not 
entirely clear, but may be due to one or a combination of the following explanations: (a) 
Previous examples of splice donor mutations have caused exon skipping of only the 
preceding exon, which is consistent with the exon definition model of splice site 
recognition (Robberson et al., 1990). Examples of multiple combinations of skipped 
adjacent exons have also been seen (albeit as part of a spectrum of associated minor 
transcripts) which have been attributed to secondary effects on mRNA processing 
(Naylor et al., 1991; Fisher et al., 1993). A consistently skipped exon 5 in the mature 
factor VIII transcript could have been due to these secondary changes even in the 
presence of normal splice recognition signals, (b, c) The average size of vertebrate 
internal exons is 137 bp (Hawkins, 1988) and experiments involving the shortening of 
internal constitutive exons (i.e. exons not normally alternatively spliced) to <51 bp have
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resulted in skipping of the exon (Dominski and Kole, 1991). These observations suggest 
that the extreme proximity of the 3' and 5' splice sites impairs their recognition. 
Furthermore, it was observed by Sterner and Berget (1993) that splicing of exon 3 of the 
chicken fast skeletal troponin I gene (sTNI), only 7 bp in length, was dependent on the 
presence of the naturally occurring upstream exon 2. In the absence of exon 2 upstream 
from it, only an internal expansion of this "mini" exon 3 permitted its efficient splicing. 
Exon 5 is only 69 bp and is the smallest exon in the factor VIII gene (Gitschier et al., 
1984). Its splicing may be similarly interlinked with that of its neighbouring exons (exon 
6). (d) Estimation of the relative efficiency of the 5' splice sites (of introns 4,5,6 and 
mutant 6) by the method of Shapiro and Senapathy (1987) also gave some clues. Table 3 
shows that the 5' splice site of intron 4 has a score of 100, whereas that of intron 5 was 
90.84. This, along with the unusual finding of a "T" at +3 in the splice donor sequence of 
intron 5 (seen in only 2% of all primates; Shapiro and Senapathy, 1987) may have also 
contributed to the relative preference of the 5' splice site of intron 4 over that of intron 5, 
resulting in the additional skipping of exon 5 (figure 45).
So far, only three examples of established recurrence of a splice site mutation 
have been reported (Dunn et al., 1989; Matsuhita et al., 1989; Weil et al., 1990; Vasan et 
al., 1991; Chen et al., 1991; Krawczak et al., 1992). Two other cases of recurrence were 
inferred on the basis of RFLP haplotyping (Atweh et al., 1987; Wong et al., 1989). In the 
present study, two patients who were apparently unrelated on the basis of a careful four 
generation family history, were found to have identical mutations. Evidence was sought 
to prove that at least one of the two patients was a true sporadic case, thus indicating an 
independent origin for the two mutations. One of the patients (GLA3) was the only 
affected person in his family (GLA8 has an affected brother and two affected maternal 
uncles and so his mother is an obligate carrier). In order to determine if GLA3 was indeed 
a sporadic case, his mother (MP1) was similarly analysed. She was also shown to be a 
carrier for the same mutation. On performing a haplotype analysis using three intragenic 
factor V ni RFLPs and the closely linked, highly polymorphic Stl4 site (DXS52) (figure 
47), it was not possible to rule out relatedness. Also this base substitution does not affect 
a hypermutable CpG dinucleotide as in one of the previously reported cases of a
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Figure 47: Haplotype analysis of the two patients with the identical 787+3A to G 
mutation
This figure shows the result obtained for the PCR analysis of the highly polymorpiic 
VNTR, Stl4 (DXS52), in the two patients with the same mutation (P1=GLA3; 
P2=GLA8). Both PI and P2 have the same allele. L=1 kb ladder; C=control.
Table 12: Analysis of the sequence in the vicinity of the single base substitutions 
detected in this study
The table lists the results of the systematic analysis of the sequence in the immediite 
vicinity of the single base substitutions detected in this study (except 787+3A to G). 
The three mutations marked with an asterisk are those that fit the definition of a 
mutational hotspot (section 4.1.2). The normal base at the mutation site is indicated by 
bold typeface and the mutant base is indicated above it. The trinucleotide "CTT" 
topoisomerase I cleavage site was observed in the vicinity of each of the six mutatiais 
and are underlined and indicated by vertical arrows. Direct repeat elements or otter 
sequence motifs (for example, "TGGA" which is the putative arrest site for DhA 
polymerase a , was noted in immediately flanking the V162M mutation site) a*e 
underlined. The site of the D56V polymorphism (which is immediately adjacent to tie 
D56E mutation detected in this study) is also indicated.
Figure 47
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Table 12: Analysis of the sequence in the vicinity of single base substitutions
M U T A T I O N S U R R O U N D I N G  S E Q U E N C E S e q u e n c e
f e a t u r e s
R - 5 X  * 
D 5 6 E  * 
V1 6 2 M  * 
G 7 0 1 D  
A 1 8 3 4 T  
R 1 8 6 9 1
I t  I
5' T G T G C C T T T T G C G A T T C T G C T T T A G T  3'
3' A C A C G G A A A A C G C T A A G A C G A A A T C A  5'
T A  I
5' A G A A T T C A C G G A T C A C C T T T T C A A C  3 1 
3' T C T T A A G T G C C T A G T G G A A A A G T T G  5'
I  A
5' T A T C T T T C T C A T G T G G A C C T G G T A A A A  3' 
3' A T A G A A A G A G T A C A C C T G G A C C A T T T T  5'
A  vL 
5' T T C G G A A C A G A G G C A T G A C C G C C T T A  3' 
3' A A G C C T T G T C T C C G T A C T G G C G G A A T  5'
I k  1
5' T T G A C T G C A A A G C C T G G G C T T A T T T C  3' 
3' A A C T G A C G T T T C G G A C C C G A A T A A A G  5'
T I
5' C T G C T C A T G G G A G A C A A G T G A C A G T A  3 1 
3' G A C G A G T A C C C T C T G T T C A C T G T C A T  5'
" C p G "  site, 
" C T T "  s i t e + +
" T C A C "  r e p e a t  
" C T T "  s i t e +
" T G G A "  m o t i f  
" C T T "  s i t e +
" C T T "  s i t e +
" C T T "  s i t e + +
"GA" r e p e a t  
" C T T "  s i t e +
recurrence (Dunn et al., 1989). The possibility of this mutation, in two patients in this 
study, representing a true recurrence, seems unlikely.
The single base pair substitutions
Single base-pair substitutions by far constitute the most common form of 
mutagenesis in the factor VIII gene. The most common and perhaps the best understood 
mechanism for the creation of single base substitutions is due to deamination of the 
hypermutable 5-methylcytosine (5mC) at CpG dinucleotides. Consequently the most 
common spontaneous single base substitutions observed include C—>T and G—>A at CpG 
dinucleotides. 38% of the point mutations reported in the database of mutations in 
haemophilia A represent these changes (Tuddenham et al., 1991). Cooper and Krawczak 
(1993) observed a frequency of methylation-mediated substitutions at CpG dinucleotides 
in 32.8% of a sample of 880 single base substitutions. This figure is similar to the study of 
factor VIII mutations by Higuchi et al. (1991a,b), who observed a frequency of 32%. The 
higher figure noted in the database represents (at least) in part the result of the deliberate 
search for mutations at CpG sites (Gitschier et al., 1985c, 1988; Pattinson et al., 1990a). 
Due to their hypermutability, these represent the most common cause for independent 
origins of the same point mutation in unrelated individuals. At least 16 of the CpG sites in 
the factor VIII gene have been observed in recurrent mutations (Tuddenham et al., 1991). 
In the present study, a nonsense mutation was detected at a CpG dinucleotide at codon -5 
in the signal peptide (not one of the above 16 sites), coding for an arginine residue (CGA 
-»TGA; R-5X). This mutation has been reported twice before (Pattinson et al., 1990a; 
Reiner and Thompson, 1992). In the absence of a haplotype analysis, it will be difficult to 
assess if this is truly a recurrence at this site.
Cooper and Krawczak (1990, 1993) have analysed an unbiased sample of 880 
point mutations (including all such mutations reported up until May 1992 and excluding 
mutations reported either in the factor IX gene, as recurrences, at splice sites, in 
oncogenes or in the mitochondrial genome) and noted that 62% occurred in dinucleotides 
other than "CG". It was observed that a definite non-randomness existed in their 
distribution with respect to DNA sequence and several possible mechanisms were 
reviewed (Cooper and Krawczak, 1993). In the present study, 5 non-CpG site
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substitutions were detected (excluding the splice site mutation). The sequence 
surrounding these mutations was similarly analysed. Table 12 lists all these mutations 
(including the R-5X mutation at a CpG site) along with a limited sequence flanking the 
site of the substitution.
In their analysis of single base substitutions, Cooper and Krawczak (1993) have 
defined as hotspots, those positions or codons that have been mutated more than once. 
Three of the mutations detected in the present study (R-5X, D56E, V162M) fit this 
definition (table 12). The R-5X mutation represents a recurrence at a CpG site. The 
V162M mutation has previously been reported to have recurred in two other unrelated 
individuals (Tuddenham et al., 1991; Diamond et al., 1992). The D56E mutation affects 
an adjacent position (nucleotide 224) in the same codon (Asp-56) that has a polymorphic 
site (at position 225, D56V; Lin et al., 1993).
Depurination is another important chemical mechanism for the causation of single 
base substitutions. Loeb and Preston (1986) showed that dG is the most commonly 
depurinated base. If depurination were really an important cause of point mutations then 
it would be expected that there should be an excess of G—>A transitions (after excluding 
those at CpG sites). In fact of 591 non-CpG site mutations, 111 were G—>A substitutions 
(Cooper and Krawczak, 1993). As seen in table 12, three of the five non-CpG mutations 
detected in this study were G->A transitions.
On investigating non-CpG point mutational hotspots (as defined previously), 
Cooper and Krawczak (1990, 1993) observed that certain types of sequences were seen 
overlapping or in the immediate vicinity of the substituted base. These included direct 
repeats, inverted repeats, a trinucleotide motif "CTT” which is a topoisomerase I 
cleavage site (Bullock et al., 1985) and two tetranucleotide elements "TCGA" and 
"TGGA". The latter motif also fits perfectly with the deletion hotspot consensus sequence 
previously described for human genes (Krawczak and Cooper, 1991) which is also the 
putative arrest site for DNA polymerase a , one of the major polymerases required for the 
replication and repair of vertebrate chromosomal DNA. These observations indicate that 
sites involved in the breakage and rejoining of DNA sequences are potential sites for 
single base substitutions.
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As seen in table 12, analysis of the sequence in the immediate vicinity of the single 
base substitutions showed evidence of some of the possible mechanisms for the causation 
of these mutations as described by Cooper and Krawczak (1993). This study is the third 
independent report of the V162M missense mutation and it therefore fits the definition of 
a hotspot for point mutations. Sequence analysis surrounding this non-CpG site mutation 
revealed a tetranucleotide motif "TGGA" immediately flanking the G-»A at position 541, 
which is known to be a putative arrest site (during DNA replication) for DNA polymerase 
a. In addition, the trinucleotide topoisomerase I cleavage site consensus sequence 
"CTT,, was also noted in the immediate vicinity of the V162M mutation site. A 
tetranucleotide direct repeat "TCAC" was seen immediately flanking the base change 
responsible for D56E (and overlapping the polymorphic base change causing D56V) that 
may have mediated a four-base slippage producing the misincorporation error (s). A 
similar example has been noted for two missense mutations affecting codon 1922 of the 
factor VIII gene, which involve a direct repeat motif "CAAT" (Traystman et al., 1990; 
Higuchi et al., 1991b). The trinucleotide topoisomerase I cleavage site sequence "CTT", 
was also noted in the immediate vicinity of the D56E mutation. The R-5X and A1834 
mutation sites were both flanked on either side by a "CTT" motif. Another such sequence 
was observed on the opposite strand as the R1869I mutation, which also occurred within 
a direct dinucleotide "GA" repeat sequence.
These observations do not provide enough evidence to explain the possible 
mechanisms of mutagenesis at these nucleotides. However, judging from the systematic 
analyses performed by Cooper and Krawczak (1993), it seems likely that these sequence 
elements observed at the sites of the mutations in this study, play at least some (if not a 
major) role in determining the choice of the mutated nucleotide. Perhaps, these sequence 
motifs could even be the reason for the two non-CpG hotspots, V162M and D56E.
4.1.3 EVALUATION OF THE STRATEGY FOR MUTATION DETECTION
The majority of cases of haemophilia A result from a variety of single base 
substitutions, distributed across the large coding sequence of the factor VIII gene. At the 
time of the design of this project, the common intron 22-mediated inversion had not yet
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been discovered, but it was known that up to half the severe haemophilia A cases did not 
possess mutations in the regions screened (or by the method used) by Higuchi et al. 
(1991b). Any mutation screening strategy designed for the effective screening of the 
factor VIII gene, therefore had to screen the entire essential sequence of the gene, and be 
sensitive enough to enable the efficient detection of single base substitutions. The method 
used in this study was that described by Naylor et al. (1991) which is a rapid, simple and 
more cost-effective method of amplifying the entire essential sequence of the factor VIII 
gene and exploits the presence of ectopic transcripts in peripheral lymphocytes.
The choice of the mutation detection method was determined by the size of the 
PCR fragments to be screened. CCM analysis has been successfully used for segments up 
to 1.7 kb in length (Grompe, 1993) and was used for the screening of the entire coding 
sequence, which was amplified in segments >1 kb in length. Individual exons that were 
screened for mutations ranged in size from 151 bp (for exon 12) to 262 bp (for exon 8), 
and were all amplified as PCR products of less than 400 bp. SSCP analysis was used to 
screen these exons for mutations.
The results summarised in table 4, show that the strategy of RT-PCR / DNA-PCR 
followed by CCM analysis, was successful in detecting at least one mutation in each of 
the 13 patients thus screened, and that three of them showed more than one mutation 
each. Potentially pathogenic mutations were fully characterised in 11 of these 13 patients. 
It was also possible to detect an error of splicing, a gross deletion of an exon and the 
characteristic intron 22 mRNA abnormality (Naylor et al., 1992,1993a). This strategy for 
mutation screening was therefore found to be very successful and it is assumed that a 
near total ascertainment of mutations was possible.
The estimation of the efficiency of mutation detection for the strategy involving 
the PCR-SSCP of individual exons was not as straightforward. Since each of the six 
exons were successfully amplified in each of the 12 patients, this ruled out the presence of 
any gross abnormalities involving these exons. Altogether, the six exons comprised 1276 
bp or 17.9% of the factor VIII coding sequence. If it is assumed that (i) the distribution 
of small alterations in the factor VIII gene is random, (ii) gross rearrangements occur at a 
rate of just under 6% (Antonarakis and Kazazian, 1988) and (iii) the F8A-mediated DNA
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inversion accounts for 20% of all haemophilia A patients (Lakich et al., 1993; Naylor et 
al., 1993a,b), then identification of mutations would be expected in 24% of the cases 
analysed. Using this method, a reproducible SSCP mobility shift was detected in two of 
twelve patients. This represents a detection rate of 17% (2/12) or a 70% mutation 
screening efficiency using SSCP in this sample. This observed efficiency is likely to be an 
overestimate due to (i) the observed non-random distribution of mutations involving 
these exons, (ii) a higher detection rate for small deletions/insertions (one of the 
mutations thus detected was a 5 bp deletion in exon 4) and (iii) the small number of cases 
in this study. It was also demonstrated that in order to improve the efficiency of SSCP 
analysis more than one gel electrophoretic condition was necessary.
In summary, even though CCM analysis is a lengthy and potentially hazardous 
procedure, its high sensitivity (>95%, and so its capacity to exclude the presence of 
mutations in regions found negative; Grompe, 1993), accuracy of localisation and ability 
to screen large segments, make it an ideal screening method for the factor VIII gene. 
SSCP on the other hand is a rapid, easy and reasonably sensitive screening method, but 
with limited utility in screening a gene like that of factor VIII.
If a mutation screening protocol were to be designed now, it would be 
appropriate to initially screen every severe haemophilia A patient for the presence of the 
common inversion. This can be performed by a Southern blot analysis (Goodeve et al.,
1994) or by RT-PCR (Naylor et al., 1992, 1993a; see results). The former method 
requires only a DNA sample and is more definitive. It is also more informative as it is 
possible to directly diagnose female carriers and to tell whether the F8A gene in intron 22 
recombines with the proximal or distal homologous sequence 5' to the factor VUI gene.
Analysis of the sequence in the vicinity of mutations characterised in this study, 
revealed the presence of several motifs that could explain the choice of the mutation site 
and perhaps also play a role in determining recurrences at some of these sites. These 
findings are in accordance with the observations made by Cooper and Krawczak (1993) 
regarding the role of the local DNA sequence in the pathogenesis of mutations.
In cases like that of the factor VIII gene, it is beneficial to catalogue all the 
naturally occuring mutations reported. This is necessary because of the difficulties
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associated with detection of mutations in this large gene, and the consequent reporting of 
only few mutations by individual groups. A comprehensive analysis of these mutations 
will serve to ultimately characterise all sites that are functionally/structurally important 
and those sites that can tolerate changes better than others. In countries like the UK, 
where the health service is offered and controlled by one (or a few) central governing 
body(ies), mutations in the majority of known haemophilia A patients can be 
characterised and held in a database to enable a rapid and sensitive diagnostic genetic 
testing of relatives.
4.2 KER ATINOCYTE-SPECIFIC EXPRESSION OF FACTOR IX FOR GENE 
THERAPY FOR HAEMOPHILIA B
The second objective of this project was to investigate the role of keratinocytes as 
a delivery system for ectopically synthesised proteins. A cytokeratin gene promoter was 
used to achieve keratinocyte-specific expression, to result in tissue-specific synthesis of a 
heterologous protein (section 1.10.3). In this project, the role of keratinocyte-specific 
expression of clotting factor IX was investigated as a potential method to deliver somatic 
gene therapy for haemophilia B. The reasons for gene therapy for haemophilia and the 
advantages of using keratinocytes as the target cell type have been discussed (sections 
1.9.1 and 1.10.1). The reason for selecting a cellular promoter was to eventually achieve 
long-term expression in vivo (section 1.10.2). The HaCaT cell line was selected as the in 
vitro model for gene expression studies because of its ability to express a wide variety of 
keratins including the differentiation-specific K10 (section 1.10.4). The assessment of 
factor IX gene expression resulting from the various constructs and the overall evaluation 
of the strategy in relation to the recent progress made towards gene therapy for 
haemophilia B are discussed here.
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4.2.1 KERATINOCYTE-SPECIFIC EXPRESSION OF FACTOR IX
Keratinocytes (HaCaT cells) secrete y-carboxylated factor IX
Factor IX is primarily synthesised in the liver and subjected to at least four post- 
translational modifications before being secreted into the bloodstream (section 1.3.4). 
These modifications include glycosylation, proteolytic cleavage of the pre and 
propeptides, vitamin K-dependent y-carboxylation of 12 N-terminal glutamic acid 
residues and |3-hydroxylation of an aspartic add residue at position 64. Due to the 
complex nature of post-translational modifications, factor IX production using 
recombinant DNA techniques requires the use of mammalian cells. Although many 
mammalian cell types including fibroblasts (St. Louis and Verma, 1988; Palmer et al., 
1989; Axelrod et al., 1990; Scharfmann et al., 1991), endothelial cells (Yao et al., 1991), 
myoblasts (Dai et al., 1992; Yao and Kurachi, 1992) and hepatocytes (Armentano et al., 
1990; Kay et al., 1993) have been successfully used for the production of biologically- 
active factor IX, many cells which only produce partially 7-carboxylated factor IX (with 
lower biological activity) have been reported (Anson et al., 1985; Busby et al., 1985; De 
La Salle et al., 1985; Kaufmann et al., 1986; Balland et al., 1988; Derian et al., 1989).
One of the aims of this project was to determine if keratinocytes are capable of 
carrying out y-carboxylation of factor IX. All pools and individual clones of transfected 
cells were analysed for their ability to secrete 7-carboxylated factor IX into the serum-free 
tissue culture medium in the presence of vitamin K (as a catalyst for the vitamin K- 
dependent y-glutamyl carboxylase; Wu et al., 1991). All transfected cells produced 
readings above the background (negative control) following a 24 hour incubation. The 
OD readings were converted to ng/million cells/24 hours in order to determine the 
relative efficiencies of factor IX secretion and the values so obtained ranged from 8.7 to 
34.6 ng/million cells/24 hours (tables 8 and 9). The A7 antibody detects the calcium- 
dependent epitope in the light chain of factor IX and therefore distinguishes between 
biologically-active factor IX that contains y-carboxyglutamic acids and factor IX which 
does not (Smith et al., 1986; Smith, 1988). This indicates that keratinocytes (HaCaT 
cells) have 7-glutamyl carboxylase activity and can secrete biologically active factor IX.
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These results however do not determine the proportion of secreted factor IX that is y- 
carboxylated and therefore cannot elucidate the efficiency of y-carboxylation in 
keratinocytes. Recently, Gerrard et al. (1993) demonstrated the capacity of primary 
human keratinocytes to secrete y-carboxylated factor IX. They used a retroviral vector to 
transduce primary keratinocytes and showed using the same A5/A7 sandwich ELISA that 
88% and 22% of secreted factor IX was active in the presence or absence of vitamin K, 
respectively.
ELISAs were performed on platelet-poor plasma samples from the Y-line 
transgenic mice (with K10-FIX-I) which also revealed the presence of y-carboxylated 
factor IX (table 8). From the results obtained by Bailleul et al. (1990), who used the same 
(BKVIb/KlO) promoter, it would be expected that the foregut would also express factor
IX. However, the detection of factor IX mRNA in the epidermis of these mice (by 
Northern blots) and the previously demonstrated ability of keratinocytes to secrete factor 
IX into the systemic circulation (Gerrard et al., 1993), suggests that the keratinocyte- 
specific expression was probably the major source of factor IX in the systemic circulation. 
These findings together prove that keratinocytes, which are an attractive cell type for ex 
vivo and in vivo somatic gene therapy, are suitable for the ectopic production of factor IX 
for the treatment of haemophilia B.
Comparative analysis of the various expression constructs 
Northern blot analysis
While all transfected pools were positive using RT-PCR, it was not possible to 
determine the relative levels of factor IX mRNA expression. Northern analysis revealed 
that the pools of transfected K10-FIX-I and II (i.e. basic) constructs, expressed much less 
factor IX mRNA than the manipulated constructs (K10-FIX-G4, K10RB-FIX, K10RB- 
FIX-G4). The following questions needed to be answered: (i) is this result true i.e., are 
the number of cells expressing factor IX mRNA in each transfected pool the same 
(similar) and is the relative proportion of high, low and non expressing clones similar in 
each case? If yes, then (ii) does this difference in level of factor IX transcript represent 
lower transcription levels or a reduced mRNA stability for the basic construct?
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First of all, as the pools analysed consisted of G418-resistant clones, most of the 
cells will contain the transfected expression vector. Furthermore, the initial transfection 
efficiencies are likely to be similar because the DNA preparations, purification and 
quantities used were identical and the transfections were performed simultaneously, using 
the same protocol and efficiencies estimated in duplicate. This means that the total 
number of cells transfected would be similar and therefore statistically also the 
distribution of high, low and non expressing clones. To increase the statistical significance 
of the results obtained from the analysis of the pooled samples, expression at the levels of 
RNA and protein were determined at relatively early passages after transfection and 
selection. From the number of cells transfected, the observed transfection efficiency and 
the number of passages, it is estimated that each pool of transfected cells used for gene 
expression analyses represented between 125-750 individual clones. It is also very 
unlikely that purely by chance both, K10-FIX-I and K10-FIX-II would have a higher 
proportion of low and non expressers and the other three manipulated constructs, more 
efficient expressers. It therefore seems very likely that there are similar numbers and 
distribution of cells expressing factor IX mRNA in the case of each construct i.e., that the 
result is a true one.
Is this reduced mRNA level due to a reduced transcription rate? The only 
difference between K10-FIX-II (basic construct) and K10-FIX-G4 is the presence of the 
induced mutation Q-45V (in order to achieve a 'G' at +4; section 3.5.3), the same 
difference that exists between K10RB-FIX and K10RB-FIX-G4. Northern analysis 
however revealed a large difference in the quantities of recombinant factor IX mRNA, 
only between the former two constructs and not between the latter. It is therefore 
unlikely that Q-45V could have resulted in this difference in factor IX mRNA abundance 
by an increase in the transcriptional level. However, nuclear run-on experiments will have 
to be performed to be absolutely certain.
The main difference that exists between the two groups of constructs with high 
and low mRNA levels is the sequence manipulation introduced to enhance their 
translational efficiency. It would be expected that the repaired K10 cap site and 5'UTR 
and the introduction of the 'G' at position +4 will improve the translatability of the
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otherwise similarly transcribed mRNAs. In view of these observations it is proposed that 
the levels of mRNA are regulated at a post-transcriptional level, that is, due to a 
modulation of their stabilities, which in turn could be related to the process or product of 
translation. The modulation of stability of mRNAs in relation to translation is not 
unknown. Two well characterised examples include the regulation of mRNA for (3-tubulin 
and histones. In the case of the (3-tubulin mRNA, a set of elegant studies have shown that 
mRNA stability is determined by translation of a short length (-13) of nucleotides near 
the 5' end of the message (Yen et al., 1988). In the case of the histone mRNA the 
sequence responsible for mRNA stability was localised to a -30 nucleotide segment in the 
3'UTR. It was shown that premature termination of translation, ending before this 
segment led to abolition of the stability-modulating function (Graves et al., 1987; and 
reviewed in Marzluff and Pandey, 1988). It is significant to note in this respect that the 
3'UTRs of the various constructs tested are identical. It is also unlikely that the Q-45V 
mutation (the only sequence difference between the basic construct and K10-F1X-G4) is 
directly responsible for this effect because this difference was not reproduced between 
K10RB-FTX and K10RB-FTX-G4.
It is widely accepted that efficiently translated mRNAs are more stable due to a 
protective effect of the polysome. In models describing mRNA degradation, the initial 
event is thought to be due to endonucleolytic cleavages proceeding in a 5' to 3' direction, 
following the last ribosome (Lewin, 1994). The released fragments are then degraded by 
exonucleolytic digestion in a 3' to 5' direction. Lim et al. (1992) demonstrated the 
occurrence of degraded (3-globin mRNAs (with loss of varying lengths at the 5' end) in 
response to various nonsense mutations, in transgenic mice. Recently, Lynch et al. (1993) 
localised a 1.2 kb segment of the factor VIII coding sequence with the ability to act as a 
dominant inhibitor of RNA accumulation. Using nuclear run-on experiments it was 
previously shown that the factor VIII mRNA is transcribed at normal rates but does not 
accumulate accordingly, and the defect is therefore at a post-transcriptional level 
(Kaufmann et al., 1989). The evidence in favour of the process of translation in 
influencing the susceptibility of translated mRNAs to nucleolytic activity has been 
reviewed by Brawerman (1989) and Ross (1988).
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In order to determine the integrity and relative quantities of RNA loaded in each 
lane, the same Northern filters were also hybridised with a ubiquitiously transcribed 
GAPDH cDNA probe. All lanes indicated that the RNA was largely intact and the 
difference in the quantities loaded was only minimal. The result of the GAPDH transcript 
was obtained after a 24 hour exposure and that of factor IX required a 5 day 
autoradiographic exposure. This indicates that the levels of factor IX mRNA (not 
necessarily the rate of transcription) is much lower than that of GAPDH.
Assay of secreted factor IX bv ELISA
It was demonstrated that a structurally intact transgene had stably integrated in all 
pools and individual clones of transfected cells. Pools of transfected cells contain a 
mixture of high, low and non-expressing clones. To eliminate the effect produced by the 
varying proportion of expressers and to isolate at least some high expressers, individual 
stable clones were generated. It is also known that transgenes in individual stable clones 
are generally more stable (Mather, 1990). However, the low success rate of the cloning 
procedure allowed the isolation of only a few stable transfectants (table 7). ELIS As were 
performed on all pools and clones and this revealed no individual stably transfected high 
expressing clone i.e. expressing significantly more than the corresponding pooled sample 
(table 8). This is likely to be due to the low number of clones tested. It was assumed that 
the proportion of high, low and non-expressers in each transfected pool would not be 
significantly different in the case of each expression construct. Also, as mentioned before, 
expression analyses were performed at relatively early passages to maximise the statistical 
significance. It was estimated that the number of clones per individual pooled sample 
represented between 125-750 individual expressing clones. This would then mean that the 
expression levels obtained for a pool of transfected clones with a particular expression 
construct would reflect the expressivity of that particular construct, thus allowing a 
comparative analysis. For this purpose, a comparative study of the factor IX levels 
estimated (by ELISA) for each transfected pool of clones i.e. K10-FIX-I, K10-FIX-II, 
K10-FIX-G4, K10RB-FTX and K10RB-FIX-G4, was performed.
An analysis was performed to assess the following factors: (i) effect of the 
sequence manipulations introduced into the basic construct; (ii) identification of the most
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efficient expression construct and (iii) effect of the S136T and Q-45V missense 
mutations.
The mean of the triplicate results of factor IX expression for each of the five 
pools and the variation by ±2SD are listed in table 9. In order to assess the effect of the 
sequence manipulations introduced into the basic construct (K10-FTX-II), a student t test 
of significance was performed. It is seen in table 9 that the basic construct (K10-FIX-II) 
expresses the least factor IX (18.1 ng/106 cells/24 hours) and that all the manipulated 
constructs (K10-FIX-G4, K10RB-FTX and K10RB-FIX-G4) express significantly higher 
levels (p<0.01). This indicates that both, the creation of a favourable sequence context 
around the "AUG" initiator codon and the introduction of the K10 cap site and 5'UTR 
into the basic construct were favourable modifications.
Even though it seems that the factor IX expression is higher in the K10-FIX-I 
(basic construct + S136T) construct (22 ng/106 cells/24 hours), the difference was not 
statistically significant (p<0.1). This indicates that the S136T missense mutation is likely 
to be conservative, as predicted from the similar properties of the normal and mutated 
amino acids (although a functional assay will have to be performed to be sure). 
Furthermore, the Y-line transgenic mice (created with this gene construct) were shown to 
have recombinant human factor IX at a level of 28 ng/ml in their plasma.
The highest expression of biologically active factor IX was obtained with the 
K10-FIX-G4 construct, which secreted 35 ng/106 cells/24 hours. The student t test 
revealed that this was significantly higher than the level obtained for the basic construct 
(p<0.01). Introduction of the 'G' at position +4 to achieve a favourable sequence around 
the "AUG" initiator codon had resulted in a missense mutation at the second codon of the 
factor IX mRNA (Q-45V). When mutating the 'C' at +4 to 'G', the alteration of the 
sequence at the second codon (-45; Anson et al., 1984) of the factor IX cDNA was 
chosen, so as to be the most conservative change possible. The expression results suggest 
that this mutation is also likely to be conservative, as predicted. Perhaps significantly, 
neither this mutation nor the S136T mutation (also shown to be conservative previously) 
have been reported in the database of mutations affecting the factor IX genes of 806 
haemophilia B patients (4th edition; Giannelli et al., 1993).
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Although all the manipulated constructs (K10-FTX-G4, K10RB-FIX and K10RB- 
FIX-G4) expressed significantly higher levels of factor IX than the basic construct, the t 
test revealed that no significant difference existed amongst the three of them. The 
K10RB-FIX-G4 construct has the repaired K10 cap site and 5'UTR sequence in addition 
to the appropriate sequence context surrounding the "AUG" initiator codon. It seems 
likely that the sequence manipulation surrounding the "AUG" codon was responsible for 
the more efficient expression of K10-FIX-G4 compared to the basic construct. It was 
therefore expected, on theoretical grounds, that K10RB-FTX-G4 might express more 
factor IX than K10-FTX-G4 and perhaps even be the highest expressing construct. This 
was clearly not the case (table 9). The sequence that would form the 5'UTR of the 
K10RB-FTX-G4 construct was retrospectively analysed for potential negative features 
that could result in lowered expression. No upstream "AUG" sites were found. A 
structural analysis was performed using a computer program "STEMLOOP" (which is 
part of the GCG package) to predict the formation of hairpin structures in the 5'UTR. 
These are known to be an important cause of poor translation of mRNAs. The 5'UTRs of 
all the other constructs and the BKVIb gene were also simultaneously analysed. As is 
seen in figure 48, the K10RB-FIX and K10RB-FIX-G4 constructs are predicted to form 
hairpin structures in the 5'UTR. Although the sequence of the 5'UTR was designed to be 
identical to that of the BKVIb gene, the Kpnl site used for subcloning the synthetic 
fragment (absent in the BKVIb gene) was responsible for the stemloop formation with the 
complementary sequence in the BKVIb 5'UTR. In contrast, neither of the other 
constructs nor BKVIb are predicted to produce mRNAs with hairpin structures in their 
5'UTRs.
Kozak (1991b) has summarised certain experimentally established rules regarding 
the theoretical prediction of the negative effects on translation attributed to secondary 
structures upstream from the "AUG" codon. In general, it depends on the strength and 
position of the hairpin. A modest amount of secondary structure within 12 nucleotides of 
the cap site drastically inhibits translation by preventing the binding of 40S ribosome 
subunits (Kozak, 1989b). On the other hand, when the secondary structure is sufficiently 
far from the cap site then the entry of the 40S ribosome is not affected and the stability of
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Figure 48: Structural analysis of the 5'UTRs of the various K10-FIX gene expression 
constructs
This figure shows the result of the analysis of the 5'UTRs of the various gene 
constructs. The computer program "STEMLOOP" was used to perform a search for 
potentially deleterious hairpin structures. The sequence of the 5'UTRs are shown with 
the cap sites underlined. The 5'UTR of the K10 (BKVIb) gene is also analysed. The 
Kpril recognition sequence in the K10RB-FIX and K10RB-FIX-G4 constructs is also 
indicated. Only the constructs with the repaired 5'UTR show the formation of a hairpin 
structure. The stem is 6 bp long and the loop is a symmetrical structure with 11 
nucleotides. The only difference that exists between the natural K10 gene and the 
repaired constructs (in this region), was the presence of the Kpnl recognition 
sequence, and it can be seen from the sequence of the stemloop that this is what is 
responsible for the formation of the secondary structure (indicated by an arrow). The 
base of the stemloop is situated 4 nucleotides downstream from the cap site and 3 
nucleotides upstream from the " ATG" initiation codon.
Figure 48: "STEMLOOP” Analysis
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the structure determines whether or not it inhibits scanning. It has been shown that the 
structure has to be more stable than -30 kcal/mol in order to impair translation in COS 
cells (Kozak, 1986b) or cell free systems (Kozak, 1989b). As seen in figure 48, the 
hairpin structure predicted in the mRNAs generated from K10RB-FIX and K10RB-FIX- 
G4 is situated 4 nucleotides from the cap site, a distance at which even moderately stable 
structures can have a major effect.
The following conclusions can therefore be drawn from the above observations: 
(i) Sequence manipulations introduced into the basic construct (K10-FIX-H) to create 
K10-FIX-G4, K10RB-FIX and K10RB-FIX-G4, resulted in a significant improvement of 
gene expression, (ii) The sequence at the two positions, -3 (A/G) and +4 (G) are indeed 
important for efficient translation initiation, possibly resulting in enhanced message 
stability, (iii) Secondary structures near the cap site possibly inhibit translation. A 
preliminary analysis for secondary structures should be performed prior to the 
construction of gene expression vectors. As illustrated in this case, simply a choice of a 
different cloning site in the polylinker may have averted the generation of these 
potentially inhibitory structures, (iv) Both S136T and Q-45V are likely to be conservative 
mutations (a functional assay will have to be performed to be entirely sure), (v) The K10- 
FIX-I construct is effective in vivo. This conclusion was made in collaboration with Dr. 
Y. Alexander who made the transgenic mice and performed Northern blot and in situ 
hybridisation analysis to demonstrate factor IX mRNA in epidermis. As part of this 
project factor IX protein was assayed in the plasma of these (Y-line) mice.
4.2.2 EVALUATION OF THE STRATEGY
Many groups have achieved high levels of factor IX expression in vitro. Although 
a wide variety of cell types have been used, all those achieving high levels have used 
strong viral promoters to drive the expression of factor IX. The levels achieved have 
ranged from 70 to >3000 ng/106 cells/24 hours (Palmer et al., 1989; Armentano et al., 
1990; Yao et al., 1991; Yao and Kurachi, 1992; Gerrard et al., 1993; Kay et al., 1993; 
Lozier et al., 1994). As mentioned before, to achieve long-term expression, cellular 
promoters were used, which resulted in sustained but low levels of factor IX expression
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(Scharfmann et al., 1991; Dai et al., 1992). In this project a cellular promoter was used to 
drive expression of factor IX in a tissue- and differentiation-specific fashion. Using the 
K10 promoter to express factor IX in keratinocytes, a maximum level of 34.6 (26-45) 
ng/106 cells/24 hours of biologically active factor IX was secreted into the conditioned 
medium. This level is perhaps as much as ten to fifteen fold less than what most 
investigators have achieved using strong viral promoters.
It is however very likely that these relatively low levels are not due to the 
inefficient expression of the factor IX gene construct per se. The results most probably 
are a reflection of the limitations of the experimental system. The K10 gene though highly 
expressed in vivo, is not expressed in conventional keratinocyte cultures and so the only 
way to test the efficacy of the K10 promoter in vitro, was to use the HaCaT cell line that 
expresses an unusually wide variety of keratins, including K10. The expression of K10 in 
HaCaT cells is, however, very low and even though it increases with increasing cell 
densities, it is still expressed at much lower levels than the other keratins (Boukamp et al.,
1988). Moreover, using immunofluoresence it was shown that K10 was expressed in only 
a few cells in the total culture and that the increased expression with increasing cell 
density was due to the increase in staining observed in the few KlO-positive cells in the 
culture (Ryle et al., 1989). By extension, this indicates that the K10 promoter will be 
expressed in only a fraction of the cells transfected. Furthermore, even after enriching the 
cultures for cells containing the transgene (by G418 selection) and incubating cells at high 
density, the factor IX secretion is likely to originate from far fewer cells than in 
comparable studies using viral promoters, where all cells in the culture are expected to be 
efficient expressers. It is therefore not entirely surprising that a ten-fold lower level of 
factor IX was detected in the present study. Indeed this might represent a reasonably high 
level of expression assuming that less than 10% of HaCaT cells actually express K10. An 
estimate of the relative efficiencies of factor IX expression can be made by a comparison 
with the results of two recent studies that employed retroviral-mediated transfer for the 
expression of factor IX (Kay et al., 1993; Gerrard et al., 1993). Kay et al. (1993) 
obtained expression of factor IX at levels of 225 ng/106 cells/24 hours and Gerrard et al. 
(1993) obtained expression of 580 ng/106 cells/24 hours (the latter group used primary
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human keratinocytes). The former group did not selectively enrich for transduced cells 
and estimated (using a lacZ reporter construct) a transfection efficiency of 30-40%. 
Gerrard et al. (1993) had at least twice as many cells expressing factor IX as they 
selectively enriched the transduced cell population (using G418). If it is assumed that 5- 
10% of the transfected HaCaT cells expressed factor IX from the K10 promoter, then it 
would seem that the efficiency of expression was comparable to that achieved by the 
retroviral LTR, which is indeed high. Demonstration of the ability of the K10-FTX-I 
construct to express biologically active factor IX in vivo (in the Y-line mice) at a level of 
28 ng/ml also adds credence to this. Dai et al. (1992) who injected mice with retrovirally 
transduced primary mouse myoblasts, achieved long-term expression of factor IX in vivo 
at a maximum level of 20 ng/ml (after two consecutive administrations of 1-2 x 107 cells). 
Also Kay et al. (1993) who achieved between 0.3-1.0% hepatic transduction efficiency by 
direct intra-portal delivery of recombinant retroviral vectors into (2/3 partial) 
hepatectomised canine haemophilia B dogs, achieved sustained plasma factor IX levels of 
between 2-10 ng/ml. Moreover, judging from the in vitro results presented in this project, 
it could be predicted that the expression of factor IX from the manipulated constructs in 
vivo might be even higher than that from K10-FIX-I (perhaps as much as two-fold).
There are however other reasons to indicate that this experimental system may 
not be optimum: (i) Due to the high sequence identity observed in the non-coding 
sequences (including extensive intronic regions) of the human, bovine and murine 
counterparts of the K10 gene, Reiger et al. (1988) inferred that there may be c/s-acting 
elements for transcriptional enhancement in regions other than the (5 kb) 5' flanking 
sequence that was used in this project, (ii) Jallat et al. (1990) showed that the factor IX 
cDNA (i.e. without any introns) may not be an ideal sequence for the expression of factor 
IX. They observed a 40-200 fold increased expression with the inclusion of introns in 
transgenic mice (constructs containing only the first intron or all introns gave similar 
results). These results are nevertheless likely to pertain to the observations of Brinster et 
al. (1988) who demonstrated the necessity for any intron for efficient expression in 
transgenic mice. The heterologous SV40 small t-intron (used in this project) may serve 
this non-specific function, (iii) HaCaT cells are not 'normal' keratinocytes and may differ
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from the primary human keratinocytes (in secretory function and y-carboxylation) that 
were successfully used by Gerrard et al. (1993). This is however not likely to be a major 
problem judging from the expression levels (in the presence of vitamin K) detected using 
the A7 antibody, that detects y-carboxylated factor IX. (iv) The ELISAs in this project 
had a high background reading (that had to be subtracted from the expression results) 
which made the assay less sensitive and therefore the results might represent 
underestimates of the true expression level. Other investigators have reported similar 
sensitivities where they could detect up to 1 ng/ml (Smith et al., 1993) and 2.5 ng/ml 
(Jallat et al., 1990). Gerrard et al. (1993) who used the same A5/A7 antibodies, however, 
reported a much higher sensitivity of <0.1 ng/ml human recombinant factor IX in mouse 
plasma, (v) Other mundane possibilities such as a mutation in the factor IX coding 
sequence and disruption of the transcriptional unit during random integration were also 
considered. A comprehensive mutation analysis, linearisation of the constructs by cutting 
in a nonessential region and an expected sized transcript detected by Northern blots, 
served to adequately rule out these possibilities.
4.2.3 FUTURE PERSPECTIVES
Keratinocytes are an attractive cell type for somatic gene therapy. Fenjves et al. 
(1989) demonstrated that the dermo-epidermal basement membrane can allow ectopically 
synthesised proteins access to the systemic circulation. In addition, Gerrard et al. (1993) 
also demonstrated that keratinocytes are capable of carrying out the required post- 
translational modifications to result in biologically active factor IX. In an attempt to 
exploit this cell type and to achieve long-term expression in vivo, this project has 
demonstrated the use of a cytokeratin gene promoter to direct the expression of (y- 
carboxylated) factor IX in a keratinocyte-specific fashion. It was shown that a gene 
construct produced in this project was also effective in vivo. As has been discussed, the 
levels of expression attained are considered comparable to those achieved by other 
groups who used strong viral promoters.
The epidermis is unique in that it can be completely regenerated from cultured 
somatic cells. Rheinwald and Green (1975) showed that it was possible to serially
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cultivate human diploid keratinocytes on lethally irradiated fibroblasts and produce 
sufficient coherent epithelial sheets to cover the entire body surface (Green et al., 1979; 
Gallico et al., 1984). The basal layer of the epidermis is the proliferative compartment, of 
which up to 10% is comprised of epidermal stem cells. These cells give rise to the 
suprabasal keratinocytes, which migrate outwards and eventually get comified and are 
shed by desquamation. To transfer gene constructs into keratinocytes, sufficient numbers 
of stem cells would have to be transfected in order to continuously replenish the 
recombinant keratinocytes lost by desquamation. From the experience gained in the use 
of cultured epithelial autografts for the healing of full-thickness bum wounds, it is now 
known that epidermal stem cells survive in culture (Gallico et al., 1984; Compton et al.,
1989). Recently Jones and Watt (1993) discovered that epidermal stem cells could be 
purified on the basis of high surface expression of pi integrins and rapid adhesion to type 
IV collagen, fibronectin or keratinocyte extracellular matrix. This should greatly aid in the 
targeting of sufficient stem cell numbers in vitro and achieve the required long term 
expression from genetically manipulated autologous grafts. Keratinocytes from neonates 
or paediatric age groups will be more suitable for this form of therapy due to the higher 
plating efficiency and growth potential of these cells (Green, 1989). In this respect, 
allogenic grafts will not be useful because it is known that they repair epidermis by 
stimulating stem cells in the surrounding normal keratinocytes and do not therefore 
integrate into the regenerated epidermis (Green, 1989). Besides die ex vivo approach, 
gene constructs could be transferred to keratinocytes directly in vivo. This could be 
achieved by the use of liposomes or recombinant viral vectors (with a keratin promoter 
driving expression), either via topical application or intradermal injection. To target 
sufficient stem cells by this method however, repeated administrations might be required. 
The possibility of stimulating the stem cell compartment to become more receptive to 
transfected DNA in vivo has not yet been investigated by anyone. This is an area of 
biology which deserves more attention if keratinocyte gene therapy was to be furthered. 
The first clinical trial using a cationic-liposome delivery system for treatment of 
subcutaneous lesions of metastatic melanoma has been approved (January, 1992) and
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amongst the main aims of this trial are to assess the safety and efficacy of this delivery 
system (Nabel and Feigner, 1993).
To estimate the number of keratinocytes required to actively express factor IX in 
vivo, the method described by Teumer et al. (1990) was used. The formula used was as 
follows: equilibrium concentration (ng / ml) = [factor IX production from the graft (ng / 
h) / equilibrium volume (ml)] / K, where K = In2 / T^/2- The equilibrium volume 
(extracellular volume) is calculated as 14,000 ml (20% of body weight in a 70 kg human 
male) and T^/2 (half life of factor IX in human plasma) = 25 h (Biggs and Denson, 1963). 
To maintain a plasma factor IX level of 50 ng / ml (i.e., 1% of normal plasma factor IX 
concentration), it is calculated that a graft will have to synthesise 19.4 pg / h or 465.6 pg 
/ 24 h. Judging from the level of expression achieved by the HaCaT cells transfected with 
K10-FIX-G4 (35 ng / 106 cells / 24 h), there would have to be 1.3 X 1010 cells in the 
graft, to achieve therapeutic expression levels. If it is assumed that only 10% of the 
recombinant HaCaT cells were expressing factor IX in die in vitro model used in this 
project (section 4.2.2), whereas in vivo one would hope to obtain >95% expression, then
1.3 X 109 cells would be required. It is roughly estimated that the number of suprabasal 
keratinocytes in human epidermis (12 -15 cell layers) is about 1.8 X 10® cells /  100 cm2. 
This means that at presently observed expression levels, an approximately 722 cm2 graft 
(4% of the adult body surface area) would be required to achieve and maintain a steady 
state level of 1% of normal plasma factor IX. These measurements are based on the 
assumption that every suprabasal keratinocyte in die patch would express the foreign 
gene. This is thought to be possible, provided sufficient stem cells are targeted. The 
targeting of sufficient stem cells in vitro may be possible by using a combination of 
selection for epidermal stem cells and using a very efficient transfection protocol. Levels 
of factor IX greater than 1% with grafts of a smaller size could therefore be achieved by 
selecting for stem cells, improving the efficiency of transfection and gene expression. It 
remains to be seen if the enriched stem cell population can successfully generate 
epidermis with a normal architecture. Due to the easy accessibility of the graft, it may 
also be possible to apply an inductive agent topically and thus stimulate an inducible
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enhancer element to upregulate heterologous gene expression, for e.g., topical steroids to 
stimulate a steroid responsive element (Vogel et al., 1993).
The results obtained from the Y-line transgenic mice provide a means of assessing 
the efficacy of the gene constructs in vivo also taking into account the delivery of factor 
IX from suprabasal keratinocytes into the systemic circulation by transport across the 
dermo-epidermal basement membrane. The Y-line mice were created using K10-FTX-I, 
which has been shown to be a less effective gene construct than K10-FIX-G4 in vitro. On 
the basis of the in vitro factor IX expression obtained from HaCaT cells transfected with 
K10-FIX-I (22 ng / 106 cells / 24 h), it is estimated that a 100 cm2 graft of human 
epidermis will express about 40 pg / 24 h (instead of 64.5 pg / 24 h as for K10-FIX-G4). 
Using the formula described by Teumer et al. (1990) it is estimated that the suprabasal 
keratinocytes of a Y-line mouse must produce 242.4 ng / 24 h to maintain the circulating 
factor IX level of 28 ng/ml in plasma. For these calculations the following values were 
used: T y2  of human factor IX in mouse plasma = 12 h (Gerrard et al., 1992) and 
equilibrium volume = 6.6 ml (22% of total body weight in a 30 g mouse; Teumer et al.,
1990). In order to estimate the amount of factor IX that would be produced by the 
suprabasal keratinocytes in a similar area (-100 cm2) of human epidermis, the structural 
differences between mouse and human epidermis and the results obtained by in situ 
hybridisation on the Y-line epidermis (performed by Dr. Y. Alexander) were considered. 
The mouse epidermis has only 2 layers of suprabasal keratinocytes compared to 12 - 15 
in human, and in situ hybridisation showed about 25% of each layer expressed the 
transgene at high levels. By correcting for this, it is estimated that the suprabasal 
keratinocytes in a 100 cm2 graft of human epidermis will express factor IX at about 6.8 p 
g / 24 h. This 6 fold difference between the expected and observed levels of factor IX 
expression in vivo can be due to one or a combination of the following reasons: (i) The 
effect of the difference in the cellular environments in vivo and in vitro. It is known that 
gene expression in vivo does not always correlate with levels observed in vitro (Kriegler, 
1990a). (ii) The difference between HaCaT cells (which is a spontaneously transformed 
cell line) and normal keratinocytes in vivo. Even though the calculations have accounted 
for the fewer number of HaCaT cells expressing K10 in vitro, it is also known that these
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cells express K10 at lower levels than suprabasal keratinocytes in vivo (Boukamp et al., 
1988; Ryle et al., 1989), thus further distorting the correlation, (iii) The observed 
suppression of ELISA readings (by up to 40%) by plasma, leading to an underestimation 
of the plasma factor IX levels in the Y-line mice (Smith et al., 1993). (iv) The possible 
instability of factor IX with the S136T missense mutation in vivo (even though no such 
effect was seen in vitro) and (v) The inefficient transport of factor IX (57 kD) across the 
dermo-epidermal basement membrane. Gerrard et al. (1993) transplanted genetically 
modified primary keratinocytes at a sub-dermal site and therefore the demonstration of 
factor IX in the systemic circulation of the recipient athymic mice in their experiments, 
does not necessarily indicate that the basement membrane is permeable to factor IX. 
However, the demonstration of the transport of apolipoprotein E (30 kD) from epidermis 
to blood (Fenjves et al., 1989), and the movement of large plasma proteins (albumin and 
immunoglobulins) from blood to epidermis (Coruh and Mason, 1980), indicate that the 
last reason is not likely to be the major cause. With regard to this problem, it may be 
beneficial to attempt keratinocyte-specific expression using the cytokeratin 5 and 6 (K5 
and K6) gene promoters. Expression of K5 and K6 are specific to the basal layer of the 
epidermis and hair follicles, respectively, both of which are situated closer to the systemic 
circulation than suprabasal keratinocytes. The K5 promoter will however drive expression 
in only a single (basal) cell layer and will therefore result in a lot fewer expressing cells in 
a graft.
Dai et al. (1992) were among the first to achieve sustained (but low) levels of 
factor IX expression in vivo (via intramuscular injections of genetically modified 
myoblasts) by the incorporation of a cellular enhancer element in their recombinant factor 
IX expressing retroviral vector. Clearly, a better understanding of the various sequence 
elements in the promoter/enhancers will be required to achieve high level expression 
using cellular promoters. A considerable amount of research is being performed in order 
to determine the various modulators of gene expression in keratins (Fuchs et al., 1994). 
Modifications that could be attempted include for example, deletion of negative 
regulatory elements identified in promoter/enhancers (e.g. in the HPRT gene, Rincon- 
Limas et al., 1991) or identification and use of positive elements present in other regions
149
of genes, that are not normally used for directing heterologous gene expression (e.g. in 
the second intron and 3' to the structural gene for human (3-globin; Behringer et al., 
1987). Smith et al. (1993), using adenoviral vectors in vivo, achieved very high but 
transient factor IX expression due to the host immune response. Development of less 
immunogenic adenoviral vectors would greatly improve the outlook for this convenient 
method of gene delivery (Yang et al., 1994). Low but sustained levels of factor IX 
expression were attained by an in vivo approach used by Kay et al. (1993), who 
administered recombinant retroviral vectors directly into the portal circulation to 
transduce hepatocytes in vivo (in partially-hepatectomised haemophilia B dogs). 
Improvement in the level of expression would be possible if higher titres and transduction 
efficiencies (they had between 0.3-1.0% efficiency) could be achieved.
The results obtained by Kay et al. (1993) are especially encouraging because they 
demonstrate that a phenotypic improvement is indeed possible by the secretion of 
relatively low levels of factor IX in vivo. With factor IX antigen levels after gene transfer 
being only 0.1% of the endogenous normal level, they achieved a sustained (up to nine 
months in dog 1) reduction in the WBCT (whole blood clotting time) from 45-55 min to 
15-20 min (normal = 6-8 min) and a shortening of the PTT (partial thromboplastin time) 
from 322 to 174 seconds.
In conclusion, the results obtained in this study show that keratinocytes appear to 
be effective target cells for somatic gene therapy of haemophilia B and in addition, 
indicate the suitability of using tissue-specific cellular promoters to achieve sustained and 
high level expression of factor IX. However, optimisation of the regulatory elements, and 
investigation of a means to efficiently target epidermal stem cells, may have to be 
performed before this approach can be considered suitable for formal preclinical studies.
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APPENDIX I
Primers for amplification of the factor VIII cDNA *
Primer 1 Position Sequence 5' to 3'
Rl-A -69 GGG AGC TAA AGA TAT TTT AGA GAA G
Rl-B 1322 TTC CTA CCA ATC CGC TGA GG
Rl-C -50 GAG AAG AAT TAA CCT TTT GCT TCT C
Rl-D 1223 CAG CAG CAA TGT AAT GTA CC
R2-A 1080 AGA AGC GGA AGA CTA TGA TG
R2-B 2316 TTG CCT AGT GCT AGG GAG TC
R2-C 1114 TCT GAA ATG GAT GTG GTC AG
R2-D 2282 AAG CTT CTT GGT TCA ATG GC
Dl-A 2214 GTC TAT GGA TTC TGG GGT GC
Dl-B 3692 GGC AAA ACT ACA TTC TCT TG
D2-A 3537 CGT AGG ACT CAA AGA GAT GG
D2-B 5219 CTG TTT CTT AGA ACA TGT GG
R4-A 5924 TTC ATT TCA GTG GAC ATG TG
R4-B 7164 TGT CTG CTA GGA TTT AGC AC
R4-C 6071 ATC TAC ATG CTG GGA TGA GC
R4-D 7143 AAG GTA GAA GGC AAG CCA GG
* Sequence information was obtained from Professor F. Giannelli; Primers that 
end in A/C and B/D are forward and reverse primers, respectively; Those that end 
in A/B and C/D were used for the initial PCR and nested PCR amplifications, 
respectively. See figure 3 for the various PCRs. mRNA positions are according to 
Wood et al. (1984).
Primers for the amplification of individual exons of the factor VIII gene *
Primer 1 Sequence 5f to 3*
2X TTG AAG TGT CCA CCA AAA TGA ACG ACT
2Y GAT ACC CAA TTT CAT AAA TAG CAT TCA
4X TAC AGT GGA TAT AGA AAG GAC AAT TTT
4Y TGC TTA TTT CAT CTC AAT CCT ACG CTT
5X CCT CCT AGT GAC AAT TTC CTA CAA TGA
5Y AGC AGA GGA TTT CTT TCA GGA ATC CAA
6X CAT GAG ACA CCA TGC TTA GCT GAC TCT A
6Y AAC TCT GGT GCT GAA TTT GGA AGA CCC T
7X TCA GAT TCT CTA CTT CAT AGC CAT AGG T
7Y GTA GGA CTG GAT ATT TAT AAT ATT CAT T
8X ATA TAG CAA GAC ACT CTG ACA TTG
8Y AGA GAG TAC CAA TAG TCA AA
11X ATG GTT TTG CTT GTG GGT AG
11Y GGA TCC GAC ATA CAC TGA GAA TGA A
12X CTA GCT CCT ACC TGA CAA CAT CAG TAG C
12Y CTC AAG CTG CAC TCC AGC TG
14X GAG AAC CTC TAA CAG AAC GT
14Y AGC AGA GCA AAG GAA TAA CC
16X GTC GTT ATT GTT CTA CAG GTA
16Y GTG GTC AAG CAC AAT AGA CAC CTG C
17X TGA TGA GAA ATC CAC TCT GG
17Y GTG CAA TCT GCA TTT CAC AG
20X ATT TTG TGC ACT CTA GTT ACT GTG T
20Y TAT AAT CAG CCC AGG TTC TTG GAG C
21X ATA TAG CAA GAC ACT CTG ACA TTG
21Y GAG TGA ATG TGA TAC ATT TCC CAT CA
22X AAA TAG GTT AAA ATA AAG TGT TAT
22Y TGA CTA ATT ACA TAC CAT TAA GGT T
23X CTC TGT ATT CAC TTT CCA TG
23Y AAG GAT ATG GGA TGA CTT GGC ACT
* Sequence information was obtained from Higuchi et al. (1991a); Primers that 
end with an "X" and "Y" are forward and reverse primers, respectively.
Appendix II
Student's t test for significance of the difference between the means of two 
samples
The t value is calculated as the ratio o f the observed difference between the 
two means to the calculated standard error o f that difference.
t =  Ml - M2
Vs f^y+S2/^
M l and M2 are the means o f the observations in the two samples; "sH is the 
standard deviation in the universe and nj and n2 are the number o f observations 
made in the same two samples.
To calculate s2, the sum of the squared deviations o f the observations from their 
means is calculated for each separate group. Then a combined estimate o f the 
standard deviation is made as follows:
s2 = sum (Xi - M l)2 + sum ( X i  - M2)2
(ni - l) + (n2 - 1)
The probability for a given value o f t is then looked up in statistical tables with (nj 
-1 )  + (n2 -1 )  degrees o f freedom.
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